{
  "cjc-1295, ipamorelin": {
    "title": "CJC-1295 (no DAC), Ipamorelin 10mg (Blend)",
    "url": "https://www.peptidesciences.com/cjc-1295",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Dual-receptor signaling analysis via GHRHR and GHSR-1a\nPulsatile endocrine signaling and receptor cross-talk studies\ncAMP- and Ca2+-dependent second messenger pathway evaluation\nDownstream IGF-axis modulation in preclinical models"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical studies in cellular and animal models have examined GHRH analogs and ghrelin receptor agonists for receptor selectivity, endocrine pulsatility, and downstream signaling dynamics. All findings are derived from non-clinical research environments."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.\n\nDr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [10] under the",
    "citations": [
      "K. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]",
      "N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]",
      "J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]",
      "E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]",
      "D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]",
      "B. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus,” J. Exp. Pharmacol., vol. 4, pp. 149–165, Oct. 2012. [PubMed]",
      "M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]",
      "M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]",
      "M. C. Van Hout and E. Hearne, “Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions,” Subst. Use Misuse, vol. 51, no. 1, pp. 73–84, Jan. 2016. [PubMed]",
      "Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]"
    ]
  },
  "tesamorelin, ipamorelin": {
    "title": "Tesamorelin, Ipamorelin 8mg (Blend)",
    "url": "https://www.peptidesciences.com/tesamorelin-ipamorelin-8mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "David E. Beck, MD, co-author of “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients” specializes in colon and rectal surgery.\n\nDavid E. Beck, MD is being referenced as one of the leading scientists involved in the research and development of Ipamorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. David E. Beck, MD is listed in [4] under the",
    "citations": []
  },
  "melanotan 2": {
    "title": "Melanotan 2 (MT2) (3mg x 10 Vials = 30mg)",
    "url": "https://www.peptidesciences.com/melanotan-2-2mg-x-10-vials",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "121062-08-6",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Melanotan 2 (MT2): Research Applications",
        "content": "MT-2 is used in research environments to study melanocortin receptor activation across multiple tissue types and neural circuits. Experimental applications include investigation of receptor-specific signaling bias, ligand–receptor affinity profiles, and downstream transcriptional responses mediated by melanocortin receptor subtypes.\n\nAdditional research contexts include analysis of neuroendocrine signaling networks, hypothalamic peptide integration, and receptor-driven modulation of intracellular signaling pathways in rodent and cellular model systems."
      },
      {
        "heading": "Melanotan 2 (MT2): Preclinical Research Summary",
        "content": "Preclinical investigations utilizing MT-2 have explored melanocortin receptor signaling in rodent behavioral paradigms, neuroendocrine circuits, and metabolic signaling networks. These studies are used to map receptor distribution, signal propagation, and receptor-specific pathway engagement at molecular and cellular resolution.\n\nAdditional experimental literature evaluates MT-2-associated modulation of hypothalamic signaling nodes, limbic system activity, and central peptide integration using in-vivo animal models and in-vitro neuronal culture systems. Findings are interpreted within a mechanistic framework without translational inference."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Wessells is a UW professor, chair of the Department of Urology, and has served on several national and international professional and government committees, including the WHO International Consultations on Erectile and Sexual Dysfunction, an NIDDK working group on urological complications of diabetes, and a NIH symposium on diabetes. He is a surgeon, researcher and expert on urogenital trauma and erectile dysfunction. His clinical interests include reconstructive surgery of the genitourinary tract, acute injury management and complex surgery for male sexual dysfunction.  His research interests are in urogenital trauma epidemiology and management; the physiology and pathophysiology of erectile dysfunction; reconstructive surgery; crash injury mechanics; and urological complications of diabetes. A proerectile melanocortin agonist developed by Dr. Wessells and his collaborators at the University of Arizona is in clinical trials for the treatment of erectile dysfunction.\n\nDr. Wessells is being referenced as one of the leading scientists involved in the research and development of Melanotan 2. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this pep",
    "citations": [
      "E. Minakova et al., “Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism,” PLoS ONE, vol. 14, no. 1, Jan. 2019. [PubMed]",
      "A. van der Klaauw et al., “Role of melanocortin signaling in the preference for dietary macronutrients in human beings,” Lancet Lond. Engl., vol. 385 Suppl 1, p. S12, Feb. 2015. [PubMed]",
      "H. Shimizu, K. Inoue, and M. Mori, “The leptin-dependent and -independent melanocortin signaling system: regulation of feeding and energy expenditure,” J. Endocrinol., vol. 193, no. 1, pp. 1–9, Apr. 2007. [Research Gate]",
      "C. Bjørbaek and A. N. Hollenberg, “Leptin and melanocortin signaling in the hypothalamus,” Vitam. Horm., vol. 65, pp. 281–311, 2002. [PubMed]",
      "F. Guo, K. Bakal, Y. Minokoshi, and A. N. Hollenberg, “Leptin Signaling Targets the Thyrotropin-Releasing Hormone Gene Promoter in Vivo,” Endocrinology, vol. 145, no. 5, pp. 2221–2227, May 2004. [PubMed]",
      "Y. H. Lee, M.-Y. Wang, X.-X. Yu, and R. H. Unger, “Glucagon is the key factor in the development of diabetes,” Diabetologia, vol. 59, no. 7, pp. 1372–1375, 2016. [PubMed]",
      "C. Toda et al., “Distinct effects of leptin and a melanocortin receptor agonist injected into medial hypothalamic nuclei on glucose uptake in peripheral tissues,” Diabetes, vol. 58, no. 12, pp. 2757–2765, Dec. 2009. [PubMed]",
      "D. A. York, S. Boghossian, and M. Park-York, “Melanocortin activity in the amygdala influences alcohol intake,” Pharmacol. Biochem. Behav., vol. 98, no. 1, pp. 112–119, Mar. 2011. [PubMed]",
      "M. Navarro, F. Carvajal, J. M. Lerma-Cabrera, I. Cubero, M. J. Picker, and T. E. Thiele, “Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice,” Alcohol. Clin. Exp. Res., vol. 39, no. 8, pp. 1425–1433, Aug. 2015. [PubMed]",
      "M. T. Islam et al., “Vasopressin neurons in the paraventricular hypothalamus promote wakefulness via lateral hypothalamic orexin neurons,” Curr. Biol. CB, pp. S0960-9822(22)01121–6, Jul. 2022, doi: 10.1016/j.cub.2022.07.020. [PubMed]",
      "J. K. Y. Lau et al., “Melanocortin receptor activation alleviates amyloid pathology and glial reactivity in an Alzheimer’s disease transgenic mouse model,” Sci. Rep., vol. 11, no. 1, p. 4359, Feb. 2021, doi: 10.1038/s41598-021-83932-4. [PubMed]"
    ]
  },
  "pt-141": {
    "title": "PT-141 10mg",
    "url": "https://www.peptidesciences.com/pt-141-10mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "C50H68N14O10",
    "molecularWeight": "1024.52428442",
    "casNumber": "",
    "pubChem": "Bremelanotide Laboratory Chemical Safety Summary",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "1. Melanocortin Receptor Pharmacology & Ligand–Receptor Selectivity\nPT-141 is used as an agonist probe in receptor pharmacology to measure melanocortin receptor activation and to compare signaling behavior across receptor subtypes under controlled assay conditions. Common endpoints include concentration–response profiling, receptor desensitization/internalization studies, and pathway bias assessment using second-messenger and phospho-protein readouts.\n2. CNS-Relevant Signaling Networks in Animal Models\nMelanocortin receptor agonism is frequently examined in rodent models to map receptor-linked signaling across CNS-associated circuits. Experimental designs may quantify downstream molecular endpoints (e.g., cAMP-regulated transcriptional signatures, ERK phosphorylation, immediate-early gene expression) and incorporate receptor subtype attribution strategies using pharmacologic blockade or genetic models.[1]\n3. Inflammation & Host-Response Pathway Interrogation\nMC1R-associated signaling is studied in immune-adjacent models to characterize how melanocortin pathway activation intersects with inflammatory mediator regulation and macrophage-associated phenotypes. In preclinical infection and inflammation paradigms, melanocortin ligands have been used to quantify cytokine-linked endpoints, leukocyte signaling markers, and tissue-level inflammatory signatures in controlled animal systems.[4]\n4. Pigmentation-Linked Signaling & Photobiology Mechanisms\nIn melanocyte-focused experimental systems, melanocortin signaling is used to study cAMP/PKA-driven transcriptional control of pigmentation-associated enzymes and melanosome biology. MC1R pathway mapping may include evaluation of signaling cross-talk with MAPK cascades and DNA damage-response markers in mechanistic photobiology workflows."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical research involving melanocortin receptor agonism includes rodent behavioral and neuroendocrine models used to map MC4R-linked signaling networks and downstream transcriptional responses. Genetic MC4R-deficient mouse models have been used to evaluate pathway consequences of disrupted melanocortin signaling, supporting mechanistic interpretation of receptor involvement across measured endpoints.[1]\nAdditional animal studies using melanocortin agonist frameworks have examined receptor-linked effects on neurobehavioral signaling and related molecular markers in controlled preclinical contexts.[2], [3]\nIn immune-adjacent models, melanocortin signaling has been evaluated for its relationship to inflammatory mediator regulation and macrophage-associated pathways in controlled animal infection paradigms.[4]"
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "tesofensine": {
    "title": "Tesofensine 500mcg (30 Capsules)",
    "url": "https://www.peptidesciences.com/tesofensine-500mcg-30-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "195875-84-4",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Tesofensine: Research Applications",
        "content": "In research settings, tesofensine has been utilized as an experimental variable in:\n\nMonoamine transporter binding and uptake assays\nNeurochemical concentration measurements in animal models\nBehavioral and metabolic readout collection under controlled conditions\nComparative pharmacology studies involving monoamine-associated compounds\n\nAll reported applications are limited to laboratory and preclinical research use."
      },
      {
        "heading": "Tesofensine: Preclinical Research Summary",
        "content": "Preclinical investigations involving tesofensine include rodent-based models in which researchers reported measured endpoints related to neurotransmitter dynamics, behavioral metrics, and metabolic parameters. Transcriptomic and proteomic analyses describe differential expression patterns among neurotrophic and metabolic gene sets under experimental exposure conditions.\n\nSafety-related observations in the literature are reported as trial-level or study-level findings without extrapolation beyond the original experimental context."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "aicar": {
    "title": "AICAR 50mg",
    "url": "https://www.peptidesciences.com/aicar-50mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "3031-94-5",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "AMPK activation assays for pathway mapping, phosphorylation-state profiling, and metabolic flux experiments.\nGlucose transport research in muscle models, including insulin-stimulated uptake and GLUT-4 content/trafficking endpoints.\nInflammation and immune-signaling studies evaluating AMPK-linked modulation of macrophage signaling and cytokine outputs.\nCell-cycle and apoptosis research assessing AMPK-associated p38 MAPK signaling, p21-related checkpoints, and caspase-linked pathways.\nVascular biology experiments evaluating smooth muscle proliferation and leukocyte rolling/adhesion mechanisms in preclinical models.\nReproductive biology tool studies evaluating AMPK-linked regulation of spermatozoa energy metabolism and motility endpoints in species-specific systems."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "In mouse models, AICAR has been used as an AMPK-activating tool compound to evaluate adipose inflammatory signaling and insulin resistance-associated endpoints, including studies describing dependence on myeloid SIRT1 in specific experimental settings[1]. Additional preclinical work reports AMPK activation effects on inflammatory response markers and metabolic disorder phenotypes in particulate exposure models[2].\n\nIn rat skeletal muscle models, AICAR has been used to compare exercise-linked signaling to AMPK activation, including insulin-stimulated glucose uptake and GLUT-4 content endpoints[3]. In cell culture and animal models, AICAR-mediated AMPK activation has been evaluated in proliferation and survival assays in multiple cell lines, including studies reporting AMPK-associated growth control and stress susceptibility effects[4], [5].\n\nIn inflammation-focused models, AICAR has been used to assess immune signaling mechanisms (including NF-κB-associated macrophage signaling and TH1/TH17-type cytokine outputs) in preclinical colitis paradigms[9]. In vascular biology, AMPK activation has been evaluated for effects on vascular smooth muscle proliferation via cell-cycle regulation[10], and microcirculation models have been used to study leukocyte rolling/adhesion endpoints in AICAR-associated preconditioning experiments[14].\n\nIn reproductive biology tool studies, AMPK activators including AICAR have been used in species-specific systems to evaluate spermatozoa energy metabolism and motility endpoints[12], [13].\n\nAICAR inhibits clonal growth of glioma (C6) and prostate cells.\nSource: Journal of Biological Chemistry\n\nAMPK activators, like AICAR, influence a number of pathways that can impact cancer growth.\nSource: PubMed"
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "all peptides": {
    "title": "All Peptides",
    "url": "https://www.peptidesciences.com/all-peptides",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "peptide sciences research": {
    "title": "Peptide Sciences Research",
    "url": "https://www.peptidesciences.com/peptide-research",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "about peptidesciences": {
    "title": "About PeptideSciences",
    "url": "https://www.peptidesciences.com/about",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "peptide sciences": {
    "title": "Peptide Sciences",
    "url": "https://www.peptidesciences.com/contact",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "aod9604": {
    "title": "AOD9604 6mg",
    "url": "https://www.peptidesciences.com/aod9604",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "C78H123N23O23S2",
    "molecularWeight": "1813.86035961",
    "casNumber": "",
    "pubChem": "Aod-9604 Laboratory Chemical Safety Summary",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "ghrp-2": {
    "title": "GHRP-2",
    "url": "https://www.peptidesciences.com/ghrp-2",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "GHRP-2 is employed in laboratory research to support mechanistic investigations across multiple biological domains, including:\n\nReceptor pharmacology: evaluation of GHSR1a activation, ligand specificity, and downstream signaling dynamics in cell-based assays.\nMuscle biology: analysis of protein synthesis and degradation pathways, including ubiquitin–proteasome system components, in animal and cellular models.\nEnergy balance and feeding circuits: mapping ghrelin receptor involvement in hypothalamic and peripheral signaling networks regulating nutrient sensing in preclinical models.\nCardiac cell stress models: investigation of apoptosis-associated markers and oxidative stress pathways in cardiomyocyte cultures and animal myocardial injury paradigms.\nImmunology research: examination of thymic signaling pathways and T-cell maturation processes influenced by ghrelin-associated endocrine signaling in animal studies.\nNeurobiology: exploration of sleep architecture regulation, nociceptive processing, and receptor crosstalk in rodent and murine models."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Muscle protein turnover models\n\nAnimal studies, including large-animal and livestock models, have examined the effects of GHRP-2 on muscle protein deposition and degradation pathways. Reported outcomes include modulation of ubiquitin ligases such as atrogin-1 and MuRF1 and altered balance between anabolic and catabolic signaling in skeletal muscle tissue under growth-restricted conditions.[1], [2], [3]\n\nFeeding behavior and metabolic signaling\n\nRodent and other preclinical models have demonstrated that ghrelin receptor agonism influences hypothalamic circuits involved in nutrient intake and energy balance. These models are used to quantify food intake patterns, endocrine signaling changes, and receptor-mediated behavioral outputs.[4], [5]\n\nCardiomyocyte apoptosis studies\n\nCell culture and animal-based myocardial stress models have utilized GHRP-2 and related peptides to evaluate apoptosis-associated signaling and oxidative stress markers. These investigations support ongoing efforts to characterize ghrelin receptor involvement in cardiac cellular stress responses.[6], [7]\n\nThymic signaling and immune cell development\n\nPreclinical immunology research has explored how ghrelin-associated signaling pathways influence thymic architecture and T-cell maturation processes. These studies typically assess thymic output, cellular diversity, and signaling pathway engagement in aging or stress-related animal models.[8]\n\nSleep architecture and neuroendocrine rhythms\n\nExperimental models examining sleep–wake regulation have used ghrelin receptor agonists to analyze changes in sleep-stage distribution and neuroendocrine rhythm modulation. Outcomes are assessed using electrophysiologic and behavioral endpoints in controlled laboratory settings.[9]\n\nNociception and opioid receptor interaction\n\nMurine studies have reported that GHRP-2 interacts with supraspinal opioid receptor systems, enabling investigation of selective receptor engagement and pain-processing pathways. These models are used to study receptor specificity and signaling overlap between ghrelin and opioid systems.[10]"
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Jean-Alain Fehrentz was born in Nancy, France, in 1955. He received his Ph.D. degree in Chemistry from the University of Nancy in 1983 and joined the Centre CNRS-INSERM de Pharmacologie Endocrinologie of Montpellier in the research group of Professor B. Castro. From 1989 to 1992 he was appointed as researcher at Sanofi Research in Montpellier. Then he moved to the Faculty of Pharmacy of Montpellier, working under the direction of Professor J. Martinez. His research interests focus on peptide aldehydes, enzyme inhibitors, peptidomimetics, growth hormone interactions, and heterocycle based receptor ligands. He has published more than 150 scientific papers.\n\nJean-Alain Fehrentz is referenced here to acknowledge published work related to ghrelin receptor ligands and growth hormone secretagogues. This reference does not imply endorsement or advocacy of purchase, sale, or use of this product. No affiliation or relationship is implied between the seller and this scientist. A representative publication is included within the citations below.",
    "citations": []
  },
  "ghrp-6": {
    "title": "GHRP-6",
    "url": "https://www.peptidesciences.com/ghrp-6",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "GHRP-6 is used in research workflows as a ghrelin receptor agonist to support the following preclinical objectives:\n\nReceptor pharmacology: ligand-response profiling of GHSR1a in cell-based reporter systems, second-messenger assays, and receptor distribution studies.\nNeuroscience research: interrogation of GHSR1a signaling in brain regions implicated in learning and memory paradigms and synaptic plasticity assays in animal models.\nIschemia and cellular stress models: evaluation of GHSR-linked modulation of inflammatory mediators, oxidative stress markers, and programmed cell death pathways in preclinical injury paradigms.\nTissue remodeling and extracellular matrix biology: mechanistic studies examining how GHSR activation interfaces with matrix protein expression, cellular migration, and remodeling signatures in animal wound models and proteome-level surveys.\nCardiac cell stress paradigms: investigation of oxidant-associated cytotoxicity endpoints and necrosis-related markers in large-animal myocardial injury models.\nMotivation and reward circuitry: mapping GHSR-dependent modulation of behavioral outputs in controlled rodent paradigms used to study reward-seeking and motivated behavior."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Neural plasticity and memory-related paradigms (rodent studies)\n\nPreclinical studies have used ghrelin pathway modulation to examine learning- and memory-associated endpoints and synaptic plasticity measures in rodents. In these experimental contexts, GHSR signaling has been implicated in the regulation of extinction learning, long-term depression in the amygdala, and memory encoding processes. Related work has evaluated spatial learning outcomes following localized ghrelin pathway manipulations in the amygdala in rodent models.[1], [2], [3]\n\nIschemic brain injury models (preclinical)\n\nIn animal models designed to study ischemia-associated injury cascades, ghrelin pathway agonism has been investigated for its effects on apoptosis-associated markers and neuroinflammatory signaling. These models are used to quantify molecular and histologic correlates of injury and to characterize timing-dependent pathway effects in preclinical settings.[4], [5]\n\nDopaminergic system and substantia nigra receptor mapping (rodent studies)\n\nPreclinical research has reported ghrelin receptor expression in the substantia nigra and has explored how altered receptor expression relates to motor dysfunction phenotypes in genetic and pharmacologic rodent paradigms. These studies are commonly used to assess receptor expression changes, pathway responsiveness to agonism/antagonism, and apoptosis-associated endpoints in dopaminergic neuron populations under controlled experimental conditions.[6]\n\nExtracellular matrix remodeling and proteome-level profiling (animal wound models)\n\nIn rat wound-model systems, GHRP-6 and related pathway probes have been used to investigate tissue remodeling dynamics, including extracellular matrix protein deposition patterns and proteome-level shifts during the remodeling phase. Reported endpoints include collagen-associated signatures, matrix organization measures, and broader protein expression changes observed in mechanistic surveys.[7], [8]\n\nOxidative stress endpoints in myocardial injury models (large-animal studies)\n\nPorcine myocardial injury models have been used to evaluate whether ghrelin pathway agonism modulates oxidant-associated cytotoxicity readouts and necrosis-related markers. These studies typically quantify biochemical injury indices, histologic changes, and oxidative stress-associated endpoints to characterize pathway involvement in tissue stress responses in vivo.[9]\n\nMotivation and reward-seeking behavior paradigms (rodent studies)\n\nRodent behavioral studies have examined how central ghrelin receptor stimulation modulates motivated behavior in a site-dependent manner. Experimental designs commonly use receptor agonists and antagonists to localize functional contributions of specific brain regions to reward-seeking and motivated behavioral outputs.[10]"
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Márta Korbonits graduated in Medicine in Budapest and undertook her early clinical training at the Internal Medicine Department of the Postgraduate Medical School, Budapest. She joined the Department of Endocrinology at St. Bartholomew’s Hospital under the mentorship of Professors Ashley Grossman and Michael Besser. Her MD and later PhD studies contributed to the understanding of the effects of growth hormone secretagogues on hypothalamic hormone release and the nature and causes of pituitary tumorigenesis. She was awarded an MRC Clinician Scientist Fellowship and commenced studies that produced novel insights into ghrelin physiology and genetics. Her findings related to the regulation of the metabolic enzyme AMPK by ghrelin, cannabinoid and glucocorticoid opened a new aspect of hormonal regulation of metabolism. In 2008, Márta Korbonits was promoted to Professor of Endocrinology and Metabolism and since 2012, has led the Centre of Endocrinology at Barts and the London School of Medicine. In 2016, Márta Korbonits was appointed a Deputy Head of the William Harvey Research Institute. Professor Korbonits continues to integrate human studies alongside with laboratory-based research and has pioneered several projects in translational medicine.\n\nMárta Korbonits is referenced as a scientist with published contributions related to growth hormone secretagogues and ghrelin physiology. This reference does not imply endorsement or advocacy of purchase, sale, or use of this product. No af",
    "citations": []
  },
  "hexarelin": {
    "title": "Hexarelin",
    "url": "https://www.peptidesciences.com/hexarelin-5mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "140703-51-1",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Receptor pharmacology studies involving GHSR signaling and ligand–receptor selectivity\nCellular stress-response experiments assessing survival-associated pathway readouts under defined conditions (e.g., nutrient deprivation or oxidative challenge models)\nMechanistic studies of intracellular calcium dynamics and excitation–contraction coupling markers in cardiomyocyte model systems\nPreclinical investigation of fibrosis-associated molecular endpoints and remodeling-associated signaling in animal models\nMetabolic pathway studies evaluating lipid and insulin-resistance endpoints in defined preclinical models\nSkeletal muscle model research assessing mitochondrial integrity and calcium homeostasis markers in cachexia-associated paradigms"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Cardiac Model Systems (Cell Survival, Remodeling Markers, and Functional Readouts)\n\nRodent studies and cardiomyocyte model experiments have evaluated hexarelin in ischemia/reperfusion paradigms and related stress models, measuring apoptosis-associated markers, oxidative stress endpoints, inflammatory mediators, and function-related readouts within controlled experimental designs[1], [2], [4], [5], [8].\n\nPreclinical myocardial injury model readouts comparing experimental groups.\nSource: PubMed\n\nAdditional animal-model work has examined myocardial fibrosis-associated endpoints and remodeling-associated molecular markers in infarction and hypertension-associated paradigms[4], [5]. Studies have also investigated intracellular calcium regulation in in vitro ischemia/reperfusion models as a candidate mechanistic contributor to observed pathway readouts in cardiomyocytes[7], [8].\n\nMechanistic schematic illustrating pathway nodes evaluated in preclinical myocardial injury models.\nSource: PubMed\n\nMetabolic Model Context (Lipid and Insulin-Resistance Endpoints)\n\nIn defined preclinical metabolic models, investigators have reported lipid-related measurements and insulin-resistance endpoints following hexarelin exposure, supporting continued mechanistic study of ghrelin-analogue signaling in metabolic pathway research[9].\n\nSkeletal Muscle and Cachexia-Associated Model Systems\n\nGrowth hormone secretagogue peptides, including hexarelin, have been studied in rat cachexia-associated paradigms to evaluate mitochondrial integrity markers, skeletal muscle calcium homeostasis, and related molecular endpoints under chemotherapy-associated stress conditions[10], [11].\n\nA. Mitochondrial DNA content relative to control\nB. Content of MCH1 and MHC2A mRNA\nC. Protein content of muscle cells relative to control\nSource: PubMed\n\nReceptor Pharmacology and Ligand Development Context\n\nAdditional literature has described the development and characterization of ghrelin receptor ligands, including potency and selectivity assessments and endocrine/extraendocrine signaling observations in preclinical research contexts[12]."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": [
      "J. Huang, Y. Li, J. Zhang, Y. Liu, and Q. Lu, “The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway,” Int. Heart. J., vol. 58, no. 2, pp. 257–263, Apr. 2017. [PubMed]",
      "Y. Mao et al., “Hexarelin treatment in male ghrelin knockout mice after myocardial infarction,” Endocrinology, vol. 154, no. 10, pp. 3847–3854, Oct. 2013. [PubMed]",
      "E. Agbo et al., “Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats,” Turk. J. Med. Sci., vol. 49, no. 3, May 2019. [PubMed]",
      "H. McDonald et al., “Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction,” Physiol. Rep., vol. 6, no. 9, p. e13699, 2018. [PubMed]",
      "X. Xu et al., “Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat,” Am. J. Physiol. Heart Circ. Physiol., vol. 303, no. 6, pp. H703-711, Sep. 2012. [PubMed]",
      "X. Zhang, L. Qu, L. Chen, and C. Chen, “Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats,” Physiol. Rep., vol. 6, no. 4, 2018. [PubMed]",
      "Y. Mao, T. Tokudome, I. Kishimoto, K. Otani, M. Miyazato, and K. Kangawa, “One dose of oral hexarelin protects chronic cardiac function after myocardial infarction,” Peptides, vol. 56, pp. 156–162, Jun. 2014. [PubMed]",
      "R. Mosa et al., “Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice,” Endocrinology, vol. 158, no. 10, pp. 3174–3187, 01 2017. [PubMed]",
      "E. Conte et al., “Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia,” J. Cachexia Sarcopenia Muscle, vol. 8, no. 3, pp. 386–404, Jun. 2017. [PubMed]"
    ]
  },
  "hgh fragment 176-191": {
    "title": "hGH Fragment 176-191 6mg",
    "url": "https://www.peptidesciences.com/fragment-176-191",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "66004-57-7",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Fragment 176-191 may be used as a research reagent in controlled studies investigating:\n\nAdipose biology & lipolysis: pathway mapping of lipid mobilization, adipose mass changes, and fat oxidation endpoints in preclinical models.\nEnergy homeostasis: mechanistic studies of weight trajectories, energy expenditure proxies, and substrate utilization signatures.\nReceptor/pathway attribution designs: evaluating candidate upstream drivers (e.g., adrenergic signaling involvement) using knockout models, pharmacologic controls, or comparator peptides.\nComparative hGH-fragment research: contrasting full-length hGH versus fragment-based inputs to distinguish lipolytic-focused effects from broader endocrine outputs in defined experimental systems.\nExploratory connective tissue models: related hGH-fragment lineages have been explored in cartilage and joint-tissue paradigms to interrogate tissue-response mechanisms in preclinical settings.\n\nThese examples describe research uses only and are not intended as medical, diagnostic, or therapeutic claims."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "1) Glucose-Related Signaling Exploration (Preclinical)\n\nEarlier animal work evaluating multiple synthetic C-terminal fragments of hGH explored glucose-related effects, and Fragment 176-191 was described as comparatively active in those experimental conditions, with reported changes occurring alongside sustained increases in plasma insulin levels in the study’s model system.[1] This line of research contributed to broader interest in how specific hGH-derived regions may interact with metabolic signaling readouts.\n\n2) Lipid Mobilization, Weight Trajectories, and β3-AR Discussion (Preclinical)\n\nObesity-model studies have reported reduced weight gain and adipose-tissue changes following chronic treatment paradigms involving the hGH lipolytic fragment lineage, with mechanistic discussions that include β3-AR pathway involvement in certain experimental contexts.[2] Additional preclinical literature has discussed β3-AR agonism and its relationship to lipid stores and fat oxidation in rodent models.[3]\n\nRelated metabolic studies of AOD9604 (a synthetic lipolytic domain in the same research lineage) reported outcomes consistent with changes in energy expenditure and weight-related endpoints under their study designs, including discussion of measured parameters such as glucose tolerance, insulin sensitivity, and IGF-1 within that framework.[4]\n\nBody weight in genetically obese mice after two weeks of treatment with a single daily dose of Fragment 176-191\nSource: Oxford Academic\n\nEffect of saline (control), Fragment 176-191, and hGH on white adipose tissue mass in obese mice over 14 days\nSource: Oxford Academic\n\n3) Safety/Tolerability Framing and Study Design Considerations\n\nBecause long-term exogenous hGH exposure is discussed clinically in association with potential adverse outcomes (e.g., insulin resistance and related metabolic issues), research has evaluated whether lipolytic fragments or domains can be studied with a more targeted profile in defined settings. A publication assessing safety and tolerability of the hexadecapeptide AOD9604 in humans is included among the cited sources.[5] Additional cited metabolic studies reported no meaningful differences versus placebo in several measured parameters under their study designs, including glucose tolerance, insulin sensitivity, and IGF-1 levels.[4]\n\nPreclinical work has also discussed selection of lipolytic fragments for studying fat oxidation and weight outcomes rather than anabolic signaling, including discussion of endpoints related to proliferation in specific experimental contexts.[6]\n\n4) Exploratory Connective Tissue / Cartilage Models (Preclinical)\n\nBeyond metabolism, related hGH-fragment research has been explored in connective tissue models. A rabbit osteoarthritis study investigated intra-articular AOD9604 (with or without hyaluronic acid) and reported findings consistent with changes in cartilage-related measures in that experimental context.[7]\n\nNote: The studies summarized above describe mechanistic or experimental endpoints in laboratory and preclinical systems and are not intended as medical claims."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Frank Ng, M.D. has been cited for contributions to research exploring growth-hormone–derived lipolytic domains and fragments (including AOD9604 and Fragment 176-191 lineage), with published work spanning lipid metabolism in obesity models and related metabolic endpoints under experimental control.\n\nThis reference is provided to acknowledge scientific contributions and does not imply endorsement or advocacy of purchase, sale, or use of this product. No affiliation or relationship is implied between the seller and this scientist. The cited work appears in the references below.",
    "citations": []
  },
  "ipamorelin": {
    "title": "Ipamorelin",
    "url": "https://www.peptidesciences.com/ipamorelin-5mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "170851-70-4",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Ipamorelin is supplied exclusively for laboratory research and is used in preclinical or in-vitro studies involving:\n\nGHSR-1a binding affinity and selectivity assays\nSecond-messenger signaling analysis, including adenylate cyclase/cAMP and calcium-dependent pathway readouts\nReceptor–ligand SAR investigations and comparator studies versus other ghrelin mimetics\nEndocrine-axis modeling in animal systems as a receptor-selective pharmacology tool compound\nExperimental models evaluating GI motility signaling, pancreatic islet signaling, and metabolic pathway endpoints in controlled preclinical contexts\n\nAll applications are restricted to non-clinical experimental contexts."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Glucocorticoid-Associated Signaling Models\n\nRodent studies have evaluated ipamorelin in experimental systems modeling glucocorticoid-associated alterations in bone, muscle, and nitrogen metabolism. Reported endpoints include osteoblastic activity markers, bone formation indices, and nitrogen-balance–related measurements under controlled laboratory conditions[2], [3], [4].\n\nPancreatic Islet and Metabolic Signaling\n\nIn isolated pancreas preparations and diabetic rodent models, ipamorelin has been investigated for effects on insulin-release–associated mechanisms, including experimental observations related to calcium-dependent signaling in pancreatic islet cells within defined study designs[5].\n\nGastrointestinal Motility Models\n\nPreclinical rodent models of postoperative ileus have been used to examine ghrelin-mimetic signaling on gastrointestinal motility. These studies assess parameters such as gastric emptying and intestinal transit distribution using radiolabeled markers to support mechanistic exploration of enteric signaling pathways[7].\n\nSource: PubMed\n\nMolecular Imaging Probe Development\n\nDue to receptor selectivity and synthetic accessibility, ipamorelin has been explored as a scaffold for peptidomimetic derivatives in molecular imaging research. In-vitro feasibility studies have evaluated radiolabeled analogues for ghrelin receptor visualization to support experimental imaging system development[8]."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above scientific material was researched, compiled, and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a Bachelor of Science degree in molecular biology. The content reflects a synthesis of publicly available preclinical literature and biochemical research intended solely for laboratory reference.",
    "scientificJournalAuthor": "David E. Beck, MD is a contributing author to peer-reviewed research examining ghrelin mimetics, including ipamorelin, within controlled experimental and clinical research environments. His academic work focuses on gastrointestinal physiology and surgical outcomes, providing foundational data relevant to mechanistic and translational research models.\n\nDavid E. Beck, MD is cited strictly for academic attribution purposes. No endorsement, affiliation, or commercial relationship is implied or expressed between this researcher and any product offering. Reference is provided solely to acknowledge published scientific contributions. David E. Beck, MD is listed in [6] under the",
    "citations": []
  },
  "cjc-1295 no dac": {
    "title": "CJC-1295 no DAC (Mod GRF 1-29)",
    "url": "https://www.peptidesciences.com/cjc-1295-dac-5mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Modified GRF (1-29) is used in laboratory research to investigate growth hormone–releasing hormone receptor (GHRHR) activation and associated intracellular signaling cascades. The peptide is applied as a tool compound for studying ligand–receptor dynamics, receptor kinetics, and second-messenger pathway modulation in controlled experimental systems.\n\nCommon experimental applications include:\n\nGHRHR binding affinity and kinetics assays\nAdenylate cyclase activation and cyclic AMP signaling studies\nStructure–activity relationship (SAR) comparisons among GRF(1-29) analogues\nEndocrine and neuroendocrine signaling investigations in cellular and animal research models\n\nThe absence of DAC modification is leveraged in experimental design to evaluate transient signaling events without long-acting affinity contributions."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical studies employing Modified GRF (1-29) have focused on receptor activation profiles, comparative potency among GRF analogues, and intracellular signaling kinetics in cell-based systems. In vivo animal studies have been used to examine endocrine-axis signaling regulation and peptide distribution characteristics using established laboratory endpoints.\n\nThese investigations contribute to foundational knowledge regarding peptide hormone signaling mechanisms and receptor pharmacology. All reported findings are derived exclusively from non-clinical experimental systems."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": [
      "L. Jetté et al., “Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog,” Endocrinology, vol. 146, no. 7, pp. 3052–3058, 2005. [PubMed]",
      "L. A. Frohman et al., “Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus,” J. Clin. Invest., vol. 78, no. 4, pp. 906–913, 1986. [PubMed]",
      "J. Izdebski et al., “New potent hGH-RH analogues with increased resistance to enzymatic degradation,” J. Pept. Sci., vol. 8, no. 7, pp. 289–296, 2002. [PubMed]"
    ]
  },
  "sermorelin": {
    "title": "Sermorelin",
    "url": "https://www.peptidesciences.com/sermorelin",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Sermorelin is supplied for research workflows that may include (non-exhaustive):\n\nGHRH receptor (GHRHR) pharmacology, including ligand binding and receptor-selectivity studies\ncAMP/PKA signaling and downstream transcriptional regulation in somatotroph-derived or engineered receptor-expression systems\nGH/IGF-axis pathway mapping in controlled preclinical models (molecular and tissue-level endpoints)\nNeuroendocrine signaling studies assessing hypothalamic peptide networks and sleep/feeding-related signaling mediators\nExploratory in-vivo model work evaluating remodeling signatures (e.g., extracellular matrix turnover, angiogenesis markers, and inflammatory mediator profiles) under controlled experimental conditions"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "GHRH-Analogue Signaling in Cardiac Remodeling Models\n\nPreclinical large-animal studies have evaluated GHRH-analogue signaling in controlled ischemic injury models. Reported experimental endpoints include remodeling-associated measures such as apoptosis-associated markers, extracellular matrix organization, and microvascular/capillary density in peri-injury tissue regions, along with inflammatory mediator profiling in myocardial tissue[1], [2].\n\nThese investigations are typically used to inform mechanistic remodeling biology experiments (e.g., ECM deposition/turnover, angiogenesis-related gene expression, and inflammatory signaling changes) in vitro and in vivo, and are presented here solely as preclinical pathway context.\n\nGHRH-Analogue Activity in Experimental Seizure Models\n\nRodent epilepsy models have been used to explore interactions between GHRH analogues and inhibitory neurotransmission systems. Published work has examined relationships between GHRH-family signaling and GABA receptor biology in brain tissue and experimental seizure paradigms, supporting mechanistic evaluation of receptor cross-talk in neurophysiological signaling networks[3].\n\nNeuroendocrine Axis Coupling in Sleep-Related Signaling\n\nSleep–wake regulatory pathways are frequently investigated through neuropeptide systems, including orexin/hypocretin networks. In fish models, studies have assessed endocrine coupling between GHRH-axis activity and orexigenic signaling, providing a basis for mechanistic experiments examining neuroendocrine coordination and peptide–receptor signaling integration under controlled laboratory conditions[4].\n\nReceptor Regulation and Desensitization Concepts in Peptide Signaling\n\nExperimental frameworks for peptide ligands frequently assess receptor regulation phenomena (e.g., desensitization, internalization, and signaling bias) using established in-vitro models and systems-level readouts. Literature discussing receptor response dynamics and tachyphylaxis/desensitization concepts is frequently used to inform receptor pharmacology experiment design and interpretation of longitudinal signaling measurements in controlled settings[5], [6].\n\nAll research summaries above reflect preclinical and laboratory observations and are provided solely to support experimental planning and mechanistic discussion."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Richard F. Walker, Ph.D, R.Ph, lead author of A better approach to management of adult-onset growth hormone insufficiency?”, received a BS in pharmacy from Rutgers University, a MS in Biochemistry from New Mexico State University and a PhD in a physiology from Rutgers University. He holds postdoctoral fellowships in neuroendocrinology and neuropharmacology at Duke University College of Medicine (Center for the Study of Aging and Human Development) and the University of California, Berkeley, respectively.\n\nRichard F. Walker, Ph.D, R.Ph is being referenced for academic attribution purposes. No endorsement, affiliation, or commercial relationship is implied or expressed between any researcher and any product offering. The purpose of citing the author is to acknowledge published scientific contributions. Richard F. Walker, Ph.D, R.Ph is listed in [5] under the",
    "citations": []
  },
  "melanotan 1": {
    "title": "Melanotan 1 (MT1) 10mg",
    "url": "https://www.peptidesciences.com/melanotan-1",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "75921-69-6",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "1. Melanocortin Receptor Pharmacology & Second-Messenger Readouts\n\nMelanotan 1 is used in cell-based receptor assays to quantify melanocortin receptor activation using second-messenger endpoints such as cAMP accumulation, PKA-linked reporter activity, and immediate early gene expression. Assays may be performed in recombinant expression systems or in cells endogenously expressing melanocortin receptors, with subtype attribution supported by antagonist controls and receptor-selective tool compounds.\n\n2. Pigment-Pathway Signaling in Melanocyte-Associated Model Systems\n\nIn melanocyte-focused experimental models, melanotan 1 is used to examine MC1R-linked signaling networks and transcriptional regulation of melanogenesis-associated enzyme pathways. Common readouts include cAMP dynamics, CREB-associated transcriptional activity, melanogenic gene expression panels, and melanosome biology endpoints measured in vitro.\n\n3. Neurobiology & Neuroinflammation-Linked Pathway Mapping (Preclinical)\n\nMelanocortin agonists are used in rodent models to interrogate CNS-relevant melanocortin signaling, including pathway panels associated with synaptic signaling, neurotrophin-linked transcriptional programs (e.g., BDNF-associated pathways), and inflammation-linked molecular endpoints. Study designs commonly incorporate receptor subtype modulation (often MC4R-focused paradigms) to support mechanistic attribution.\n\n4. Cardiovascular and Autonomic Signaling Endpoints (Preclinical)\n\nIn animal studies, melanocortin receptor agonists have been evaluated in experimental designs that quantify vascular tone, autonomic regulation, and hemodynamic parameters as mechanistic outputs. These models are used to examine receptor subtype involvement and downstream signaling mediators in controlled preclinical settings.\n\n5. Metabolic Pathway Interrogation (Preclinical)\n\nBecause melanocortin receptors participate in energy homeostasis circuits, melanotan 1 may be used as a receptor agonist probe in preclinical models evaluating downstream metabolic signaling networks. Experimental endpoints may include receptor-dependent second messenger signaling, gene expression signatures, and tissue-specific pathway activation associated with lipid handling and substrate utilization."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical research evaluating melanocortin agonists (including α-MSH analogs) includes rodent studies of blood pressure and vascular signaling endpoints, neuroinflammation-linked models, and CNS pathway mapping designs that quantify astrocyte/neuron signaling markers, neurotrophin-associated transcriptional readouts, and ex-vivo molecular correlates.[5], [12], [9]\n\nAdditional animal studies have assessed melanocortin pathway modulation in models of ischemic injury and cardiac arrest, using molecular and functional endpoints appropriate to the preclinical design.[10], [11] All references are provided strictly as mechanistic background for laboratory research contexts."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "igf-1 lr3": {
    "title": "IGF-1 LR3 1mg",
    "url": "https://www.peptidesciences.com/igf-1-lr3-1mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "946870-92-4",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "IGF-1 LR3: Research Applications",
        "content": "IGF1-LR3 is employed in laboratory research to study mitogenic and differentiative signaling mediated by IGF-1R activation. Common applications include cell-culture assays assessing proliferation kinetics, lineage differentiation, and survival signaling in connective tissue, epithelial, neural, hepatic, and renal model systems.\n\nAdditional experimental use includes investigation of metabolic signaling interactions between IGF-1R and insulin receptor pathways, particularly in studies examining glucose transport, lipid metabolism regulation, and energy-balance signaling in animal and cellular models."
      },
      {
        "heading": "IGF-1 LR3: Preclinical Research Summary",
        "content": "Preclinical investigations of IGF1-LR3 include in-vitro cell-culture studies and in-vivo animal models evaluating cellular proliferation, differentiation capacity, metabolic signaling, and tissue-maintenance markers. Reported findings include increased proliferative indices, modulation of glucose uptake pathways, and altered expression of genes involved in growth regulation.\n\nAnimal studies further explore interactions between IGF-1 signaling and aging-associated pathways, glucocorticoid-responsive signaling, and metabolic adaptation under experimental conditions. All findings are interpreted strictly within the context of laboratory research models."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Anastasios Philippou, Ph.D. focused on Experimental Physiology at the National & Kapodistrian University of Athens Medical School. He is now a National Center Manager and Assistant Professor, however his extensive studying and documented research pertaining to the effects of muscle regeneration, the role of IGF-1 in skeletal muscle physiology, the expression of IGF-1 isoforms after exercise induced muscle damage in humans, characterization of the MGF E peptide actions in vitro, and epigenetic regulation on gene expression induced by physical exercise are most impressive.\n\nDr. Anastasios Philippou, Ph.D. is being referenced as one of the leading scientists involved in the research and development of IGF1-LR3. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Anastasios Philippou, Ph.D. is listed in [7] and [8] under the",
    "citations": []
  },
  "peg mgf": {
    "title": "PEG MGF 5mg",
    "url": "https://www.peptidesciences.com/peg-mgf",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "1. Skeletal Muscle Injury Models & Immune-Cell Dynamics\n\nPreclinical studies have investigated MGF-related sequences in rodent skeletal muscle injury paradigms with endpoints that include inflammatory mediator expression, oxidative stress markers, and immune-cell recruitment/clearance kinetics within injured tissue.[1], [2] These experimental designs are used to map how IGF-1 isoform–linked signaling intersects with macrophage and neutrophil resolution programs and regeneration-associated gene expression profiles.\n\nRelated mechanistic literature characterizes exercise-associated expression patterns of IGF-1 isoforms and describes in-vitro assays evaluating MGF E-domain peptide inputs, supporting their use as pathway probes in muscle cell and tissue models.[3]\n\n2. IGF-1 Receptor Signaling as a Mechanistic Anchor\n\nIn receptor-focused studies, full-length MGF has been evaluated for IGF-1R activation under controlled, equimolar exposure conditions, providing a comparative framework against recombinant IGF-1 in signaling assays.[4] These data support the use of MGF-related sequences as experimental inputs for mapping IGF-1R-driven pathway readouts (e.g., PI3K/AKT and MAPK/ERK panels) and downstream transcriptional signatures in preclinical systems.\n\n3. Pegylated Formats for Time-Course & Distribution Studies\n\nIn time-dependent preclinical studies, short exposure windows can limit interpretation of non-pegylated peptide inputs. Pegylated formats (e.g., PEG-MGF) are therefore used in research designs that require longer circulating exposure relative to non-pegylated fragments, including single-dose time-course studies that track pathway activation and tissue distribution endpoints. Experimental discussion in the literature also notes delivery-route and localization constraints that motivate longer-persistence peptide formats for selected model designs.[5]\n\n4. Cardiac Hypoxia/Ischemia Models & Cell-Death Signaling Endpoints\n\nBioengineering and biomaterials studies have explored localized MGF peptide delivery platforms in rodent cardiac hypoxia/ischemia models, measuring apoptosis-associated endpoints and recruitment of progenitor/stem-like cell populations to injury sites.[6] Additional work has examined polymeric microstructure delivery of MGF E-domain peptides in myocardial infarction models with hemodynamic and remodeling-associated readouts in controlled preclinical settings.[7]\n\n5. Osteoblast Proliferation & Bone-Defect Models\n\nPreclinical orthopedic research has evaluated MGF E-domain peptides in rabbit bone-defect models, focusing on osteoblast proliferation markers and comparative timelines under controlled study conditions.[8] Such work is used to investigate growth-factor axis modulation in mineralization and bone remodeling biology in animal systems.\n\n6. Chondrocyte Migration & Mechanotransduction Pathways\n\nCell and tissue studies in mice have examined MGF-related peptide inputs in mechanical overload contexts, with mechanistic emphasis on RhoA/YAP-associated signaling and migration behavior of growth plate chondrocytes.[9] These models support use of MGF-derived peptides as probes for mechanotransduction-linked pathways in cartilage-relevant research.\n\n7. Periodontal Ligament Cell Models & MEK/ERK Signaling\n\nIn-vitro studies using periodontal ligament cell cultures have investigated stretch-associated osteogenic differentiation programs and matrix metalloproteinase expression (e.g., MMP-1, MMP-2), with mechanistic focus on MEK/ERK1/2 pathway activation.[10]\n\n8. CNS-Context Preclinical Literature\n\nPreclinical reports and reviews have discussed MGF-related sequences in CNS contexts, including animal models of neuron injury and ischemia, with endpoints that include neuronal survival-associated markers and functional readouts measured in vivo.[12], [11]"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical research involving MGF-related sequences includes in-vivo rodent injury paradigms (skeletal muscle and cardiac contexts), as well as in-vitro cell models (myoblasts, chondrocytes, periodontal ligament cells) used to measure pathway activity, gene-expression changes, and migration/proliferation-associated endpoints. Reported animal studies have evaluated inflammatory mediator profiles, immune-cell resolution kinetics, apoptosis-associated markers, and mechanotransduction-linked signaling readouts under controlled conditions.[1], [2], [6], [7], [9]\n\nPEG-MGF is used in experimental designs where peptide persistence and time-course control are key variables, including studies that compare signaling trajectories across exposure durations and delivery formats."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "matrixyl": {
    "title": "Matrixyl 200mg (Topical)",
    "url": "https://www.peptidesciences.com/matrixyl-200mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Matrixyl is supplied for laboratory research workflows that may include (non-exhaustive):\n\nFibroblast-based experiments evaluating ECM-associated transcriptional programs (e.g., collagen-related markers, matrix organization panels)\nStructure–activity comparisons of lipidated vs. non-lipidated peptide motifs in controlled assay systems\nAssays examining peptide–interface behavior (e.g., adsorption, aggregation, membrane-association models) that can influence apparent potency and exposure\nExploratory matrix remodeling studies measuring MMP/TIMP panels, cytokine/chemokine profiles, and ECM deposition endpoints (immunostaining/biochemical extraction)\nAnalytical method development for lipopeptides (identity confirmation, purity profiling, stability checks across buffers/containers)"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "1) Fibroblast / ECM Marker Studies (In Vitro)\n\nPublished laboratory work has evaluated palmitoylated peptide motifs such as C16-linked KTTKS sequences in fibroblast systems, using ECM-relevant endpoints (e.g., collagen-associated readouts) as part of controlled mechanistic study designs. These studies are frequently used to guide assay optimization and hypothesis generation for ECM signaling investigations in vitro [2].\n\n2) Translational Cosmetic-Science Literature (Human Skin Appearance Endpoints)\n\nCosmetic-science and dermatology-adjacent literature has discussed topical palmitoyl pentapeptide findings in photoaged skin appearance contexts (e.g., elasticity / fine lines) as observational outcomes reported in the cosmetic literature. These summaries are provided for background only and should be interpreted within the limitations of formulation differences, study design variability, and endpoint selection [3].\n\n3) Future Research Directions (Method Standardization & Advanced Models)\n\nOngoing research interest in lipidated peptide motifs like palmitoyl pentapeptides includes expanded structure–activity analyses, comparative evaluation across related lipopeptides, and improved standardization for quantifying ECM deposition and organization. Additional directions include evaluation in complex culture systems (e.g., 3D matrices and organotypic models) and deeper pathway mapping of matrix-associated transcriptional responses in controlled preclinical settings.\n\nImportant: All research summaries above reflect non-clinical observations and are provided solely to support experimental planning and mechanistic discussion."
      },
      {
        "heading": "3) Future Research Directions (Method Standardization & Advanced Models)",
        "content": "Ongoing research interest in lipidated peptide motifs like palmitoyl pentapeptides includes expanded structure–activity analyses, comparative evaluation across related lipopeptides, and improved standardization for quantifying ECM deposition and organization. Additional directions include evaluation in complex culture systems (e.g., 3D matrices and organotypic models) and deeper pathway mapping of matrix-associated transcriptional responses in controlled preclinical settings.\nImportant: All research summaries above reflect non-clinical observations and are provided solely to support experimental planning and mechanistic discussion."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "snap-8": {
    "title": "SNAP-8 200mg (Topical)",
    "url": "https://www.peptidesciences.com/snap-8",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "SNAP-8 is used in research environments to investigate mechanisms underlying regulated exocytosis and SNARE-dependent vesicle fusion. Common experimental applications include:\n\nSNARE assembly / disassembly studies (protein–protein interaction and complex stability assays)\nVesicle fusion kinetics assays (fluorescence dequenching, lipid-mixing, content-mixing readouts)\nCell-based exocytosis modulation models (neurosecretory or endocrine-derived cell systems)\nCompetitive peptide-interference designs to probe domain-specific contributions in fusion machinery\n\nPeptide-based competition approaches are widely used to map SNARE interface requirements and define which interaction surfaces are rate-limiting for complex formation and membrane fusion. [3]"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical SNARE research frameworks frequently combine purified-protein reconstitution assays and cell-based secretion models to quantify how perturbations in SNARE interactions influence membrane fusion outcomes. Review literature describes SNARE/SM proteins as central, complementary components of the fusion machinery, with SNARE zippering providing force generation and SM proteins supporting productive fusogenic action. [2]\n\nIn RUO experimental designs, SNAP-8 may be used as a peptide-interference tool to support:\n\nstructure–function mapping of SNARE interface contributions,\ncomparative studies across SNARE-derived peptide motifs, and\nhypothesis generation for how partial SNARE disruption modulates regulated exocytosis phenotypes.\n\nAll findings described in published SNARE-mechanism literature are context-dependent and model-dependent; SNAP-8 is supplied strictly for controlled laboratory research."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "tb-500": {
    "title": "TB-500 (Thymosin Beta-4) (43aa)",
    "url": "https://www.peptidesciences.com/tb-500-thymosin-beta-4-2mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "77591-33-4",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "TB-500 (Thymosin Beta-4): Research Applications",
        "content": "TB-500 is used in research workflows to probe cytoskeleton-dependent phenotypes and signaling readouts in controlled laboratory settings. Common experimental contexts include:\n\nActin dynamics assays (G-actin sequestration, F-actin polymerization state, stress fiber organization)\nCell migration and adhesion phenotyping (scratch assays, transwell migration, focal adhesion remodeling)\nEndothelial biology and angiogenic signaling readouts (tube formation assays, VEGF-axis transcriptional endpoints)\nOxidative stress and innate signaling modules in cell systems (e.g., TLR-adaptor pathway readouts under defined stressors)\nNeural cell support and remodeling paradigms (glial lineage responses, neurite-associated morphology in preclinical models)\nHost-pathogen and adjunct biology paradigms in animal infection models (quantitative microbiology endpoints such as CFUs and inflammatory mediator readouts)"
      },
      {
        "heading": "TB-500 (Thymosin Beta-4): Preclinical Research Summary",
        "content": "1. Neural Tissue Models & Support-Cell Biology\n\nIn rat spinal cord injury models, thymosin β4 has been evaluated using histological, vascular, and functional/behavioral readouts, with study designs interrogating cellular responses in injured tissue and associated remodeling endpoints[1]. Review literature further discusses thymosin β4 within regenerative biology frameworks for neurological injury models, emphasizing mechanistic hypotheses and preclinical evidence streams rather than clinical translation[2].\n\nIn spinal cord–derived neural stem/progenitor cell models, thymosin beta 4 has been studied under oxidative-stress conditions with pathway-level readouts mapped to the TLR4/MyD88 axis, including changes in oxidative mediator levels and viability-associated measures in vitro[3].\n\n2. Vascular Biology, Angiogenic Signaling, and ECM Remodeling\n\nThymosin β4 has been reported as a modulator of angiogenic programs in preclinical systems, with literature describing relationships to VEGF-associated signaling and vascular development/remodeling endpoints[4]. Proposed mechanistic contexts include cell migration, ECM remodeling, and endothelial/pericyte-associated processes, evaluated using model-specific molecular and histologic readouts.\n\n3. Hair Follicle and Skin-Appendage Model Readouts\n\nMouse studies involving altered thymosin beta 4 expression have reported differences in hair follicle-associated phenotypes, and thymosin beta 4 has been evaluated for effects on stem-cell migration and differentiation readouts in these experimental contexts[5].\n\n4. Infection Models and Adjunct Biology with Antibiotics\n\nIn a mouse model of Pseudomonas aeruginosa-induced keratitis, thymosin beta 4 has been studied in combination with ciprofloxacin, with outcome measures including bacterial colony forming units (CFUs), neutrophil infiltration, and oxidative/inflammatory mediator readouts after defined treatment windows[6].\n\nA. Number of colony forming units (CFUs) of bacteria after 5 days of treatment. Note that none are detectable when ciprofloxicin is combined with TB-4.\nB. Shows number of neutrophils in the corneas of treated mice, an indication of inflammation.\nC. Measure of reactive oxygen species in corneas of mice after 5 days of treatment.\nD. Nitrate levels from corneal lysates.\nSource: PubMed\n\n5. Cardiovascular and Renal Model Systems\n\nLiterature has examined thymosin β4 and related pathway components in cardiovascular and renal model contexts, including angiogenic remodeling, endothelial migration phenotypes, inflammatory mediator profiles, and fibrosis-associated molecular markers, depending on the model and experimental endpoint selection[7]. Injectable hydrogel formulations incorporating collagen and thymosin β4 have been evaluated in myocardial ischemia-related experimental paradigms with readouts such as angiogenesis-associated markers and epicardial cell migration endpoints in preclinical designs[8].\n\n6. Neurodegeneration-Adjacent Cellular Models and Proteostasis\n\nIn HT22 cell experiments using prion peptide (PrP 106–126) exposure, thymosin beta 4 has been studied for effects on autophagy-associated pathways and signaling readouts under defined in vitro conditions[9].\n\n7. Summary\n\nAcross preclinical literature, TB-4/TB-500-related experimental work is commonly positioned around cytoskeletal regulation (actin monomer sequestration), migration-associated phenotypes, stress-response signaling, and tissue remodeling endpoints. Interpretation of outcomes is model-dependent and should be evaluated within each study’s dosing regimen, route, timecourse, and assay selection. This material is presented for scientific context and does not imply suitability for any non-laboratory purpose."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Allan L. Goldstein, MD, Allan L. Goldstein is professor and Catharine B. & William McCormick Chair of the department of Biochemistry and Molecular Biology at The George Washington University School of Medicine and Health Sciences, where he has served since 1978. Thymosins were discovered in the mid 1960’s, when Allan Goldstein from the Laboratory of Abraham White at the Albert Einstein College of Medicine in New York studied the role of the thymus in development of the vertebrate immune system. He is a world-renowned authority on the thymus gland and the workings of the immune system, and co-discoverer of the thymosins. Dr. Goldstein is the author of over 400 scientific articles in professional journals, the inventor on more than 15 U.S. Patents, and the editor of several books in the fields of biochemistry, biomedicine, immunology and neuro-science. He is on the editorial boards of numerous scientific and medical journals and has been a consultant to many re-search organizations in industry and government; co-founder of The Institute for Advanced Studies in Aging and Geriatric Medicine, a non-profit research and educational institute; a member of the Board of Trustees of the Albert Sabin Vaccine Institute; and serves as the Chairman of the Board of RegeneRx Biopharmaceuticals. Dr. Goldstein received his B.S. from Wagner College in 1959 and his M.S. and Ph.D. from Rutgers University in 1964. He served as a faculty member of the Albert Einstein College of Medicine from 1964 to",
    "citations": [
      "P. Cheng, F. Kuang, H. Zhang, G. Ju, and J. Wang, “Beneficial effects of thymosin β4 on spinal cord injury in the rat,” Neuropharmacology, vol. 85, pp. 408–416, Oct. 2014. [PubMed]",
      "M. Chopp and Z. G. Zhang, “Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases,” Expert Opin. Biol. Ther., vol. 15 Suppl 1, pp. S9-12, 2015. [PubMed]",
      "H. Li, Y. Wang, X. Hu, B. Ma, and H. Zhang, “Thymosin beta 4 attenuates oxidative stress-induced injury of spinal cord-derived neural stem/progenitor cells through the TLR4/MyD88 pathway,” Gene, vol. 707, pp. 136–142, May 2019. [PubMed]",
      "K. N. Dubé and N. Smart, “Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease,” Expert Opin. Biol. Ther., vol. 18, no. sup1, pp. 131–139, 2018. [PubMed]",
      "D. Philp, S. St-Surin, H.-J. Cha, H.-S. Moon, H. K. Kleinman, and M. Elkin, “Thymosin beta 4 induces hair growth via stem cell migration and differentiation,” Ann. N. Y. Acad. Sci., vol. 1112, pp. 95–103, Sep. 2007. [PubMed]",
      "T. W. Carion et al., “Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis,” Cells, vol. 7, no. 10, Sep. 2018. [PubMed]",
      "K. M. Kassem, S. Vaid, H. Peng, S. Sarkar, and N.-E. Rhaleb, “Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?,” Can. J. Physiol. Pharmacol., pp. 1–11, Mar. 2019. [PubMed]",
      "A. D. Shaghiera, P. Widiyanti, and H. Yusuf, “Synthesis and Characterization of Injectable Hydrogels with Varying Collagen–Chitosan–Thymosin β4 Composition for Myocardial Infarction Therapy,” J. Funct. Biomater., vol. 9, no. 2, Mar. 2018. [PubMed]",
      "H.-J. Han, S. Kim, and J. Kwon, “Thymosin beta 4-Induced Autophagy Increases Cholinergic Signaling in PrP (106-126)-Treated HT22 Cells,” Neurotox. Res., Dec. 2018. [PubMed]",
      "Song, Ran & Choi, Hyun & Yang, Hyung-In & Yoo, Myung & Park, Yong-Beom & Kim, Kyoung. (2012). Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy. Clinical rheumatology. 31. 1253-8. 10.1007/s10067-012-2011-7. [Research Gate]",
      "Philp, D., et al. “Thymosin β4 Promotes Angiogenesis, Wound Healing, and Hair Follicle Development.” Mechanisms of Ageing and Development, vol. 125, no. 2, Feb. 2004, pp. 113–115, 10.1016/j.mad.2003.11.005. [PubMed]"
    ]
  },
  "peptide capsules": {
    "title": "Peptide Capsules",
    "url": "https://www.peptidesciences.com/capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "peptides": {
    "title": "Peptides",
    "url": "https://www.peptidesciences.com/peptides-all",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "melanotan peptides": {
    "title": "Melanotan Peptides",
    "url": "https://www.peptidesciences.com/melanotan-peptides",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "privacy policy": {
    "title": "Privacy Policy",
    "url": "https://www.peptidesciences.com/privacy",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "refunds & returns": {
    "title": "Refunds & Returns",
    "url": "https://www.peptidesciences.com/refunds",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "accessibility statement for peptide sciences": {
    "title": "Accessibility Statement for Peptide Sciences",
    "url": "https://www.peptidesciences.com/accessibility-statement",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "reward program terms": {
    "title": "Reward Program Terms",
    "url": "https://www.peptidesciences.com/loyalty-program-terms",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "5-amino-1mq": {
    "title": "5-Amino-1MQ 50mg (60 Capsules)",
    "url": "https://www.peptidesciences.com/5-amino-1mq-60-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "42464-96-0",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "5-Amino-1MQ: Research Applications",
        "content": "In the scientific literature, 5-Amino-1MQ has been utilized in experimental research designs to investigate NNMT-associated metabolic pathways and downstream cellular responses in non-clinical models.\n\nNNMT-mediated nicotinamide methylation pathways\nNAD+-associated metabolic regulation\nCellular energy utilization and futile cycle dynamics\nGLUT4-associated glucose transport signaling (experimental context)\nStem cell–related transcriptional markers in model systems\n\nAll applications remain restricted to controlled laboratory research environments."
      },
      {
        "heading": "5-Amino-1MQ: Preclinical Research Summary",
        "content": "Preclinical publications describe 5-Amino-1MQ-associated observations in rodent and cellular models involving metabolic flux, adipose and muscle tissue signaling markers, and NNMT-regulated transcriptional profiles.\n\nAdditional experimental studies have examined NNMT expression in relation to cellular proliferation, stem cell activation markers, and cancer-related metabolic phenotypes. These findings are limited strictly to experimental model systems and do not imply clinical relevance."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Barbara B. Kahn is chief of the Division of Endocrinology, Diabetes, and Metabolism at Beth Israel Deaconess Medical Center (BIDMC) and the George Richards Minot Professor of Medicine at Harvard Medical School. She is an internationally recognized scientist in the area of obesity and type 2 diabetes, and her lab investigates the molecular mechanisms underlying these conditions, including the regulation of insulin action, food intake, and energy balance. Kahn received BA and MD degrees from Stanford University and an MS from the University of California at Berkeley. After completing internal medicine training at the UC Davis Medical Center, she began her career in molecular research at the National Institutes of Health. Kahn has received numerous awards including the Outstanding Scientific Achievement Award from the American Diabetes Association; the H. C. Jacobaeus Prize from the Novo Nordisk Foundation and the Karolinska Institutet; the Charles H. Best Lectureship and Award from the University of Toronto; and the Gerald D. Aurbach Award Lecture from the Endocrine Society. Kahn was elected to the Institute of Medicine of the National Academies and is a fellow of the American Association for the Advancement of Science.\n\nBarbara B. Kahn is being referenced as one of the leading scientists involved in the research and development of 5-Amino-1MQ. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affil",
    "citations": []
  },
  "bpc 157": {
    "title": "BPC 157 500mcg (60 Capsules)",
    "url": "https://www.peptidesciences.com/bpc-157-60-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "BPC-157: Research",
        "content": "BPC-157: Stability and Bioavailability\n\nOne of the major factors that interests researchers in BPC-157 is its stability in the GI tract. Most medications need to be contained in pills or coated in various ways to allow them to survive the harsh environment of the stomach. This is not the case with BPC-157. While the peptide can be placed in capsules for easy research administration, such precautions are not necessary because the peptide is exceptionally stable in the GI tract. As a result of this stability, BPC-157 can be administered in a variety of ways including dissolving it in water or mixing it with food. This flexibility makes BPC-157 easy to work with in animal models.\n\nBPC-157: Muscle and Tendon Healing\n\nOne of the earliest studies on BPC-157 looked at tendon and ligament healing in rat models. Tendons and ligaments, especially ligaments, are notoriously slow to heal due to their poor blood supply and relative lack of stem cells. Tendons and ligaments not only heal slowly as a result of these factors, they often heal in a manner that leaves them weaker than they were prior to injury. Low stem cell activity and limited blood supply both lead to decreased levels of remodeling following initial injury repair. Remodeling in wound healing is necessary to provide structural integrity and to align maximum tissue strength with highest stress loads. Limitations in this step mean weaker tissue strength and higher levels of scarring. When BPC-157 is administered to rats following experimental tendon injury, they not only show faster rates of initial healing, but also display higher levels of remodeling and subsequent improvements in tendon strength as a result[1]. These findings have led to high levels of interest in the role that BPC-157 might play in promoting tendon and ligament injury[2].\n\nWhat has been especially interesting about animal trials of BPC-157 in muscle and tendon injury is the improved functional outcomes that have been observed. Researchers have seen improved clinical outcomes in rats administered BPC-157. These improved outcomes include factors like increased muscle motor function, decreased levels of joint contracture, and better preservation of walking patterns when compared to controls. These findings appear to directly correlate with the ability of BPC-157 to increase tendon outgrowth and cell survival, which leads to improvements in the microscopic structure of tendons and ligaments that improves functional outcomes[3]. In other words, the ability of BPC-157 to promote tissue remodeling following healing directly translates into measurable improvements in function.\n\nThe major way in which BPC-157 improves muscle, tendon, and ligament healing is through an increase in the expression of growth hormone receptors on fibroblasts. Several growth factors are crucial in the healing process. Notable among them are insulin-like growth factor, platelet-derived growth factor, transforming growth factor-β, basic fibroblast growth factor, and vascular endothelial growth factor. BPC-157 appears to modulate levels to all of these growth factors to achieve optimal outcomes in healing, but its major impact appears to be on natural growth hormone signaling. Research shows that growth hormone can enhance tissue regeneration and cell proliferation, particularly in skeletal muscle and bone. Growth hormone also promotes collagen secretion. Its effects are mediated either directly through the activation of tyrosine kinase or indirectly via the induction of insulin-like growth factor. These effects are controlled by binding to the growth hormone receptor on the cell membrane and subsequent changes in DNA expression patterns. BPC 157 has been shown to increase growth hormone receptor expression in tendon fibroblasts, helping to concentrate the benefits of growth hormone precisely where they are needed most. This, of course, is superior to systemic growth hormone administration, which has also been shown to enhance wound healing. "
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Predrag Sikiric, Ph.D. is a professor at the Department of Pharmacology, School of Medicine, University of Zagreb, Croatia. He received his Ph.D. degree at the Medical Faculty, University of Zagreb. He is an honorary doctor of the University of Pécs since 16 November 2017. His research interests include cytoprotection, peptides, gastrointestinal and blood vessel lesions, wounds, and the brain-gut axis. His studies are internationally well-known and accepted.\n\nPredrag Sikiric, Ph.D., is referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Predrag Sikiric, Ph.D., is listed in [6] and [11] under the",
    "citations": []
  },
  "dihexa": {
    "title": "Dihexa (5mg x 60 Capsules = 300mg)",
    "url": "https://www.peptidesciences.com/dihexa-5mg-60-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "1401708-83-5",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Dihexa: Research Applications",
        "content": "In the scientific literature, Dihexa has been referenced in non-clinical research settings involving cellular assays, ex-vivo preparations, and animal model studies. These references describe experimental contexts in which molecular interactions, signaling components, and pathway-associated markers were observed and recorded.\n\nResearch contexts reported include examination of:\n\nHGF/c-Met receptor-associated signaling components\nAngiotensin IV (AT4)-related molecular interactions\nInsulin-regulated aminopeptidase (IRAP)-associated biology\nIntracellular signaling cascade components\nExtracellular matrix–associated molecular markers\n\nAll reported applications remain confined to descriptive investigation within controlled laboratory research environments."
      },
      {
        "heading": "Dihexa: Preclinical Research Summary",
        "content": "Preclinical studies referenced in the scientific literature describe observations involving Dihexa and related angiotensin IV analogues in cellular and non-clinical animal models. Reported observations include measurement of signaling-associated proteins, pathway-linked molecular markers, and morphology-related features documented under defined experimental conditions.\n\nSeparate rodent studies have reported experimental observations involving Dihexa within study-specific protocols, including histological and biochemical assessments. All reported findings are restricted to the experimental systems employed and do not extend beyond laboratory research contexts."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "John Wright, Ph.D. is a professor of psychology who teaches courses including Research Design, Teaching Psychology, and Physiological Psychology. His research interests include Alzheimer’s disease, Parkinson’s disease, stroke-related motor dysfunctions, and the neurochemistry of memory consolidation. Dr. Wright has published extensively on these topics, with notable contributions addressing the role of matrix metalloproteinases and cell adhesion molecules in learning and addiction, the neurochemical basis of nicotine-induced behaviors, and the development of multi-target-directed ligands for the treatment of Alzheimer’s disease. He has also authored invited chapters and reviews on the brain renin-angiotensin system and therapeutic approaches for central nervous system disorders..\n\nDr. Wright. is referenced as one of the leading scientists involved in the research and development of Dihexa. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr.Wright is listed in [3] under the",
    "citations": []
  },
  "epitalon": {
    "title": "Epitalon 1mg (60 capsules) (Telomere Length)",
    "url": "https://www.peptidesciences.com/epitalon-3mg-60-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "307297-39-8",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Epitalon: Research Applications",
        "content": "Epitalon is employed in experimental research to examine peptide-mediated regulation of gene expression, telomere-associated processes, circadian gene signaling, and cellular differentiation pathways. Its physicochemical profile makes it suitable for studies involving formulation modeling, cellular uptake, and mechanistic evaluation in preclinical experimental models.\n\nEpigenetic regulation and chromatin accessibility studies\nTelomerase-associated pathway investigations\nCircadian rhythm gene expression research\nNeuronal and fibroblast differentiation models\nPeptide–genome interaction analysis"
      },
      {
        "heading": "Epitalon: Preclinical Research Summary",
        "content": "In-vitro and in-vivo animal studies have evaluated Epitalon in the context of telomere maintenance, circadian signaling, neuronal marker expression, extracellular matrix regulation, and gene transcription control. Rodent and non-human primate models have been utilized to explore its influence on peptide-driven regulatory networks at the cellular and tissue levels.\n\nAdditional investigations have examined Epitalon within experimental oncology models, focusing on transcriptional regulation, cell proliferation signaling, and genomic stability pathways. All observations remain confined to preclinical exploratory research frameworks."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "ghk-cu": {
    "title": "GHK-Cu (2mg x 60 Capsules) (Copper Tripeptide)",
    "url": "https://www.peptidesciences.com/ghk-cu-copper-tripeptide",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "49557-75-7",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "GHK-Cu: Research Applications",
        "content": "GHK-Cu is used as a research reagent in mechanistic studies of copper homeostasis and copper-sensitive signaling. Typical preclinical applications include cell-based assays examining oxidative stress response (e.g., ROS handling and antioxidant pathway activation), transcriptional profiling of metal-responsive and inflammatory gene networks, and extracellular matrix (ECM) remodeling readouts (e.g., collagen-associated transcript/protein markers, elastin-associated markers, and matrix metalloproteinase regulation) in fibroblast, epithelial, and endothelial model systems.\n\nIn vivo animal studies and ex vivo tissue models employ GHK-Cu to investigate injury-responsive programs such as angiogenesis-associated signaling, immune cell recruitment phenotypes, and remodeling-associated gene expression patterns. In neurobiology-focused preclinical research, GHK-Cu is additionally evaluated as a tool compound for probing the relationship between copper availability and protein aggregation/clearance pathways in controlled experimental contexts."
      },
      {
        "heading": "GHK-Cu: Preclinical Research Summary",
        "content": "Preclinical studies of GHK-Cu include in vitro experiments across fibroblast, endothelial, epithelial, and immune-relevant cell models, as well as in vivo animal studies in which injury-responsive endpoints are quantified. Reported findings commonly include changes in ECM-associated transcription/protein markers (e.g., collagen/elastin-related signals), modulation of inflammatory cytokine signaling (including pathways involving TNF-α and IL-6), and altered oxidative stress parameters consistent with engagement of antioxidant response pathways.\n\nAdditional animal-model literature describes changes in angiogenesis-associated signaling and remodeling markers in tissue injury paradigms. Separately, transcriptomic analyses described in the cited literature report that GHK-Cu exposure can shift expression of a substantial subset of measured genes in vitro, supporting its use as a laboratory tool for probing copper-linked transcriptional regulation and downstream pathway enrichment patterns. Research on metal-ion involvement in amyloidogenic protein chemistry has also examined GHK-Cu as a copper-sequestering variable in controlled aggregation and toxicity assay designs.\n\nAll summaries above refer only to controlled preclinical investigations and are provided to support experimental design considerations, mechanistic hypothesis generation, and pathway mapping in laboratory settings."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Loren Pickart, Ph.D. has released 109 publications and is developing patents and analyzing GHK's effects on human gene expression of 4,192 genes. In addition to GHK's published potential uses on skin inflammation, metastatic cancer and COPD, it appears to have beneficial effects on other tissue systems such as the nervous system, gastrointestinal system, and mitochondrial system. His brief but detailed autobiography dives into the motivations and background behind his dedicating to skin, anti-aging, and life-long training.\n\nLoren Pickart, Ph.D is being referenced as one of the leading scientists involved in the research and development of GHK-Cu. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Loren Pickart, Ph.D is listed in [3] [4] and [8] under the",
    "citations": []
  },
  "gut inflammation": {
    "title": "Gut Inflammation (60 Capsules) (Stable BPC-157 Arginate, KPV, Larazotide)",
    "url": "https://www.peptidesciences.com/gut-inflammation-60-capsules-stable-bpc-157-arginate-kpv-private",
    "whatIs": "What is KPV?\nWhat is Larazotide?\nSynergy Between BPC-157, Larazotide, and KPV\nReferenced Citations \nSynergy for Gut Inflammation and Gut Repair: BPC 157, Larazotide, and KPV\n\nBPC 157, Larazotide, and KPV are all peptides with important functions in the gastrointestinal tract. Their properties overlap, but are different enough that using them together may provide synergistic benefits in the setting on intestinal inflammation. Larazotide has been specifically tested in the setting of celiac disease, but a combination of the three has never been studied in either animal or human trials. The next step into",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "67727-97-3",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "longevity, performance & obesity research": {
    "title": "Longevity, Performance & Obesity Research (60 Capsules)",
    "url": "https://www.peptidesciences.com/longevity-performance-obesity-research-60-capsules-5-amino-1mq-nmn-jbsnf",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Investigation of NAD salvage pathway flux and NAD-dependent enzyme activity\nNNMT inhibition studies including enzyme kinetics and target engagement assays\nAnalysis of methyl-donor utilization (SAM/SAH ratios) and one-carbon metabolism\nQuantification of glucose transporter expression (e.g., GLUT4) in cellular and animal models\nTissue-specific metabolomics profiling of nicotinamide-derived metabolites"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical animal studies examining NNMT inhibition frequently report changes in adipose tissue morphology, metabolite distribution, and glucose handling metrics under controlled dietary conditions. These outcomes are evaluated using biochemical assays, histological analysis, and targeted gene expression profiling.\n\nNMN-based studies in rodent models often quantify NAD pool size, mitochondrial enzyme activity, and transcriptional markers associated with metabolic adaptation. These measurements are used to map pathway-level responses to altered NAD availability.\n\nCellular Turnover and Genome Maintenance (Preclinical Context)\n\nSome experimental systems additionally assess cellular turnover, progenitor cell abundance, and DNA damage response signaling. These analyses focus on measurable endpoints such as cell cycle markers, lineage-specific transcription factors, and DNA repair pathway activation states, without reference to organism-level functional outcomes.\n\nSource: ResearchGate"
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Barbara B. Kahn is chief of the Division of Endocrinology, Diabetes, and Metabolism at Beth Israel Deaconess Medical Center (BIDMC) and the George Richards Minot Professor of Medicine at Harvard Medical School. She is an internationally recognized scientist in the area of obesity and type 2 diabetes, and her lab investigates the molecular mechanisms underlying these conditions, including the regulation of insulin action, food intake, and energy balance. Kahn received BA and MD degrees from Stanford University and an MS from the University of California at Berkeley. After completing internal medicine training at the UC Davis Medical Center, she began her career in molecular research at the National Institutes of Health. Kahn has received numerous awards including the Outstanding Scientific Achievement Award from the American Diabetes Association; the H. C. Jacobaeus Prize from the Novo Nordisk Foundation and the Karolinska Institutet; the Charles H. Best Lectureship and Award from the University of Toronto; and the Gerald D. Aurbach Award Lecture from the Endocrine Society. Kahn was elected to the Institute of Medicine of the National Academies and is a fellow of the American Association for the Advancement of Science.\n\nBarbara B. Kahn is being referenced as one of the leading scientists involved in the research and development of NMN, 5-Amino-1MQ, and JBSNF-000088. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any re",
    "citations": []
  },
  "methylene blue": {
    "title": "Methylene Blue (10mg x 60 Capsules = 600mg)",
    "url": "https://www.peptidesciences.com/methylene-blue-10mg-60-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "61-73-4",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Methylene Blue: Research Applications",
        "content": "In laboratory research environments, methylene blue has been utilized across a range of experimental platforms including cell culture systems, isolated mitochondrial preparations, and animal models designed to examine bioenergetic and redox-related processes.\n\nExperimental modeling of mitochondrial electron transport dynamics\nInvestigation of oxidative and nitrosative stress pathways\nAnalysis of redox-sensitive signaling cascades\nPhotodynamic research models involving light-activated redox reactions\nUse as a histological and cellular staining reagent"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical publications report observations of methylene blue in in-vitro systems and animal models examining mitochondrial efficiency, oxidative stress modulation, cellular survival markers, and photodynamic responses.\n\nThese studies describe correlations between redox modulation and cellular energy parameters without extending conclusions beyond experimental research conditions. No clinical or translational claims are implied."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Kan Cao Ph.D. received her B.Sc. degree in Biology from Nanjing University China in 1997 and her Ph.D. in Biology from Johns Hopkins University in 2005. She completed her postdoctoral fellowship in genomics at the National Institutes of Health between 2005 and 2010. She is a professor of Cell Biology and Molecular Genetics at the University of Maryland College Park. Dr. Cao was named the New Scholar in Aging by the Ellison Medical Foundation in 2011, received the Board of Visitors junior faculty award from the University of Maryland in 2013, and was the finalist for the Invention of the Year by the University of Maryland in 2016. In 2018, she received the Norma M. Allewell Prize in Entrepreneurship from the University of Maryland. Her research topics include Hutchinson Gilford progeria, telomere and cellular senescence, alternative splicing, and human aging.\n\nDr. Cao. is referenced as one of the leading scientists involved in the research and development of Methylene Blue. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr.Cao is listed in [10] under the",
    "citations": []
  },
  "nmn": {
    "title": "NMN 500mg (60 Capsules)",
    "url": "https://www.peptidesciences.com/nmn-60-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "NMN Research",
        "content": "Biochemical Role of NMN\n\nNMN functions as a key intermediate in NAD⁺ biosynthesis via the nicotinamide salvage and Preiss–Handler pathways. In experimental systems, NMN is incorporated into NAD⁺ pools through enzymatic conversion mediated by nicotinamide phosphoribosyltransferase (NAMPT) and NMN adenylyltransferases (NMNATs). These pathways are routinely studied to quantify NAD⁺ turnover, metabolic flux, and cofactor availability.\n\nDe novo synthesis from tryptophan\nNicotinamide salvage pathway\nPreiss–Handler pathway\n\nWithin these pathways, NMN serves as a measurable node linking precursor availability to NAD⁺ production, enabling controlled interrogation of NAD⁺-dependent cellular processes.\n\nNAD⁺-Dependent Enzyme Systems\n\nIn preclinical models, NMN availability is evaluated in relation to NAD⁺-dependent enzyme families including sirtuins and poly(ADP-ribose) polymerases (PARPs). These enzymes are examined using biochemical assays to assess post-translational modification activity, chromatin-associated signaling, and DNA damage response pathways.\n\nPARP activity is commonly quantified through ADP-ribosylation assays, while sirtuin-associated pathways are evaluated using deacetylation markers and downstream transcriptional readouts. NMN is used in experimental designs to modulate intracellular NAD⁺ availability and characterize enzyme-specific pathway responses.\n\nMitochondrial and Metabolic Pathway Context\n\nNAD⁺ functions as a central redox cofactor in mitochondrial oxidative metabolism. In animal and cellular studies, NMN supplementation is used to examine mitochondrial respiration parameters, redox balance, and oxidative phosphorylation efficiency. These measurements are conducted using respirometry, enzymatic flux analysis, and mitochondrial protein expression profiling.\n\nTransport and Cellular Uptake (Preclinical)\n\nPreclinical studies in rodents have identified transporter-mediated uptake mechanisms for NMN in intestinal and tissue-specific models. These systems are used to study NMN distribution kinetics, intracellular conversion rates, and tissue-specific NAD⁺ pool dynamics using labeled tracers and mass spectrometry–based quantification.\n\nResearch Scope Summary\n\nAcross published in-vitro and animal studies, NMN is utilized as a research reagent to investigate NAD⁺ metabolism, enzymatic cofactor utilization, mitochondrial redox balance, and genome maintenance signaling. Observed effects are interpreted exclusively through molecular, biochemical, and pathway-level endpoints without extrapolation beyond controlled experimental systems."
      },
      {
        "heading": "Research Scope Summary",
        "content": "Across published in-vitro and animal studies, NMN is utilized as a research reagent to investigate NAD⁺ metabolism, enzymatic cofactor utilization, mitochondrial redox balance, and genome maintenance signaling. Observed effects are interpreted exclusively through molecular, biochemical, and pathway-level endpoints without extrapolation beyond controlled experimental systems."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Gláucia Maria Pastore graduated in Biological Sciences from the Pontifical Catholic University of Campinas and earned a Master’s and PhD in Food Science from Unicamp, where she also studied Enzyme Technology in Japan and completed postdoctoral work at Ohio State University. Since 2006, she has taught Food Biochemistry at Unicamp, overseeing the Food Science Program and teaching both undergraduate and graduate courses. Her research includes 134 articles, 239 conference proceedings, six patents, and extensive leadership in food biochemistry research.\n\nDr. Gláucia Maria Pastore is referenced solely to acknowledge contributions to the scientific literature related to NMN and NAD⁺ metabolism. No endorsement, affiliation, or implied relationship with any commercial product is stated or suggested.",
    "citations": []
  },
  "os-01": {
    "title": "OS-01 (100mg x 30 Capsules)",
    "url": "https://www.peptidesciences.com/os-01-100mg-30-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "OS-01: Research Applications",
        "content": "AMPK-regulated metabolic signaling studies\nMitochondrial biogenesis and mitophagy analysis\nOxidative stress and redox homeostasis modeling\nAutophagy-linked transcriptional regulation\nEnergy-sensing pathway interrogation in cellular and animal models\n\nAll applications are restricted to non-clinical laboratory research environments."
      },
      {
        "heading": "OS-01: Preclinical Research Summary",
        "content": "Preclinical investigations utilizing cellular assays and rodent models have examined OS-01-mediated AMPK activation in the context of mitochondrial metabolism, glucose handling, lipid utilization, and oxidative stress regulation. These studies document alterations in mitochondrial enzyme expression, respiratory capacity, and autophagic flux.\n\nAdditional experimental work has evaluated AMPK-dependent signaling in tissues characterized by high energetic demand, including skeletal muscle, renal epithelium, cardiac tissue, and neuronal systems.\n\nAMPK-mediated regulation of mitochondrial and metabolic pathways\nSource: Frontiers"
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Vaskar Das, PhD., is currently working on National Institutes of Health-funded pain research as a co-investigator. His research has focused on new non-opioid treatments for acute and chronic pain by following the key energy sensor AMPK (adenosine mono-phosphate activated kinase) and the pain-relieving effect of the ketamine metabolite (2R,6R)-hydroxynorketamine.\n\nVaskar Das, Ph.D., is referenced as one of the leading scientists involved in the research and development of OS-01. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Vaskar Das, Ph.D., is listed in [1] and [9] under the",
    "citations": []
  },
  "repair and recovery": {
    "title": "Repair and Recovery (60 Capsules) (Stable BPC-157 Arginate, Thymosin Beta-4 Fragment)",
    "url": "https://www.peptidesciences.com/repair-and-recovery-60-capsules-stable-bpc-157-arignate-thymosin-beta-4-fragment",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Actin dynamics and cytoskeletal turnover assays (e.g., actin polymerization state markers; motility indices)\nCell migration pathway studies in endothelial and fibroblast models (e.g., wound-scratch assays, transwell migration; signaling phosphorylation panels)\nExtracellular matrix organization and remodeling readouts (e.g., collagen-related transcriptional panels; matrix deposition quantification; histology in animal models)\nNitric oxide–associated signaling interrogation (e.g., NOS-linked markers, downstream pathway activation states)\nACE–substrate enzymology and peptide hydrolysis studies for Ac-SDKP (biochemical kinetics; structural binding context)\nSalt form and stability comparisons (arginate vs acetate) using forced-degradation and simulated matrix exposure protocols"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Published animal and cellular studies involving BPC-157 commonly report pathway-level changes quantified by (i) connective tissue cell migration indices, (ii) fibroblast-associated transcriptional programs, (iii) extracellular matrix composition markers, and (iv) vascular-associated signaling panels. Experimental designs typically rely on histological scoring, immunohistochemistry, gene/protein expression profiling, and biochemical marker quantification.\n\nPreclinical investigations involving Ac-SDKP frequently evaluate endothelial signaling and migration readouts, fibroblast differentiation-state markers, and stress-response pathway activation states in defined stimulation models. In parallel, ACE-mediated hydrolysis of Ac-SDKP is studied using biochemical kinetics and structural characterization approaches, providing a mechanistic basis for interpreting Ac-SDKP availability in experimental systems.\n\nThe mechanistic literature often positions these peptides in adjacent experimental themes (cell motility, matrix organization, vascular-associated signaling). Combined evaluation, where performed, is interpreted through discrete molecular endpoints rather than organism-level functional claims.\n\nAc-SDKP (TB-500 Fragment)\n\n\nSequence: Ac-SDKP\nMolecular Formula: C20H33N5O9\nMolecular Weight: 487.5 g/mol\nPubChem CID: 65938\n\nSource: PubChem\n\n\nSalt-form discussions in the BPC-157 literature are typically framed around stability and degradation kinetics measured under controlled laboratory conditions (e.g., temperature stress, light exposure, and simulated matrix exposure). These experiments are used to compare analytical recovery and integrity of different salt forms under defined handling and assay workflows."
      },
      {
        "heading": "Ac-SDKP (Thymosin Beta4 Fragment) Oral Bioavailability Research Studies",
        "content": "Masuyer, Geoffrey, et al. “Structural Basis of Ac-SDKP Hydrolysis by Angiotensin-I Converting Enzyme.” Scientific Reports, vol. 5, no. 1, 25 Sept. 2015, 10.1038/srep13742.\nNakagawa, Pablo, et al. “Ac-SDKP Decreases Mortality and Cardiac Rupture after Acute Myocardial Infarction.” PloS One, vol. 13, no. 1, 2018, p. e0190300, pubmed.ncbi.nlm.nih.gov/29364896/, 10.1371/journal.pone.0190300.\nJin, Fuyu, et al. “Ac-SDKP Attenuates Activation of Lung Macrophages and Bone Osteoclasts in Rats Exposed to Silica by Inhibition of TLR4 and RANKL Signaling Pathways.” Journal of Inflammation Research, vol. 14, 2021, pp. 1647–1660, pubmed.ncbi.nlm.nih.gov/33948088/, 10.2147/JIR.S306883.\nXu, Hong, et al. “A New Antifibrotic Target of Ac-SDKP: Inhibition of Myofibroblast Differentiation in Rat Lung with Silicosis.” PLoS ONE, vol. 7, no. 7, 3 July 2012, p. e40301, 10.1371/journal.pone.0040301.\nSrivastava, Swayam Prakash, et al. “Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.” Genes, vol. 11, no. 2, 18 Feb. 2020, p. E211, pubmed.ncbi.nlm.nih.gov/32085655/, 10.3390/genes11020211.\nShifeng, Li, et al. “Ac-SDKP Increases α-TAT 1 and Promotes the Apoptosis in Lung Fibroblasts and Epithelial Cells Double-Stimulated with TGF-β1 and Silica.” Toxicology and Applied Pharmacology, vol. 369, 15 Apr. 2019, pp. 17–29, www.sciencedirect.com/science/article/abs/pii/S0041008X19300729, 10.1016/j.taap.2019.02.015.\nKumar, Nitin, and Congcong Yin. “The Anti-Inflammatory Peptide Ac-SDKP: Synthesis, Role in ACE Inhibition, and Its Therapeutic Potential in Hypertension and Cardiovascular Diseases.” Pharmacological Research, vol. 134, Aug. 2018, pp. 268–279, 10.1016/j.phrs.2018.07.006.\nPeng, Hongmei, et al. “Ac-SDKP Inhibits Transforming Growth Factor-β1-Induced Differentiation of Human Cardiac Fibroblasts into Myofibroblasts.” American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 5, May 2010, pp. H1357–H1364, 10.1152/ajpheart.00464.2009.\nLi, Shifeng, et al. “[Inhibition Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on Myofibroblast Differentiation of MRC-5 Human Fetal Lung Fibroblasts Inuced by Ang II].” Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi = Zhonghua Laodong Weisheng Zhiyebing Zazhi = Chinese Journal of Industrial Hygiene and Occupational Diseases, vol. 32, no. 11, 1 Nov. 2014, pp. 801–805, pubmed.ncbi.nlm.nih.gov/25579022/.\nXu, Hong, et al. “A New Antifibrotic Target of Ac-SDKP: Inhibition of Myofibroblast Differentiation in Rat Lung with Silicosis.” PLoS ONE, vol. 7, no. 7, 3 July 2012, p. e40301, 10.1371/journal.pone.0040301.\nSharma, Umesh C., et al. “A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy.” Circulation: Heart Failure, vol. 11, no. 8, Aug. 2018, 10.1161/circheartfailure.117.004867.\nCavasin, Maria A., et al. “Decreased Endogenous Levels of Ac-SDKP Promote Organ Fibrosis.” Hypertension, vol. 50, no. 1, July 2007, pp. 130–136, 10.1161/hypertensionaha.106.084103.\nKassem, Kamal M., et al. “Tβ4–Ac-SDKP Pathway: Any Relevance for the Cardiovascular System?” Canadian Journal of Physiology and Pharmacology, vol. 97, no. 7, 1 July 2019, pp. 589–599, www.ncbi.nlm.nih.gov/pmc/articles/PMC6824425/, 10.1139/cjpp-2018-0570.\n\nALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.\n\nThe products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Allan L. Goldstein, MD, Allan L. Goldstein is professor and Catharine B. & William McCormick Chair of the department of Biochemistry and Molecular Biology at The George Washington University School of Medicine and Health Sciences, where he has served since 1978. Thymosins were discovered in the mid 1960’s, when Allan Goldstein from the Laboratory of Abraham White at the Albert Einstein College of Medicine in New York studied the role of the thymus in development of the vertebrate immune system. He is a world-renowned authority on the thymus gland and the workings of the immune system, and co-discoverer of the thymosins. Dr. Goldstein is the author of over 400 scientific articles in professional journals, the inventor on more than 15 U.S. Patents, and the editor of several books in the fields of biochemistry, biomedicine, immunology and neuro-science. He is on the editorial boards of numerous scientific and medical journals and has been a consultant to many re-search organizations in industry and government; co-founder of The Institute for Advanced Studies in Aging and Geriatric Medicine, a non-profit research and educational institute; a member of the Board of Trustees of the Albert Sabin Vaccine Institute; and serves as the Chairman of the Board of RegeneRx Biopharmaceuticals. Dr. Goldstein received his B.S. from Wagner College in 1959 and his M.S. and Ph.D. from Rutgers University in 1964. He served as a faculty member of the Albert Einstein College of Medicine from 1964 to",
    "citations": [
      "Song, Ran & Choi, Hyun & Yang, Hyung-In & Yoo, Myung & Park, Yong-Beom & Kim, Kyoung. (2012). Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy. Clinical rheumatology. 31. 1253-8. 10.1007/s10067-012-2011-7. [Research Gate]"
    ]
  },
  "slu-pp-332": {
    "title": "SLU-PP-332",
    "url": "https://www.peptidesciences.com/slu-pp-332-250mcg-60-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "SLU-PP-332: Research Applications",
        "content": "SLU-PP-332 is supplied strictly for laboratory research use and has been employed in controlled experimental models to investigate:\n\nERRα- and ERRγ-dependent transcriptional regulation\nMitochondrial biogenesis and ultrastructural remodeling\nOxidative phosphorylation and fatty acid oxidation pathways\nCellular energy homeostasis and metabolic gene networks\nAutophagy-associated transcriptional signaling\n\nAll applications are limited to non-clinical, non-diagnostic experimental systems."
      },
      {
        "heading": "SLU-PP-332: Preclinical Research Summary",
        "content": "Preclinical investigations utilizing rodent and cellular models have demonstrated that SLU-PP-332 modulates ERR-dependent gene networks governing mitochondrial density, substrate utilization, and oxidative capacity. These studies report alterations in mitochondrial morphology, respiratory efficiency, and lipid oxidation under controlled experimental conditions.\n\nAdditional research has examined SLU-PP-332 in models of metabolic stress, cardiac energetic demand, renal mitochondrial aging, and neuronal mitochondrial maintenance, providing insight into conserved ERR-regulated bioenergetic pathways.\n\nMitochondrial reactive oxygen species generation in cellular senescence models\nSource: PubMed"
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Dr. Hamid Nasri, M.D., is a Clinical Nephropathologist and Nephrologist affiliated with the Department of Natural Sciences at The University of Georgia in Tbilisi, Georgia. He is also a retired Professor of Nephrology as of February 2024.\n\n​Dr. Hamid Nasri, M.D., is referenced as one of the leading scientists involved in the research and development of SLU-PP-332. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr.Hamid Nasri, M.D., is listed in [1] under the",
    "citations": []
  },
  "thymosin beta-4 fragment": {
    "title": "Thymosin Beta-4 Fragment (1-4) (Ac-SDKP) 500mcg (60 Capsules)",
    "url": "https://www.peptidesciences.com/thymosin-beta-4-fragment-60-capsules",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "120081-14-3",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "In scientific research literature, Ac-SDKP has been referenced in experimental studies utilizing cell cultures, ex-vivo tissue preparations, and animal models to examine signaling pathways, immune cell behavior, and extracellular matrix dynamics.\n\nImmune cell signaling and cytokine-associated pathways\nMacrophage-related cellular responses in experimental systems\nTransforming growth factor beta (TGF-β)–associated signaling components\nExtracellular matrix remodeling markers\nOxidative stress–associated molecular pathways\n\nAll referenced applications remain restricted to laboratory-based research environments."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical publications describe Ac-SDKP-associated observations in animal and cellular models involving immune signaling markers, fibrotic pathway components, vascular-associated cell populations, and transcriptional response profiles following experimental perturbation.\n\nAll findings are confined to the specific experimental systems employed and do not imply clinical relevance or applicability."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Nitin Kumar is an ophthalmologist in Detroit, Michigan and is affiliated with multiple hospitals in the area, including Henry Ford West Bloomfield Hospital and Henry Ford Hospital. He received his medical degree from Howard University College of Medicine and has been in practice between 11-20 years. \n\nDr. Nitin Kumar is being referenced as one of the leading scientists involved in the research and development of Thymosin Beta-4 Fragment (1-4) (Ac-SDKP). In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Barbara B. Kahn is listed in [2] under the",
    "citations": []
  },
  "adipotide": {
    "title": "Adipotide (FTPP) 10mg",
    "url": "https://www.peptidesciences.com/adipotide-ftpp-10mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Adipotide is supplied exclusively for laboratory research and has been utilized in preclinical studies involving:\n\nAdipose tissue vasculature targeting and endothelial receptor mapping\nAngiogenesis and anti-angiogenic signaling pathway investigations\nMetabolic signaling studies related to adipose tissue remodeling\nLigand–receptor interaction analysis involving prohibitin-associated pathways\nExploratory oncology research examining vascular-targeting strategies in animal models"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical research involving adipotide has included studies in rodent and non-human primate models evaluating adipose tissue mass, vascular density, and metabolic signaling endpoints. Reported experimental observations include changes in adipose-associated vasculature, insulin sensitivity markers, and glucose tolerance under defined study conditions.\n\nAdditional investigations have examined the relevance of prohibitin-mediated vascular targeting in oncology-associated vasculature, supporting broader mechanistic exploration of ligand-directed endothelial modulation. All findings referenced are derived exclusively from non-clinical experimental systems."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "ara-290": {
    "title": "ARA-290 16mg",
    "url": "https://www.peptidesciences.com/ara-290-16mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "ARA-290: Research Applications",
        "content": "ARA-290 is applied in laboratory research to examine signaling pathways associated with cellular stress tolerance, immune-cell cytokine regulation, endothelial progenitor cell dynamics, and receptor-mediated intracellular signaling.\n\nCommon experimental contexts include endothelial cell culture assays, macrophage activation models, immune-cell signaling studies, and in-vivo rodent models assessing molecular and histological endpoints related to inflammation and tissue homeostasis."
      },
      {
        "heading": "ARA-290: Preclinical Research Summary",
        "content": "In animal models, ARA-290 has been studied for its influence on endothelial progenitor cell proliferation, migration, and homing behavior, as well as its effects on macrophage-mediated inflammatory signaling.\n\nAdditional preclinical investigations evaluate ARA-290 in models of experimental colitis, immune-mediated tissue injury, and metabolic stress, with outcomes measured via histological analysis, immune-cell profiling, cytokine expression, and receptor-specific signaling readouts.\n\nNeural studies focus on small-fiber nerve integrity, receptor-mediated modulation of nociceptive signaling pathways, and cellular stress resilience, assessed exclusively through laboratory and animal research methodologies."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Michael Brines received a BS with highest honors in physics and biology from the University of Notre Dame and a PhD in neurobiology and behavior from The Rockefeller University. Subsequently, he earned his MD from Yale University and completed a residency in Internal Medicine at Yale-New Haven Hospital. Following residency, he completed fellowship training in Clinical Investigation, as well as Endocrinology, Diabetes, and Metabolism at Yale. Michael Brines is board certified in Internal Medicine as well as in Endocrinology, Diabetes, & Metabolism. Michael Brines has been the inventor or co-inventor on numerous US patents and foreign counterparts, and has authored or coauthored more than 100 scientific publications.\n\nMichael Brines, M.D. is being referenced as one of the leading scientists involved in the research and development of ARA-290. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Michael Brines is listed in [9] under the",
    "citations": []
  },
  "bronchogen": {
    "title": "Bronchogen 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/bronchogen-20mg-bioregulator",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Bronchogen: Research Applications",
        "content": "Bronchogen has been used or discussed in preclinical contexts relevant to:\n\nDNA thermostability and peptide–nucleic acid interaction assays (e.g., differential scanning calorimetry/microcalorimetry paradigms)[1]\nTranscriptional regulation screening in cell systems and organotypic tissue cultures, including comparisons across age-context experimental models[2],[3]\nMechanistic studies of epithelial remodeling and inflammatory signaling readouts in animal models of obstructive lung pathology, where peptide-dependent shifts in morphofunctional state and cytokine-associated markers have been reported[5],[6]\nPlant molecular biology studies examining short exogenous peptides as regulators of developmental gene networks (CLE, KNOX1, GRF gene families) in Nicotiana tabacum[7]\n\nAppropriate endpoints for laboratory workflows may include nucleic-acid melting profiles, reporter assays for transcriptional activity, qPCR/RT-qPCR panels for pathway targets, immunoblotting for signaling intermediates, histology or morphometry in animal models, and multiplex cytokine profiling where relevant to study design."
      },
      {
        "heading": "Bronchogen: Preclinical Research Summary",
        "content": "DNA thermostability (in vitro): Microcalorimetric evaluation has reported increased DNA thermostability in the presence of Bronchogen, reflected as an elevation in melting temperature under the experimental conditions described[1]. This observation is used experimentally as a proxy measure for peptide-associated shifts in DNA duplex stability and can be integrated into mechanistic studies of DNA–ligand interactions and nucleic-acid biophysics.\n\nTissue-specific and age-context differentiation effects (preclinical culture models): Studies in organotypic tissue culture and cell systems have described tissue-biased effects of synthetic short peptides on differentiation-related outputs, including comparative observations across young and older experimental contexts[2],[3]. These reports support use of Bronchogen-class peptides as tools for probing transcriptional and differentiation dynamics in controlled model systems.\n\nRodent obstructive lung pathology models (in vivo): Preclinical rodent studies cited below have evaluated peptide-associated changes in bronchial epithelium morphofunctional parameters and inflammation-linked readouts in induced obstructive lung pathology models[5],[6]. These reports provide an experimental basis for laboratory investigation of epithelial remodeling, cytokine signaling, and barrier-state endpoints within animal model frameworks.\n\nPlant gene expression regulation (in vivo plant model): In Nicotiana tabacum, short exogenous peptides have been reported to regulate expression of CLE, KNOX1, and GRF family genes, providing a platform for mechanistic studies of peptide-driven transcriptional regulation in plant developmental biology[7]."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "b7-33": {
    "title": "B7-33 6mg",
    "url": "https://www.peptidesciences.com/b7-33-6mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "B7-33 is employed in research environments to study receptor-biased signaling at the relaxin family peptide receptor 1 (RXFP1). Experimental use focuses on quantifying kinase activation profiles, extracellular matrix turnover markers, and receptor heterodimerization behavior using molecular, cellular, and histological assays.\n\nAdditional applications include evaluation of peptide-mediated modulation of matrix metalloproteinase expression, collagen organization, and signaling pathway selectivity in in-vitro systems and in-vivo animal models."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "In preclinical animal and cellular studies, B7-33 has been investigated for its effects on extracellular matrix composition, metalloproteinase regulation, and vascular signaling endpoints. Experimental outcomes are measured using histological staining, biochemical quantification, and receptor signaling assays.\n\nAdditional research explores the incorporation of B7-33 into biomaterial coatings to evaluate cellular responses to implanted substrates, focusing on matrix deposition and capsule formation in controlled experimental systems."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Hossain is being referenced as one of the leading scientists involved in the research and development of B7-33. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor.",
    "citations": []
  },
  "cardiogen": {
    "title": "Cardiogen 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/cardiogen-20mg-bioregulator",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Cardiogen: Research Applications",
        "content": "In research environments, Cardiogen is utilized as a mechanistic probe in studies examining fibroblast biology, tissue remodeling, and apoptosis-associated transcriptional regulation. Typical applications include:\n\nFibroblast differentiation and extracellular-matrix signaling studies\nCardiac tissue culture and cardiomyocyte–fibroblast interaction models\nTumor-cell apoptosis signaling assays in rodent cancer models\nAge-associated transcriptional changes in stromal cell populations"
      },
      {
        "heading": "Cardiogen: Preclinical Research Summary",
        "content": "The peer-reviewed literature on Cardiogen consists primarily of:\n\nRodent myocardial tissue culture studies evaluating peptide effects on cardiac cell development\nRat tumor models assessing apoptosis-related molecular endpoints\nIn-vitro fibroblast culture studies examining differentiation-associated signaling molecules\nAge-associated stromal-cell gene-expression analyses\n\nAll findings are interpreted strictly within the constraints of the experimental systems described and do not imply translational, therapeutic, or clinical relevance."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "chonluten": {
    "title": "Chonluten 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/chonluten-20mg-bioregulator",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Chonluten: Mechanistic Research Context",
        "content": "Experimental research on short regulatory peptides, including di-, tri-, and tetrapeptides, demonstrates that these molecules can influence lifespan-associated biomarkers, tumor-development parameters, and transcriptional stability in animal models. These effects are interpreted through peptide-mediated regulation of gene expression, chromatin accessibility, and apoptosis-associated signaling networks in preclinical systems.\n\nMultiple studies indicate that short peptides can influence gene expression through several regulatory layers, including epigenetic mechanisms such as DNA methylation. Computational modeling and in-vitro binding assays suggest that certain short peptides may traverse cellular and nuclear membranes and interact directly with DNA regulatory regions, including promoters and suppressor elements, thereby influencing transcriptional activity.\n\nResearch programs associated with the St. Petersburg Institute of Bioregulation and Gerontology have contributed extensively to this field. Within these experimental frameworks, Chonluten has been examined as one of multiple peptide regulators used to investigate peptide–DNA interactions and downstream transcriptional control in cellular and animal models.\n\nRespiratory Tissue Gene-Expression Models\n\nPreclinical studies report tissue-selective transcriptional responses to Chonluten in respiratory epithelial models. These investigations focus on gene-expression changes affecting mucosal-barrier components, extracellular-matrix regulators, and oxidative-stress-response genes under experimentally induced inflammatory or hypoxic conditions.\n\nGenes evaluated in these models include transcription factors and stress-response regulators such as c-FOS, heat-shock proteins (e.g., HSP70), superoxide dismutase (SOD), cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-α), and related antioxidant-pathway components. These genes are commonly used as molecular readouts of cellular stress adaptation, proliferation signaling, and redox balance in laboratory research.\n\nInflammation-Associated Signaling Pathways\n\nWithin experimental inflammatory models, Chonluten has been evaluated for its association with modulation of transcriptional programs linked to cytokine signaling, oxidative-stress regulation, and epithelial-barrier dynamics. Interpretation of these findings remains limited to controlled laboratory systems and does not imply translational or clinical outcomes.\n\nGastrointestinal Tissue Models\n\nAdditional studies examine Chonluten-associated transcriptional effects in gastrointestinal tissue models, with emphasis on vascular signaling, inflammatory-response genes, and oxidative-stress markers measured in preclinical experimental designs.\n\nResearch Summary\n\nCollectively, Chonluten is characterized in the literature as a short peptide regulator of gene expression with tissue-specific transcriptional effects in respiratory and gastrointestinal experimental models. Its research utility lies in mechanistic studies of peptide-mediated transcriptional regulation, epigenetic control, and stress-response signaling in vitro and in animal systems."
      },
      {
        "heading": "Research Summary",
        "content": "Collectively, Chonluten is characterized in the literature as a short peptide regulator of gene expression with tissue-specific transcriptional effects in respiratory and gastrointestinal experimental models. Its research utility lies in mechanistic studies of peptide-mediated transcriptional regulation, epigenetic control, and stress-response signaling in vitro and in animal systems."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "cortagen": {
    "title": "Cortagen 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/cortagen-20mg-bioregulator",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Cortagen: Research Applications",
        "content": "Cortagen is supplied as a research reagent for laboratory investigations where short-peptide signaling and transcriptional regulation are of interest. Common RUO research applications include: (i) mechanistic studies of chromatin-associated transcriptional accessibility and gene-expression modulation in cellular systems; (ii) profiling experiments (e.g., microarray or transcriptomic workflows) to evaluate differential expression patterns across defined gene sets; (iii) oxidative stress and lipid peroxidation (LPO) assays in animal-derived tissue preparations or in-vivo study designs; and (iv) immune signaling experiments using in-vitro cultures (e.g., splenocyte-based assays) to evaluate cytokine-linked transcriptional responses under controlled conditions."
      },
      {
        "heading": "Cortagen: Preclinical Research Summary",
        "content": "The referenced literature includes rodent studies and in-vitro experiments evaluating Cortagen-associated changes in experimental endpoints relevant to neural tissue biology, peripheral nerve models, oxidative chemistry readouts, and immune signaling assays. Reported designs include peripheral nerve transection paradigms in rats where regeneration-related histological or morphometric endpoints are quantified under controlled conditions, as well as transcriptome profiling experiments assessing differential expression across sets of known genes in animal tissues. Additional studies evaluate free-radical–linked biochemical markers (including LPO products) and related oxidative-state indicators in blood and brain-associated samples within defined experimental frameworks.\n\nImmune-system–associated research cited includes in-vitro evaluation of cytokine-linked transcriptional responses (e.g., interleukin gene expression) using cultured immune cell preparations. Across these studies, results are presented as model-specific laboratory observations used to support mechanistic hypotheses regarding peptide-associated regulation of gene expression, chromatin organization, and biochemical marker dynamics."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "dsip": {
    "title": "DSIP 5mg",
    "url": "https://www.peptidesciences.com/dsip-5mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "62568-57-4",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "DSIP: Research Applications",
        "content": "DSIP is utilized in laboratory research to investigate neurochemical signaling networks and metabolic stress-response mechanisms. Common experimental contexts include:\n\nNeuroendocrine signaling modulation in neuronal and glial cell cultures\nMitochondrial respiration and oxidative phosphorylation assays under hypoxic or stress-induced conditions\nMonoaminergic enzyme regulation (e.g., MAO-A activity) in neural tissue models\nCircadian-associated biochemical oscillations in rodent systems\nStress-response pathway analysis involving hypothalamic-pituitary-adrenal (HPA) axis signaling components\nNeurotransmitter synthesis and turnover in controlled in vitro and in vivo models"
      },
      {
        "heading": "DSIP: Preclinical Research Summary",
        "content": "Preclinical literature documents DSIP-related activity across a range of experimental models, including rodent brain tissue, mitochondrial preparations, and stress-exposure paradigms. Reported findings include alterations in oxidative phosphorylation efficiency, monoamine enzyme activity, and biochemical markers associated with stress adaptation and circadian regulation.\n\nAnimal studies have further explored DSIP distribution in central and peripheral tissues, indicating its presence beyond canonical CNS-localized signaling frameworks. These findings support continued investigation of DSIP as a regulatory peptide with system-wide biochemical relevance in experimental biology."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Shlomo Yehuda, Ph.D. has released hundreds of publications relating to the depths of neuroscience, thermoregulation, pharmacology, and the intricacies of colliding mechanisms of action. He specifically studied the effects of mice that consumed DSIP/DSIP-P while being continuously exposed to light, DSIP as a tool for investing the sleep onset mechanism, the peculiar thermoregulatory effects of DSIP at low and high doses, and the effects of DSIP on pain thresholds during light and dark periods in rats.\n\nShlomo Yehuda, Ph.D. is being referenced as one of the leading scientists involved in the research and development of DSIP. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Shlomo Yehuda, Ph.D. is listed in [19] [20] [21] and [22] under the",
    "citations": []
  },
  "epithalon": {
    "title": "Epithalon (Epitalon)",
    "url": "https://www.peptidesciences.com/epithalon-epitalon-50mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "307297-39-8",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Epithalon (Epitalon): Research Applications",
        "content": "Telomere biology and telomerase-associated enzymology: experimental systems measuring telomerase-associated activity, telomere length metrics, and downstream genome integrity endpoints in cell-based models.\nPeptide–DNA interaction studies: research evaluating interactions of short peptides with promoter regions and associated transcriptional modulation in cultured cells.\nTranscriptional regulation and gene-expression profiling: assays quantifying changes in expression for defined targets implicated in signaling, extracellular matrix biology, and protein biogenesis pathways.\nCircadian-linked molecular signaling: studies assessing transcriptional targets associated with rhythmic regulation and pineal-linked pathways, including AANAT and pCREB-associated signaling nodes.\nExtracellular matrix pathway research: fibroblast and connective-tissue model systems evaluating MMP2-linked endpoints and matrix remodeling biomarkers under controlled conditions.\nOncology model endpoints: exploratory rodent tumor and transgenic model studies evaluating tumor-associated metrics and molecular correlates as research outcomes.\nRetinal model readouts: rodent retinal degeneration models evaluating structural and electrophysiologic endpoints as experimental measures."
      },
      {
        "heading": "Epithalon (Epitalon): Preclinical Research Summary",
        "content": "1. Telomere-Associated Enzymology and Genome Integrity Readouts\n\nPreclinical investigations include insect and rodent studies evaluating survival curves and biomarker panels under defined experimental conditions [1]. Additional rodent work reports age-associated biomarker panels and tumor-incidence endpoints as measured outcomes in specified strains and study designs [4]. Separate cell-based studies describe telomerase-associated activity and telomere-length metrics as experimental readouts [2].\n\n2. Promoter-Interaction Modeling and Gene-Expression Endpoints\n\nCell culture studies have described short peptide interactions with promoter regions of selected genes as an experimental framework for transcriptional modulation and gene-expression profiling [5]. Additional rodent work reports interferon-gamma expression as a measured molecular endpoint in aging lymphocyte models under controlled experimental conditions [6].\n\n3. Fibroblast Function and Extracellular Matrix Pathway Biomarkers\n\nThe cited literature includes rodent and in vitro studies evaluating fibroblast functional state and extracellular matrix-associated endpoints, including MMP2-linked readouts and apoptosis-pathway markers such as caspase-3 activity in cultured fibroblast systems [7] [8].\n\n4. Tumor-Model Endpoints in Rodent and Transgenic Systems\n\nMultiple studies evaluate tumor-associated endpoints in rodent and transgenic models under defined illumination regimes or genetic backgrounds, including tumor development metrics and metastasis-related observations as experimental outcomes [9] [10] [11] [12] [13].\n\nSlowed tumor growth in mice exposed to epithalon compared to controls\nSource: Wiley Online Library\n\nMechanistic literature also evaluates circadian gene regulation in oncology-related cell systems, including PER1-associated signaling as a node linked to cell-cycle control and DNA damage response pathways in experimental models [14].\n\nPER1 Causes Increased Rates of Ionizing Radiation-Induced Cell Death\nSource: Molecular Cell\n\n5. Pineal-Linked Transcriptional Targets and Rhythmic Signaling Readouts\n\nStudies describe regulatory peptide effects on gene transcription, including attention to AANAT and pCREB-associated signaling as targets evaluated in rhythmic gene-expression paradigms [15]. The referenced literature also includes investigations in non-human primates evaluating daily secretion rhythm profiles as measured endpoints under specified study designs [16].\n\n6. Retinal Model Endpoints\n\nThe referenced literature includes rodent retinal degeneration models evaluating retina structural condition and electrophysiologic function as experimental endpoints under controlled conditions [17]."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "",
    "citations": [
      "V. N. Anisimov, S. V. Mylnikov, and V. K. Khavinson, “Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats,” Mech. Ageing Dev., vol. 103, no. 2, pp. 123–132, Jun. 1998. [PubMed]",
      "V. K. Khavinson, I. E. Bondarev, and A. A. Butyugov, “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells,” Bull. Exp. Biol. Med., vol. 135, no. 6, pp. 590–592, Jun. 2003. [PubMed]",
      "T. A. Dzhokhadze, T. Z. Buadze, M. N. Gaiozishvili, M. A. Rogava, and T. A. Lazhava, “[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)],” Georgian Med. News, no. 225, pp. 94–97, Dec. 2013. [PubMed]",
      "V. N. Anisimov et al., “Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice,” Biogerontology, vol. 4, no. 4, pp. 193–202, 2003. [PubMed]",
      "V. K. Khavinson, S. I. Tarnovskaya, N. S. Linkova, V. E. Pronyaeva, L. K. Shataeva, and P. P. Yakutseni, “Short cell-penetrating peptides: a model of interactions with gene promoter sites,” Bull. Exp. Biol. Med., vol. 154, no. 3, pp. 403–410, Jan. 2013. [PubMed]",
      "N. S. Lin’kova, B. I. Kuznik, and V. K. Khavinson, “[Peptide Ala-Glu-Asp-Gly and interferon gamma: their role in immune response during aging],” Adv. Gerontol. Uspekhi Gerontol., vol. 25, no. 3, pp. 478–482, 2012. [PubMed]",
      "N. I. Chalisova, N. S. Lin’kova, A. N. Zhekalov, A. O. Orlova, G. A. Ryzhak, and V. K. Khavinson, “[Short peptides stimulate skin cell regeneration during ageing],” Adv. Gerontol. Uspekhi Gerontol., vol. 27, no. 4, pp. 699–703, 2014. [PubMed]",
      "N. S. Lin’kova et al., “Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro,” Bull. Exp. Biol. Med., vol. 161, no. 1, pp. 175–178, May 2016. [PubMed]",
      "I. A. Vinogradova, A. V. Bukalev, M. A. Zabezhinski, A. V. Semenchenko, V. K. Khavinson, and V. N. Anisimov, “Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes,” Bull. Exp. Biol. Med., vol. 144, no. 6, pp. 825–830, Dec. 2007. [PubMed]",
      "G. Kossoy, V. N. Anisimov, H. Ben-Hur, N. Kossoy, and I. Zusman, “Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice,” Vivo Athens Greece, vol. 20, no. 2, pp. 253–257, Apr. 2006. [PubMed]",
      "V. N. Anisimov et al., “Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice,” Int. J. Cancer, vol. 101, no. 1, pp. 7–10, 2002. [PubMed]",
      "V. N. Anisimov, V. K. Khavinson, I. N. Alimova, A. V. Semchenko, and A. I. Yashin, “Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice,” Bull. Exp. Biol. Med., vol. 134, no. 2, pp. 187–190, Aug. 2002. [PubMed]",
      "I. A. Vinogradova, A. V. Bukalev, M. A. Zabezhinski, A. V. Semenchenko, V. K. Khavinson, and V. N. Anisimov, “Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens,” Bull. Exp. Biol. Med., vol. 145, no. 4, pp. 472–477, Apr. 2008. [PubMed]",
      "S. Gery, N. Komatsu, L. Baldjyan, A. Yu, D. Koo, and H. P. Koeffler, “The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells,” Mol. Cell, vol. 22, no. 3, pp. 375–382, May 2006. [PubMed]",
      "V. K. Khavinson, L. K. Shataeva, and A. A. Chernova, “Effect of regulatory peptides on gene transcription,” Bull. Exp. Biol. Med., vol. 136, no. 3, pp. 288–290, Sep. 2003. [PubMed]",
      "O. V. Korkushko et al., “[Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people],” Adv. Gerontol. Uspekhi Gerontol., vol. 20, no. 1, pp. 74–85, 2007. [PubMed]",
      "V. Khavinson, M. Razumovsky, S. Trofimova, R. Grigorian, and A. Razumovskaya, “Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa,” Neuro Endocrinol. Lett., vol. 23, no. 4, pp. 365–368, Aug. 2002. [PubMed]"
    ]
  },
  "fgl-s": {
    "title": "FGL-S 10mg",
    "url": "https://www.peptidesciences.com/fgl-s-10mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "499993-62-3",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "FGL-S: Research Applications",
        "content": "In the scientific literature, FGL-S and related FGL peptides have been referenced in non-clinical research involving cellular cultures, ex-vivo preparations, and animal model studies. These publications describe experimental contexts in which molecular interactions, signaling components, and structural features were observed and recorded.\n\nReported research contexts include examination of:\n\nNCAM-associated molecular interactions\nFibroblast growth factor receptor (FGFR) signaling components\nNeurite morphology and synaptic ultrastructure in experimental models\nGlial cell–associated molecular markers\nTranscriptional responses following experimental perturbation\n\nAll reported applications remain confined to descriptive investigation within controlled laboratory research environments."
      },
      {
        "heading": "FGL-S: Preclinical Research Summary",
        "content": "Preclinical studies cited in the scientific literature describe observations involving FGL peptides in cellular and non-clinical animal models. Reported observations include measurements of neurite-associated structures, synaptic ultrastructural features, gene expression markers, and signaling-associated proteins documented under defined experimental conditions.\n\nAdditional publications describe transcriptional and cellular responses observed following experimental injury or perturbation models. All reported findings remain restricted to the experimental systems employed and do not extend beyond laboratory research contexts."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Victor I. Popov, Ph.D. is a senior researcher at the Institute of Cell Biophysics, Russian Academy of Sciences, Pushchino, Russia. His published work focuses on synaptic transmission, presynaptic mechanisms, calcium signaling, and neuronal ultrastructure in experimental research systems.\n\nDr. Popov is cited solely for attribution of scientific authorship in the referenced literature. No endorsement, affiliation, or advocacy of any product is implied or stated. The purpose of citation is to acknowledge research contributions only.",
    "citations": []
  },
  "follistatin 315": {
    "title": "Follistatin 315 1mg",
    "url": "https://www.peptidesciences.com/follistatin-315-1mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Investigation of activin sequestration and ligand–receptor availability\nModulation studies within TGF-β superfamily signaling networks\nExploration of extracellular matrix and tissue remodeling pathways\nEvaluation of signaling feedback loops in inflammatory and developmental models\nUse as a comparative reagent in isoform-specific follistatin research"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical studies utilizing cellular and animal models have explored follistatin-associated modulation of developmental signaling, inflammatory regulation, vascular biology, and fibrotic processes. Genetic disruption and recombinant protein studies have provided insights into isoform-specific functions and tissue-dependent signaling outcomes.\n\nThese investigations contribute to foundational knowledge of activin-follistatin regulatory systems without implying translational or clinical application."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": [
      "F. F. Rose, V. B. Mattis, H. Rindt, and C. L. Lorson, “Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy,” Hum. Mol. Genet., vol. 18, no. 6, pp. 997–1005, Mar. 2009. [PubMed]",
      "A. Papaporfyriou et al., “Activin A and follistatin in patients with asthma. Does severity make the difference?,” Respirol. Carlton Vic, vol. 22, no. 3, pp. 473–479, 2017. [PubMed]",
      "C. L. Hardy et al., “The activin A antagonist follistatin inhibits asthmatic airway remodelling,” Thorax, vol. 68, no. 1, pp. 9–18, Jan. 2013. [PubMed]",
      "M. P. Hedger, W. R. Winnall, D. J. Phillips, and D. M. de Kretser, “The regulation and functions of activin and follistatin in inflammation and immunity,” Vitam. Horm., vol. 85, pp. 255–297, 2011. [PubMed]",
      "H. B. Forrester, D. M. de Kretser, T. Leong, J. Hagekyriakou, and C. N. Sprung, “Follistatin attenuates radiation-induced fibrosis in a murine model,” PLoS ONE, vol. 12, no. 3, Mar. 2017. [PubMed]",
      "F. Aoki, M. Kurabayashi, Y. Hasegawa, and I. Kojima, “Attenuation of bleomycin-induced pulmonary fibrosis by follistatin,” Am. J. Respir. Crit. Care Med., vol. 172, no. 6, pp. 713–720, Sep. 2005. [PubMed]",
      "S. Kelaini et al., “Follistatin-Like 3 Enhances the Function of Endothelial Cells Derived from Pluripotent Stem Cells by Facilitating β-Catenin Nuclear Translocation Through Inhibition of Glycogen Synthase Kinase-3β Activity,” Stem Cells Dayt. Ohio, vol. 36, no. 7, pp. 1033–1044, 2018. [PubMed]",
      "N. Mehta, A. L. Gava, D. Zhang, B. Gao, and J. Krepinsky, “Follistatin Protects against Glomerular Mesangial Cell Apoptosis and Oxidative Stress to Ameliorate Chronic Kidney Disease,” Antioxid. Redox Signal., Jun. 2019. [PubMed]",
      "S.-Y. Lee et al., “High circulating follistatin-like protein 1 as a biomarker of a metabolically unhealthy state,” Endocr. J., vol. 66, no. 3, pp. 241–251, Mar. 2019. [PubMed]",
      "C. Shen et al., “Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application,” J. Pharmacol. Exp. Ther., vol. 366, no. 2, pp. 291–302, Aug. 2018. [PubMed]",
      "D. D. Seachrist, S. T. Sizemore, E. Johnson, F. W. Abdul-Karim, K. L. Weber Bonk, and R. A. Keri, “Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer,” Breast Cancer Res. BCR, vol. 19, no. 1, p. 66, 05 2017. [PubMed]"
    ]
  },
  "follistatin 344": {
    "title": "Follistatin 344 1mg",
    "url": "https://www.peptidesciences.com/follistatin-344-1mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Mechanistic studies of activin neutralization and activin receptor signaling modulation\nExperimental interrogation of myostatin/activin pathway crosstalk within TGF-β superfamily networks\nCell-based assays evaluating SMAD pathway activation, transcriptional responses, and ligand competition dynamics\nPreclinical model investigations of pathway-regulated tissue remodeling, fibrosis markers, and inflammatory signaling endpoints\nComparative analyses across follistatin isoforms and engineered variants in controlled laboratory settings"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Ligand Sequestration Studies in Myostatin/Activin Signaling Models\n\nAnimal and cellular studies have used follistatin-based approaches (including protein, mRNA, and gene-expression systems) to evaluate the consequences of myostatin/activin pathway inhibition on molecular markers, tissue morphology, and functional readouts in controlled experimental designs[1], [3], [4], [5].\n\nStrength-related readouts reported in follistatin-associated experimental paradigms.\nSource: PubMed\n\nOncology Model Context (Expression and Mechanistic Associations)\n\nPreclinical investigations and molecular profiling studies have examined follistatin expression in tumor-associated contexts and evaluated mechanistic associations with activin-related signaling, migration, and metastatic behavior in defined experimental systems, including mouse models[6], [7], [8], [9].\n\nRecurrence-associated probability curves in breast cancer datasets stratified by follistatin (FST) expression.\nSource: PubMed\n\nCell Proliferation, Fibrosis Markers, and Liver Model Systems\n\nMechanistic research in hepatocyte and hepatic stellate cell biology has examined the activin–follistatin axis in relation to proliferation-associated behavior, apoptosis markers, and fibrosis-related endpoints in controlled animal and cell-based models[10], [11], [12].\n\nDevelopmental Biology and BMP/TGF-β Signaling Context\n\nDevelopmental model studies have evaluated TGF-β and BMP signaling dynamics in processes such as optic fissure fusion, providing context for investigating how pathway antagonism and related modulators influence morphogenesis-associated signaling outcomes in model systems[13].\n\nMetabolic and Endocrine Pathway Investigations in Animal Models\n\nPreclinical studies have evaluated forced expression of follistatin in defined animal model systems to assess pathway-regulated molecular and physiological endpoints, including pancreatic β-cell biology and glycemic measurements, under controlled experimental conditions[15].\n\nNote: Citations may include a mixture of preclinical reports and broader pathway reviews. Any cited clinical material is provided solely as bibliographic context and should not be interpreted as suggesting clinical, diagnostic, or therapeutic use."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "fox04-dri": {
    "title": "FOX04-DRI 10mg (Proxofim)",
    "url": "https://www.peptidesciences.com/foxo4-dri-10mg-proxofim",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "FOX04-DRI: Research Applications",
        "content": "FOXO4-DRI is utilized in research environments to investigate senescence-associated transcriptional control, FOXO-dependent stress response signaling, and p53-mediated apoptosis pathways. Experimental applications commonly include senescent fibroblast cultures, oxidative stress-induced senescence models, and chemotoxicity-induced cellular arrest paradigms.\n\nAdditional applications include interrogation of FOXO-regulated proteostasis pathways, autophagy-linked signaling networks, and transcriptional responses associated with metabolic stress, genomic instability, and long-term cell cycle arrest in in-vitro and in-vivo animal models."
      },
      {
        "heading": "FOX04-DRI: Preclinical Research Summary",
        "content": "Preclinical studies employing FOXO4-DRI have reported selective engagement of senescent cell populations in mouse and cellular models, with downstream activation of p53-dependent transcriptional programs and apoptosis-associated signaling. These investigations are used to map senescence heterogeneity, evaluate tissue-level accumulation of non-dividing cells, and study consequences of senescent cell removal on local cellular environments.\n\nAdditional research explores FOXO-regulated proteasome activity, autophagy signaling, and oxidative stress handling in cardiovascular, neural, and metabolic tissues using animal and cellular models. These studies emphasize mechanistic interpretation rather than outcome prediction."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "The aim of Dr. Peter de Keizer’s group is to unravel the molecular mechanisms that cause cells to become senescent and to identify how these cells drive aging and age-related diseases. The role of senescence in late-stage therapy-resistant cancer is a major component of this research. The research has a strong translational component and a spearpoint of the group is to develop methods to target the deleterious effects of senescent and senescent-like cancer cells, for instance by eliminating them altogether. In 2004, Peter obtained his MSc in Biomolecular Science form Utrecht University. The final part of his training was performed at Harvard Medical School / Massachusetts General Hospital in Boston, USA. Here, he focused on therapy-resistant Glioblastoma, the most lethal form of brain cancer, something which is now on of the focus areas of the group. In 2009, Peter obtained his PhD from UMC Utrecht on the regulation of FOXO proteins under conditions of stress and their role in tumor suppression.\n\nDr. Peter de Keizer is being referenced as one of the leading scientists involved in the research and development of FOXO4-DRI. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by th",
    "citations": []
  },
  "ghk basic": {
    "title": "GHK Basic 50mg",
    "url": "https://www.peptidesciences.com/ghk-basic-50mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "GHK Basic: Research Applications",
        "content": "GHK and GHK-Cu have been used as research reagents in experimental workflows including:\n\nTranscriptomic profiling studies reporting differential expression patterns following peptide exposure in cultured cell models\nMetal–ligand binding and redox chemistry assays focused on Cu(II)/Cu(I) coordination, stability, and speciation\nExtracellular matrix–adjacent peptide biology studies examining associations between proteolytic fragments and matrix-related pathway annotations\nCytokine-linked signaling assays using measured cytokine concentrations, transcript levels, or pathway reporters as endpoints\nProteostasis and stress-response models evaluating ubiquitin–proteasome system (UPS) gene sets and related pathway markers\n\nThese applications are discussed strictly in the context of laboratory endpoints and preclinical research designs."
      },
      {
        "heading": "GHK Basic: Preclinical Research Summary",
        "content": "1. Fibrinogen-Associated Transcript Readouts\n\nIn the cited literature, fibrinogen-related interpretation is described using transcript-level endpoints and pathway-level inference. Reported datasets include differential expression patterns involving the fibrinogen beta chain gene (FGB) and related transcript annotations under defined experimental conditions.\n\nSeparate reports describe IL-6–linked measurements in selected cell systems (e.g., fibroblast or sebocyte models), where IL-6 is referenced as part of fibrinogen-associated transcriptional regulation. These descriptions are anchored to reported secretion values, transcript readouts, or pathway annotations within the described assays.\n\n2. Ubiquitin–Proteasome System (UPS) Gene Sets\n\nPublished transcriptomic summaries describe differential expression patterns across multiple UPS-annotated genes in association with GHK exposure in specific datasets. Interpretation in these contexts is limited to reported gene-directionality counts and pathway enrichment outputs.\n\n3. DNA Repair–Annotated Gene Categories\n\nThe referenced sources describe differential expression trends among DNA repair–annotated genes in expression profiling analyses. These findings are presented as transcriptional endpoints and gene-category observations rather than direct functional measurements of DNA repair kinetics.\n\n4. Oxidative Stress / Antioxidant Gene Categories\n\nCertain reports summarize expression-level patterns across antioxidant and pro-oxidant gene category annotations in compiled analyses. These summaries are presented as dataset-level endpoints used to contextualize redox-response biology in the relevant experimental systems.\n\n5. Insulin / IGF-Like Signaling Gene Sets\n\nThe cited literature includes discussion of differential expression patterns across insulin/IGF-like pathway gene sets in transcriptomic datasets, with interpretation based on pathway annotations and directionality distributions reported in those analyses.\n\n6. TGF Superfamily Context in Fibroblast-Oriented Models\n\nSome reports describe pathway-associated readouts referencing TGF-beta superfamily components in fibroblast-centered experimental designs. In these contexts, statements are limited to measured gene/protein endpoints and observed dataset-level associations reported in the cited sources.\n\n7. Gene-Signature Analyses Referencing Cancer-Associated Panels\n\nThe referenced sources discuss computational or signature-based analyses (e.g., connectivity mapping) that compare differential expression panels associated with specific biological states. Where GHK is referenced, statements pertain to in silico signature comparisons and observed correlations in transcriptomic contexts, rather than organism-level outcomes.\n\nConclusion\n\nOverall, the cited literature presents GHK and GHK-Cu as research reagents used to interrogate metal–peptide coordination chemistry and transcriptomic pathway annotations. Reported findings are predominantly based on differential expression patterns, cytokine-linked measurements in selected cell models, and dataset-level pathway interpretation within the constraints of the underlying assays."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "ghk-cu  copper peptide": {
    "title": "GHK-Cu 50mg Copper Peptide",
    "url": "https://www.peptidesciences.com/ghk-cu-50mg-copper-peptide",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "89030-95-5",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "GHK-Cu: Research Applications",
        "content": "GHK-Cu is widely utilized in laboratory research to investigate fibroblast migration, immune-cell recruitment, angiogenic signaling, and extracellular matrix synthesis. Experimental systems include dermal fibroblast cultures, endothelial cell assays, neuronal regeneration models, and controlled animal studies.\n\nAdditional applications include investigation of oxidative stress modulation, antimicrobial peptide interactions, stem-cell–associated signaling markers, and transcriptional responses related to tissue regeneration under controlled experimental conditions."
      },
      {
        "heading": "GHK-Cu: Preclinical Research Summary",
        "content": "Preclinical investigations of GHK-Cu include in-vitro fibroblast and keratinocyte models, neuronal regeneration assays, antimicrobial interaction studies, and multiple in-vivo animal models of tissue injury and inflammation.\n\nExperimental observations report enhanced cellular migration, increased extracellular matrix deposition, modulation of inflammatory mediators, and altered gene-expression patterns associated with regeneration and stress response. These findings are presented solely as laboratory observations without implication of clinical, cosmetic, or therapeutic outcomes."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Loren Pickart, Ph.D. has released 109 publications and is developing patents and analyzing GHK's effects on human gene expression of 4,192 genes. In addition to GHK's published potential uses on skin inflammation, metastatic cancer and COPD, it appears to have beneficial effects on other tissue systems such as the nervous system, gastrointestinal system, and mitochondrial system. His brief but detailed autobiography dives into the motivations and background behind his dedicating to skin, anti-aging, and life-long training.\n\nLoren Pickart, Ph.D is being referenced as one of the leading scientists involved in the research and development of GHK-Cu. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Loren Pickart, Ph.D is listed in [1] [3] and [8] under the",
    "citations": [
      "A. Gruchlik, E. Chodurek, and Z. Dzierzewicz, “Effect of GLY-HIS-LYS and its copper complex on TGF-β secretion in normal human dermal fibroblasts,” Acta Pol. Pharm., vol. 71, no. 6, pp. 954–958, Dec. 2014. [PubMed]",
      "L. Pickart and A. Margolina, “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data,” Int. J. Mol. Sci., vol. 19, no. 7, Jul. 2018. [PubMed]",
      "X. Wang et al., “GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis,” Wound Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair Soc., vol. 25, no. 2, pp. 270–278, 2017. [PubMed]",
      "G. D. Mulder et al., “Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper,” Wound Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair Soc., vol. 2, no. 4, pp. 259–269, Oct. 1994. [PubMed]",
      "S. O. Canapp et al., “The effect of topical tripeptide-copper complex on healing of ischemic open wounds,” Vet. Surg. VS, vol. 32, no. 6, pp. 515–523, Dec. 2003. [PubMed]",
      "L. Pickart, J. M. Vasquez-Soltero, and A. Margolina, “The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline,” Brain Sci., vol. 7, no. 2, Feb. 2017. [PubMed]",
      "H. Zhang, Y. Wang, and Z. He, “Glycine-Histidine-Lysine (GHK) Alleviates Neuronal Apoptosis Due to Intracerebral Hemorrhage via the miR-339-5p/VEGFA Pathway,” Front. Neurosci., vol. 12, p. 644, 2018. [PubMed]",
      "X.-M. Zhou et al., “GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFβ1/Smad-Mediated Epithelial-to-Mesenchymal Transition,” Front. Pharmacol., vol. 8, p. 904, 2017. [PubMed]",
      "J.-R. Park, H. Lee, S.-I. Kim, and S.-R. Yang, “The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice,” Oncotarget, vol. 7, no. 36, pp. 58405–58417, Sep. 2016. [PubMed]",
      "L. А. Sever’yanova and D. V. Plotnikov, “Binding of Glyprolines to L-Arginine Inverts Its Analgesic and Antiagressogenic Effects,” Bull. Exp. Biol. Med., vol. 165, no. 5, pp. 621–624, Sep. 2018. [PubMed]"
    ]
  },
  "ghrh": {
    "title": "GHRH 5mg",
    "url": "https://www.peptidesciences.com/ghrh-5mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "9034-39-3",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "1. Receptor Pharmacology & Ligand Benchmarking\n\nGHRH is used as a reference ligand in GHRHR activation assays to benchmark receptor responsiveness, concentration–response behavior, and signaling bias across second-messenger and phosphorylation readouts. These assays are commonly conducted in pituitary-derived cell models or engineered receptor-expression systems using cAMP-linked and downstream pathway endpoints.\n\n2. Temporal Signaling & Desensitization Modeling\n\nIn systems biology and endocrine-axis modeling workflows, GHRH can be applied to probe how stimulus timing influences receptor resensitization, internalization kinetics, and downstream transcriptional programs. These designs evaluate mechanistic features of patterned signaling rather than any outcome-based interpretation.\n\n3. Tissue Expression Datasets & Peripheral Signaling Hypotheses\n\nExpression atlases and research datasets have reported GHRH transcripts across tissue contexts, motivating experimental designs that examine local GHRH/GHRHR signaling in controlled cellular systems and ectopic-expression models used in experimental biology.[1]\n\nSource: The Human Protein Atlas\n\n4. Neuroendocrine Circuitry in Animal Models\n\nRodent studies have evaluated mechanistic relationships between GHRH signaling and sleep-state regulation, using genetic and pharmacologic perturbations to interrogate hypothalamic circuitry and receptor-linked phenotypes in vivo.[2], [3]"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical investigations of GHRH include receptor-function studies in pituitary-derived and engineered cellular models, as well as in-vivo rodent studies probing neuroendocrine signaling interfaces. Published animal work has evaluated sleep-state regulation in mice with altered GHRH receptor function and has explored inflammatory pain signaling interfaces in rodent models of localized inflammatory hyperalgesia.[3], [5]\n\nAdditional preclinical literature has examined pharmacologic antagonism of growth hormone–releasing hormone pathways in controlled cellular systems, including inflammation-linked proliferation readouts in epithelial model contexts.[6]"
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "l-glutathione": {
    "title": "L-Glutathione 600mg",
    "url": "https://www.peptidesciences.com/l-glutathione-600mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "L-Glutathione: Research Applications",
        "content": "L-Glutathione is routinely utilized in laboratory research investigating:\n\n• Cellular redox buffering and oxidative stress modeling\n\n• Enzymatic detoxification pathways (e.g., conjugation reactions mediated by glutathione-dependent enzymes)\n\n• Protein folding and disulfide bond formation within the endoplasmic reticulum\n\n• Ferroptosis and lipid peroxidation signaling in cell-death research\n\n• Neurochemical redox modulation and glial signaling studies\n\n• Redox-dependent regulation of immune cell activation and proliferation in vitro"
      },
      {
        "heading": "L-Glutathione: Preclinical Research Summary",
        "content": "Extensive preclinical literature demonstrates that experimentally induced glutathione depletion alters oxidative stress sensitivity, mitochondrial integrity, and genome stability in cell culture and animal models[1], [2]. Such models are frequently used to investigate mechanisms of cellular senescence, ferroptosis, and redox-dependent transcriptional regulation.\n\nIn nervous system research, glutathione availability has been shown to modulate iron-dependent lipid peroxidation pathways and glial signaling mechanisms associated with neuronal vulnerability in animal models[10], [11]. Additional studies describe glutathione-dependent regulation of retinal support cells and lens protein redox maintenance in ocular biology research[12]–[15].\n\nIn oncology-focused laboratory research, glutathione metabolism is examined as a determinant of cellular resistance to oxidative and xenobiotic stress, with context-dependent effects on tumor cell survival and experimental treatment resistance models[8], [9]."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "gonadorelin": {
    "title": "Gonadorelin 10mg",
    "url": "https://www.peptidesciences.com/gonadorelin-10mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "9034-40-6",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Gonadorelin: Research Applications",
        "content": "Gonadorelin is employed exclusively as a research reagent in laboratory settings to support mechanistic and exploratory investigations of endocrine signaling. Common experimental applications include GnRHR pharmacology (agonist potency, efficacy, signaling bias, and receptor desensitization), second-messenger and kinase pathway analysis, endocrine feedback modeling in animal systems, and integrated omics approaches linking controlled GnRH pathway activation to transcriptional, proteomic, and metabolomic outputs in target tissues and cultured cells."
      },
      {
        "heading": "Gonadorelin: Preclinical Research Summary",
        "content": "The referenced scientific literature consists solely of preclinical and mechanistic studies conducted in cellular systems and animal models. These investigations utilize GnRH pathway modulation as an experimental variable to examine endocrine signaling dynamics, steroidogenic pathway regulation, hormone-responsive transcriptional programs, and neuroendocrine signal integration. All reported findings are context-dependent and limited to the specific experimental systems, species, and analytical methodologies described in the cited publications."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Giorgio Secreto currently studies at the IRCCS National Cancer Institute in Italy. His accolades include, a 1963 High School degree, Maturità Classica 1969 Degree in Medicine and Surgery, University of Milan, Italy 1974 Degree Specialist in Endocrinology, University of Turin, Italy. Doctor Secreto has been working at the National Cancer Institute of Milan since 1970 up to now, after his retirement in December 2010. The role of androgens in breast cancer is his main field of study. He has been teacher at the Italian School of Senology (1989-1996), Associate Professor in Oncology, L.U.de.S. University, Lugano, Switzerland (1999-2008), and Associate Professor in Endocrinology, Nurses’ School, University of Milan (2003-2008). He is active member of the New York Academy of Sciences and the American Association for the Advancement of Sciences. He published about 100 papers, including a few that pertain to GnRH's effects on the reduction of breast cancer via minimizing excessive androgens.\n\nDr. Giorgio Secreto is being referenced as one of the leading scientists involved in the research and development of Gonadorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scien",
    "citations": []
  },
  "humanin": {
    "title": "Humanin 10mg",
    "url": "https://www.peptidesciences.com/humanin-10mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "330936-69-1",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Humanin is utilized as a molecular tool in laboratory research to investigate mitochondrial stress signaling, apoptosis initiation thresholds, and micro-peptide–protein interaction networks. Experimental systems include neuronal, vascular, retinal, musculoskeletal, and endocrine-derived cell cultures, as well as in-vivo animal models.\n\nResearch applications frequently examine how humanin modulates intracellular signaling cascades associated with oxidative stress, mitochondrial membrane integrity, and programmed cell death regulation in controlled preclinical environments."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical investigations in rodent and cell-based models have evaluated humanin-associated modulation of apoptosis markers, oxidative stress indicators, and mitochondrial function under experimentally induced stress conditions. These studies are commonly used to map tissue-specific expression patterns, signaling responsiveness, and mitochondrial resilience metrics.\n\nAdditional experimental literature explores humanin-related signaling in vascular endothelium, retinal pigment epithelial cells, chondrocytes, osteoclast precursor populations, and neural circuits, with emphasis on molecular endpoints rather than translational outcomes."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Pinchas Cohen, MD, is the dean of the USC Leonard Davis School of Gerontology, executive director of the Ethel Percy Andrus Gerontology Center, and holder of the William and Sylvia Kugel Dean’s Chair in Gerontology. He is an expert in the study of mitochondrial peptides and their possible therapeutic benefits for diabetes, Alzheimer’s, and other diseases related to aging. Cohen’s current research focus is on the emerging science of mitochondria-derived peptides, which he discovered. These peptides include humanin, a 24-amino acid peptide encoded from the mt-16S-rRNA. It is a novel, centrally acting insulin sensitizer and metaboloprotective factor representing a new therapeutic and diagnostic target in diabetes and related disease. Other mitochondrial peptides of interest include MOTS-c, a second peptide encoded from a small ORF in the 12S region of the mitochondrial chromosome that has potent anti-diabetes and anti-obesity effect and acts as an exercise-mimetic, and SHLP2, a peptide encoded from the light strand of the mt-16S-rRNA region whose levels correlate with prostate cancer.\n\nDr. Alfonso Eirin has received his MD in 2004 from the University of the Republic in Montevideo Uruguay. Currently, he is working as a senior research fellow in the Division of Nephrology and Hypertension at Mayo Clinic, Rochester, MN. Dr. Eirin’s research is focused on understanding the pathogenesis of renal and cardiac injury due to atherosclerotic renovascular disease (ARVD) and the developing ",
    "citations": []
  },
  "kisspeptin-10": {
    "title": "Kisspeptin-10 5mg",
    "url": "https://www.peptidesciences.com/kisspeptin-10",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Pathway / Mechanistic Context\n\nKisspeptin-10 is used in laboratory research to activate KISS1R and interrogate downstream signaling modules that couple receptor activation to intracellular calcium mobilization, kinase cascades, and transcriptional responses. In neuroendocrine-focused models, kisspeptin signaling is a common experimental handle for studying GnRH neuron excitability, pulsatile gonadotropin release patterns, and regulatory feedback logic within the hypothalamic-pituitary-gonadal axis as defined in nonclinical experimental settings [1] [2].\n\nPreclinical Research Summary: GnRH Neuron Activation & Gonadotropin Dynamics\n\nExperimental work evaluating kisspeptin ligands has characterized KISS1R-dependent activation of GnRH neuron signaling and associated changes in downstream gonadotropin secretion dynamics in controlled study designs [1] [2]. These models are frequently used to examine pulse generation, receptor desensitization, and axis-level response characteristics under defined stimulation paradigms.\n\nPreclinical Research Summary: Energy Balance Interfaces\n\nKisspeptin neurons are widely studied as integrators of metabolic state signals with neuroendocrine outputs. Preclinical genetics and receptor-localization studies have reported Kiss1r expression in adipose tissues and have used receptor loss-of-function approaches to evaluate changes in adiposity-related phenotypes and energy expenditure endpoints in animal models [3]. These findings support ongoing research into how KISS1R signaling intersects with metabolic pathways, peripheral tissue signaling, and neuroendocrine control circuitry.\n\nPreclinical Research Summary: Oncology & Cell Migration Phenotypes\n\nKISS1/kisspeptin signaling has been investigated in oncology research primarily for its association with metastatic behavior and cell motility phenotypes. Published work has reported kisspeptin-linked modulation of tumor cell migration and related adhesion/invasion-associated processes in experimental models, with observations across multiple tumor contexts [4] [5]. These studies are often framed around pathway complexity, context-specific signaling, and heterogeneity of tumor biology across cell lines and model systems.\n\nSource: ScienceDirect\n\nAdditional reports discuss potential coupling between kisspeptin signaling, circadian/light-cycle variables, and melatonin pathway markers in mouse-based experimental designs evaluating tumor growth endpoints [6]. These observations are typically used to motivate further mechanistic work on endocrine-circadian crosstalk and tumor microenvironment signaling.\n\nPreclinical Research Summary: Learning/Memory-Related Behavioral Paradigms\n\nSelect studies have evaluated kisspeptin-related peptide analogs in rodent behavioral paradigms that measure spatial learning, navigation, and cognitive flexibility under defined experimental conditions [7]. Such work is generally used to probe neuromodulatory signaling hypotheses and to map peptide-receptor activity onto circuit-level function in nonclinical models.\n\nPreclinical Research Summary: Neural Circuit Processing\n\nResearch has examined kisspeptin-associated modulation of limbic and reward-circuit activity using experimental brain processing readouts, supporting broader investigation into how neuroendocrine peptides interface with motivational circuitry and affective processing in controlled study designs [8].\n\nPreclinical Research Summary: Kidney and Cardiovascular Biology\n\nKisspeptin and KISS1R expression has been reported in renal tissue, and receptor-deficient mouse models have been used to study developmental and functional endpoints relevant to renal biology [9]. In cardiovascular research, kisspeptin signaling has been evaluated for context-specific effects in vascular beds, including experimental endpoints related to vasoreactivity and vascular signaling pathways, with emphasis on mechanistic interpretation and tissue-specific receptor biology [9].\n\nForm & Analytical Testing\n\n"
      },
      {
        "heading": "Preclinical Research Summary: GnRH Neuron Activation & Gonadotropin Dynamics",
        "content": "Experimental work evaluating kisspeptin ligands has characterized KISS1R-dependent activation of GnRH neuron signaling and associated changes in downstream gonadotropin secretion dynamics in controlled study designs [1] [2]. These models are frequently used to examine pulse generation, receptor desensitization, and axis-level response characteristics under defined stimulation paradigms."
      },
      {
        "heading": "Preclinical Research Summary: Energy Balance Interfaces",
        "content": "Kisspeptin neurons are widely studied as integrators of metabolic state signals with neuroendocrine outputs. Preclinical genetics and receptor-localization studies have reported Kiss1r expression in adipose tissues and have used receptor loss-of-function approaches to evaluate changes in adiposity-related phenotypes and energy expenditure endpoints in animal models [3]. These findings support ongoing research into how KISS1R signaling intersects with metabolic pathways, peripheral tissue signaling, and neuroendocrine control circuitry."
      },
      {
        "heading": "Preclinical Research Summary: Oncology & Cell Migration Phenotypes",
        "content": "KISS1/kisspeptin signaling has been investigated in oncology research primarily for its association with metastatic behavior and cell motility phenotypes. Published work has reported kisspeptin-linked modulation of tumor cell migration and related adhesion/invasion-associated processes in experimental models, with observations across multiple tumor contexts [4] [5]. These studies are often framed around pathway complexity, context-specific signaling, and heterogeneity of tumor biology across cell lines and model systems.\n\nSource: ScienceDirect\nAdditional reports discuss potential coupling between kisspeptin signaling, circadian/light-cycle variables, and melatonin pathway markers in mouse-based experimental designs evaluating tumor growth endpoints [6]. These observations are typically used to motivate further mechanistic work on endocrine-circadian crosstalk and tumor microenvironment signaling."
      },
      {
        "heading": "Preclinical Research Summary: Learning/Memory-Related Behavioral Paradigms",
        "content": "Select studies have evaluated kisspeptin-related peptide analogs in rodent behavioral paradigms that measure spatial learning, navigation, and cognitive flexibility under defined experimental conditions [7]. Such work is generally used to probe neuromodulatory signaling hypotheses and to map peptide-receptor activity onto circuit-level function in nonclinical models."
      },
      {
        "heading": "Preclinical Research Summary: Neural Circuit Processing",
        "content": "Research has examined kisspeptin-associated modulation of limbic and reward-circuit activity using experimental brain processing readouts, supporting broader investigation into how neuroendocrine peptides interface with motivational circuitry and affective processing in controlled study designs [8]."
      },
      {
        "heading": "Preclinical Research Summary: Kidney and Cardiovascular Biology",
        "content": "Kisspeptin and KISS1R expression has been reported in renal tissue, and receptor-deficient mouse models have been used to study developmental and functional endpoints relevant to renal biology [9]. In cardiovascular research, kisspeptin signaling has been evaluated for context-specific effects in vascular beds, including experimental endpoints related to vasoreactivity and vascular signaling pathways, with emphasis on mechanistic interpretation and tissue-specific receptor biology [9]."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Floriana Morgillo, M.D. is an Associate Professor of Medical Oncology at the University of Campania “Luigi Vanvitelli”. She received her Medical Degree, cum laude, in 2000 and in 2004 she completed her specialisation in Medical Oncology with Professor Fortunato Ciardiello at the Second University of Naples. In February 2008 she completed the PhD course in Medical Oncology at the same University. From February 2004 to February 2006, she worked at the MD Anderson Cancer Center in the Thoracic Head and Neck Medical Department. During this time she was deeply involved in the studies of acquired resistance to anti-EGFR targeted drugs in non-small cell lung cancer. In June 2009 she received a Translational Research fellowship from ESMO. She is the Principal Investigator and covers the role of Sub-Investigator in several clinical trials and has been a co-author in various publications in important international journals, including one study on the effects of Kisspeptin-10 antitumor efficacy. Floriana Morgillo, M.D. is listed in [10] under the",
    "citations": []
  },
  "kpv": {
    "title": "KPV (Ac-KPV-NH2) 5mg",
    "url": "https://www.peptidesciences.com/ac-kpv-nh2-5mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "112965-21-6",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "KPV (Ac-KPV-NH2): Research Applications",
        "content": "Ac-KPV-NH2 has been used in preclinical research workflows including:\n\n• Experimental intestinal inflammation models to quantify cytokine-associated signaling and tissue inflammatory markers.\n\n• Epithelial transport studies evaluating PepT1-mediated uptake and inflammation-linked transporter expression changes.\n\n• Cell-based pathway assays measuring NF-kappaB and MAPK activity endpoints under inflammatory stimulation paradigms.\n\n• Antimicrobial assay systems assessing peptide–microbe interactions and structure–activity relationships under controlled culture conditions.\n\n• Matrix remodeling models examining collagen-related endpoints and cytokine-regulated fibroblast signaling markers."
      },
      {
        "heading": "KPV (Ac-KPV-NH2): Preclinical Research Summary",
        "content": "Intestinal Inflammation\n\nIn murine models of experimentally induced intestinal inflammation, Ac-KPV-NH2 exposure has been reported to be associated with measurable changes in inflammation-related endpoints, including inflammatory cell–associated histological markers, MPO activity measurements, and tissue morphology readouts, relative to control conditions. Reported group-level differences have also included changes in weight-associated parameters and other observational readouts used within the model design[2].\n\nDelivery strategies such as nanoparticle loading and hyaluronic acid functionalization have been used in animal studies to evaluate intestinal localization and compartmental exposure. These approaches are typically assessed using local cytokine concentration measurements (e.g., TNF-alpha–associated readouts) and mucosal tissue endpoints in the relevant experimental model[3].\n\nInflammation-Associated Models\n\nAdditional preclinical paradigms (e.g., dermatitis models and immune activation settings) have evaluated alpha-MSH fragments using experimentally measured endpoints such as tissue swelling indices, leukocyte migration measures, and cytokine-associated readouts. Comparative discussions between alpha-MSH and shorter fragments commonly focus on differences in receptor engagement and downstream signaling signatures within the specific assay design.\n\nGraph shows ear swelling due to contact dermatitis at 24 hours (left) and 2 weeks (right). Note that co-administration of Ac-KPV-NH2 with the irritant is nearly as effective as co-administration of alpha-MSH with the irritant at 24 hours. At 2 weeks, however, exposure to the stimulus without co-administration of the peptides shows much less swelling with alpha-MSH compared to Ac-KPV-NH2.\n\nSource: PubChem\n\nKPV (Ac-KPV-NH2): Matrix Remodeling / Collagen Pathways\n\nIn experimental wound repair and remodeling studies, alpha-MSH–related peptides are discussed in relation to cytokine-dependent fibroblast signaling and extracellular matrix markers. Reported molecular associations include IL-8–linked measurements and collagen-related pathway endpoints used to interpret remodeling-phase dynamics in preclinical systems.\n\nSource: Wiley Online Library\n\nReceptor Engagement Context\n\nReported receptor-blocking studies in animal models describe that certain inflammation-associated endpoints attributed to Ac-KPV-NH2 can remain detectable despite blockade of melanocortin receptors implicated in alpha-MSH signaling (e.g., MC3/MC4), supporting mechanistic discussion of receptor-independent or non-canonical signaling routes in specific experimental contexts."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Didier Merlin, Ph.D. is a professor at Georgia State University and research career scientist at Veterans Affairs Medical Center, Decatur, Ga. His research area is the study of intestinal epithelia, as directly related to intestinal bowel disease (IBD). Over one million adults and children in the U.S., including members of the VA population, suffer from IBD, and about 50,000 new cases are diagnosed each year. The VA IBD patients have a much higher rate of colorectal cancer compared to the general population. New therapeutic strategies based on a better understanding of the pathogenesis of IBD will improve the clinical care of veteran and non-veteran patients with this disorder.\n\nDidier Merlin is being referenced as one of the leading scientists involved in the research and development of Ac-KPV-NH2. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Didier Merlin is listed in [4] under the",
    "citations": []
  },
  "livagen": {
    "title": "Livagen 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/livagen-20mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Livagen has been used in research programs investigating peptide-regulated genome function, particularly:\n\n• Chromatin state modulation in lymphocyte-enriched cell populations (e.g., quantifying condensation/decondensation phenotypes and transcriptional accessibility)\n\n• Gene expression shifts associated with nucleolar activity and ribosomal gene transcription (e.g., rRNA biogenesis markers, protein synthesis capacity proxies)\n\n• Cellular functional outputs downstream of altered chromatin accessibility (e.g., cytokine transcription profiles in immune cells, proliferation indices, and stress-response transcriptional programs in vitro)\n\n• Enzyme activity assays relevant to peptide metabolism and degradation pathways in biological matrices (e.g., peptidase activity measurements)\n\n• Neuroimmune and gastrointestinal signaling research in animal models where endogenous opioid peptide systems and mucosal protection pathways are assessed via receptor pharmacology, mediator quantification (e.g., nitric oxide and prostaglandin signaling), and barrier function endpoints"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Published studies in the peptide bioregulator field report that short peptides, including Livagen and related sequences, can induce experimental markers consistent with chromatin “reactivation,” including shifts in condensation status and changes in transcriptional activity in lymphocyte-enriched systems[3]. In this literature, reported endpoints include chromatin decondensation phenotypes, altered gene expression patterns, and indices of increased nucleolar/ribosomal gene activity[2], [3].\n\nLymphocytes comprise multiple immune cell subsets (including B- and T-lineage populations) and are frequently used as model systems to study transcriptional control, cytokine signaling programs, and immunogenetic regulation under defined stimulation conditions[4]. Accordingly, chromatin accessibility shifts in these cells may be studied as upstream regulators of immune-relevant transcriptional circuits (e.g., stimulus-induced transcription, mediator production, and proliferation programs), without implying any diagnostic or therapeutic intent.\n\nGenome Regulation Readouts in Cardiovascular-Related Research\n\n\nSeparate preclinical and translational research programs have examined chromatin organization and genomic instability markers in contexts associated with cardiovascular biology, including studies that evaluate heterochromatin state, NOR activity, and acrocentric chromosome associations in lymphocyte-based assays as experimental readouts[5], [6], [7], [8]. Within these experimental frameworks, peptide-driven modulation of chromatin accessibility is treated as a variable that may influence transcriptional programs and cellular phenotypes measurable in vitro.\n\nPeptidase Modulation and Endogenous Opioid Peptide Signaling (Preclinical Context)\n\n\nEndogenous opioid peptides (e.g., enkephalins) are regulated by enzymatic degradation pathways. In biochemical research, modulation of enkephalin-degrading enzyme activity provides a mechanistic handle to study how changes in peptide turnover can shift receptor-ligand availability and downstream signaling dynamics in controlled systems[9].\n\nPreclinical pharmacology literature further supports a role for μ- and δ-opioid receptor signaling in experimental models of gastric mucosal protection in rodents, with downstream mediator changes (including nitric oxide and prostaglandin signaling) commonly quantified as mechanistic endpoints[10]. These findings are used to design laboratory experiments probing receptor-mediated signaling, mediator production, and barrier biology in animal models and ex vivo tissues.\n\nChromatin State, Genome Stability, and Cellular Aging Models\n\n\nChromatin remodeling and genome stability are frequently studied in cellular aging paradigms using cytogenetic markers (e.g., chromosomal aberrations, heterochromatin organization, and DNA repair-associated readouts) and transcriptional profiling[11]. Within this mechanistic space, peptide-driven chromatin decondensation has been discussed as a tool to interrogate relationships between higher-order genome packaging, transcriptional accessibility, and cellular functional outputs in model systems[12].\n\nLivagen Summary\n\n\nLivagen (Lys-Glu-Asp-Ala) is a short peptide used in research settings to investigate peptide-mediated regulation of genome function, with a primary emphasis on chromatin accessibility, transcriptional activation patterns, and downstream cellular phenotypes in lymphocyte-enriched preparations and other preclinical models. Additional published work has explored enzyme activity modulation relevant to endogenous peptide turnover and mechanistic links to receptor-mediated signaling in animal-model gastrointestinal protection paradigms."
      },
      {
        "heading": "Genome Regulation Readouts in Cardiovascular-Related Research",
        "content": "Separate preclinical and translational research programs have examined chromatin organization and genomic instability markers in contexts associated with cardiovascular biology, including studies that evaluate heterochromatin state, NOR activity, and acrocentric chromosome associations in lymphocyte-based assays as experimental readouts[5], [6], [7], [8]. Within these experimental frameworks, peptide-driven modulation of chromatin accessibility is treated as a variable that may influence transcriptional programs and cellular phenotypes measurable in vitro."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "ll-37": {
    "title": "LL-37 5mg (CAP-18)",
    "url": "https://www.peptidesciences.com/ll-37-5mg-cap-18",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "154947-66-7",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "LL-37: Research Applications",
        "content": "LL-37 is commonly employed as a mechanistic probe across multiple preclinical research settings, including:\n\nHost–pathogen interface assays: evaluation of peptide–membrane interactions, microbial growth inhibition, and synergy studies with other innate defense factors (e.g., defensins, lysozyme) in controlled in vitro systems.\nPattern-recognition and innate signaling studies: interrogation of LPS binding/neutralization and downstream modulation of innate immune pathways in cell-based assays.\nLeukocyte behavior assays: chemotaxis and migration studies in neutrophils/eosinophils and immune-cell activation-state–dependent response profiling.\nEpithelial barrier models: scratch/wound-closure assays, epithelial migration, and barrier integrity measurements under inflammatory stimuli in culture models.\nVascular biology models: endothelial signaling experiments focused on eicosanoid pathways and angiogenic programs in vitro and in vivo (animal models).\nInflammation-network mapping: cytokine and interferon response profiling (e.g., IFN-α, IL-18) and macrophage polarization response modulation in vitro.\n\nSelection of assay format and controls should account for known matrix effects (e.g., serum inhibition), peptide adsorption to plastics, and concentration-dependent cytotoxicity observed in some experimental contexts reported in preclinical literature."
      },
      {
        "heading": "LL-37: Preclinical Research Summary",
        "content": "Inflammation-Associated Models\n\nIn preclinical and ex vivo systems, LL-37 is repeatedly described as a context-dependent immunomodulator. Reported observations include altered keratinocyte survival programs, interferon and interleukin production changes (including IFN-α and IL-18 in defined models), chemotaxis effects in granulocyte lineages, and modulation of receptor-linked inflammatory signaling networks (including reported effects involving TLR4-associated signaling in selected assay systems)[1].\n\nCell-based studies also indicate that immune-cell activation state can shift LL-37–linked outcomes, including differential inflammatory signatures in lymphocyte populations under distinct stimulation conditions[2]. These findings support the use of LL-37 as a tool for mapping homeostatic versus pro-inflammatory network behaviors in tightly controlled experimental designs.\n\nAntimicrobial and LPS-Interaction Studies\n\nLL-37 is widely used in antimicrobial mechanism-of-action experiments, including studies of inducible peptide accumulation in barrier tissues under infectious challenge and synergy experiments with other innate defense factors such as human beta-defensin 2[3]. A common mechanistic emphasis is LL-37 binding to LPS, with experimental readouts examining LPS-neutralization capacity, antimicrobial potency, and matrix-dependent inhibition (e.g., serum-associated attenuation) in vitro[4].\n\nAlthough membrane-targeting activity is frequently highlighted in Gram-negative contexts, LL-37 has also been studied against Gram-positive organisms. In vitro reports describe cooperative effects with lysozyme and defensins against organisms such as Staphylococcus aureus, supporting its use as a probe for envelope-stress and multi-effector synergy paradigms[5].\n\nAirway and Epithelial Model Systems\n\nAirway-focused preclinical studies examine LL-37 in the setting of inhaled inflammatory triggers and barrier perturbation models, often using LPS-driven stimuli to interrogate innate response dynamics. In epithelial culture models, LL-37 has been reported to stimulate airway epithelial proliferation and scratch-wound closure responses, enabling pathway interrogation of epithelial restitution and repair-associated signaling in vitro[7].\n\nArthritis-Linked Experimental Literature\n\nIn rodent studies and observational analyses in inflamed joint environments, cathelicidins (including LL-37 and related species orthologs) have been evaluated for associations with inflammatory events and tissue remodeling signatures[8]. Separate work in mouse models reports no evidence for a required pathogenic role of cathelicidins in select lupus/arthritis model settings, supporting the interpretation that cathelicidin upregulation can reflect inflammatory-state biomarkers rather than necessary drivers in some paradigms[9].\n\nDerivatives of LL-37 have also been used as mechanistic tools in collagen-induced arthritis models to interrogate collagen damage–associated pathways and antibody-response correlates in vivo (murine), including modulation of readouts linked to type II collagen reactivity[10]. Additional in vitro work evaluates LL-37/derivatives within cytokine-driven inflammation models (e.g., IL-32–stimulated systems) to map upstream/downstream signaling responses[11].\n\nStudies also evaluate Toll-like receptor expression dynamics in synovial fibroblast systems (e.g., TLR3 upregulation under immune-cell influence) as a framework for assessing how LL-37 may intersect with PRR-linked inflammatory amplification circuits in vitro and in animal models[12]. Macrophage-focused work further reports selective attenuation of pro-inflammatory macrophage responses under defined conditions, emphasizing the peptide’s use for dissecting polarization-associated signaling outputs[13].\n\nIntestinal Barrier Models and Related Systems\n\nIn vitro intestinal epithelial systems report LL-37–linked effects on epithelial migration and barrier integrity under inflammatory stress conditions, s"
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Daniela Xhindoli, PhD. operates from the University of Trieste, UNITS · Department of Life Sciences. Her focus surrounds gram-negative bacteria, the biological activities of LL-37 on simultaneously modulating pro-inflammatory and anti-inflationary pathways, and the antibacterial and antimicrobial effects of LL-37.\n\nDaniela Xhindoli, PhD. is being referenced as one of the leading scientists involved in the research and development of LL-37. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Daniela Xhindoli, PhD. is listed in [18] under the",
    "citations": []
  },
  "mgf igf-1 ec": {
    "title": "MGF IGF-1 Ec 5mg",
    "url": "https://www.peptidesciences.com/mgf-c-terminal-5mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "C121H199N41O40",
    "molecularWeight": "2866.4798003",
    "casNumber": "",
    "pubChem": "MGF Laboratory Chemical Safety Summary",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "1. IGF-1 Isoform Biology & Alternative Splicing Workflows\nMGF is frequently discussed in the context of IGF-1 alternative splicing, where transcript structure and expression kinetics are evaluated across tissues, developmental stages, and perturbation paradigms. Experimental endpoints include isoform-specific mRNA quantification, promoter usage analysis, and mapping of post-translational processing routes that expand IGF-1–related peptide diversity.[1], [2]\n2. Muscle Cell Models & Injury-Response Signaling\nIn skeletal muscle research, MGF-related sequences are used as probes to examine signaling networks associated with myogenic lineage programs in cell culture and animal injury paradigms. Studies often quantify markers of proliferation/differentiation, transcriptional remodeling, and immune-cell–linked resolution signatures in controlled preclinical systems.[3], [4]\n3. Mechanotransduction in Cartilage and Intervertebral Disc Models\nMGF-related peptides have been used in mechanobiology workflows to map how mechanical overload interfaces with intracellular signaling nodes and migration/apoptosis-associated endpoints in cartilage-relevant and disc-relevant cell systems. These models commonly quantify pathway activation and stress-response signaling under defined mechanical input parameters.[7], [8]\n4. Neural and Cardiac Injury Paradigms (Preclinical)\nIn CNS and cardiac research, MGF/IGF-1 isoform frameworks have been used to explore pathway behavior in ischemia and injury settings in animal models, with endpoints including molecular injury markers, cell survival-associated signaling, and tissue-level functional correlates measured in controlled study designs.[9], [11], [12]"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Splicing and isoform regulation: IGF-1 transcript structure and isoform expression profiles vary across developmental stage and experimental perturbations, enabling mechanistic study of transcription/splicing control in aging and tissue maintenance models.[2]\n\n\nImmune-resolution dynamics in muscle injury: Preclinical muscle injury paradigms have evaluated IGF-1 isoform frameworks (including MGF-linked constructs) alongside immune-cell recruitment/resolution markers and cytokine-linked endpoints under controlled conditions.[4]\n\n\nMechanotransduction in cartilage-relevant systems: Mechanical overload studies in mice have examined MGF-related peptide signaling with mechanistic emphasis on chondrocyte migration behavior and RhoA/YAP-associated pathway outputs.[7]\n\n\nDisc cell stress signaling: Rodent and cell-model work has explored MGF-related peptide exposure in overload-induced apoptosis paradigms, including reported involvement of p38 MAPK signaling endpoints.[8]\n\n\nNeuro and cardiac injury models: Animal studies have reported MGF/IGF-1 isoform-linked observations in ischemia and injury contexts, using molecular and functional readouts to characterize pathway behavior in CNS and myocardium-relevant systems.[9], [11], [12]"
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "mots-c": {
    "title": "MOTS-c",
    "url": "https://www.peptidesciences.com/mots-c-10mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "1627580-64-6",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "MOTS-c: Research Applications",
        "content": "In the scientific literature, MOTS-c has been referenced in non-clinical research involving cellular assays and animal model studies. These publications describe experimental contexts in which molecular interactions, signaling components, and pathway-associated markers were observed and recorded.\n\nReported research contexts include examination of:\n\nMitochondrial signaling-associated molecular components\nNuclear translocation phenomena under experimental conditions\nAMPK-associated signaling elements\nMetabolic pathway–related molecular markers\nGene expression patterns evaluated in cellular and animal models\n\nAll reported applications are confined to descriptive investigation within controlled laboratory research environments."
      },
      {
        "heading": "MOTS-c: Preclinical Research Summary",
        "content": "Preclinical studies cited in the scientific literature describe observations involving MOTS-c in cellular and animal model systems. Reported observations include measurements of signaling-associated proteins, metabolite profiles, and gene expression markers recorded under defined experimental conditions.\n\nAdditional publications describe associations between MOTS-c and molecular features observed in experimental models of metabolic stress and mitochondrial perturbation. All reported findings are restricted to the experimental systems employed."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Changhan David Lee, contributor to “MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism,” and “The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress,” is a researcher at the School of Gerontology at USC Leonard Davis.\n\nPinchas Cohen, MD, is the dean of the USC Leonard Davis School of Gerontology, executive director of the Ethel Percy Andrus Gerontology Center, and holder of the William and Sylvia Kugel Dean’s Chair in Gerontology. He is an expert in the study of mitochondrial peptides and their possible therapeutic benefits for diabetes, Alzheimer’s, and other diseases related to aging. Cohen’s current research focus is on the emerging science of mitochondria-derived peptides, which he discovered. These peptides include humanin, a 24-amino acid peptide encoded from the mt-16S-rRNA. It is a novel, centrally acting insulin sensitizer and metaboloprotective factor representing a new therapeutic and diagnostic target in diabetes and related disease. Other mitochondrial peptides of interest include MOTS-c, a second peptide encoded from a small ORF in the 12S region of the mitochondrial chromosome that has potent anti-diabetes and anti-obesity effect and acts as an exercise-mimetic, and SHLP2, a peptide encoded from the light strand of the mt-16S-rRNA region whose levels correlate with prostate cancer.\n\nDr. Changhan David Lee and Dr. Pinchas Cohen are being referenc",
    "citations": [
      "H. Lu et al., “MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction,” J. Mol. Med. Berl. Ger., vol. 97, no. 4, pp. 473–485, Apr. 2019. [PubMed]",
      "S.-J. Kim et al., “The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity,” Physiol. Rep., vol. 7, no. 13, p. e14171, Jul. 2019. [PubMed]",
      "L. R. Cataldo, R. Fernández-Verdejo, J. L. Santos, and J. E. Galgani, “Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals,” J. Investig. Med., vol. 66, no. 6, pp. 1019–1022, Aug. 2018. [PubMed]",
      "N. Che et al., “MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway,” Eur. Rev. Med. Pharmacol. Sci., vol. 23, no. 8, pp. 3183–3189, Apr. 2019. [PubMed]",
      "B.-T. Hu and W.-Z. Chen, “MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway,” Eur. Rev. Med. Pharmacol. Sci., vol. 22, no. 21, pp. 7156–7163, Nov. 2018. [PubMed]",
      "N. Fuku et al., “The mitochondrial-derived peptide MOTS-c: A player in exceptional longevity?,” Aging Cell, vol. 14, Aug. 2015. [Research Gate]",
      "Q. Qin et al., “Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction,” Int. J. Cardiol., vol. 254, pp. 23–27, 01 2018. [PubMed]",
      "Y. Yang et al., “The role of mitochondria-derived peptides in cardiovascular disease: Recent updates,” Biomed. Pharmacother. Biomedecine Pharmacother., vol. 117, p. 109075, Jun. 2019. [PubMed]"
    ]
  },
  "n-acetyl epithalon amidate": {
    "title": "N-Acetyl Epithalon Amidate 20mg",
    "url": "https://www.peptidesciences.com/n-acetyl-epithalon-amidate-20mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "307297-39-8",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "N-Acetyl Epithalon Amidate: Research Applications",
        "content": "N-Acetyl Epithalon Amidate is supplied exclusively as a research reagent for use in non-clinical laboratory investigations focused on short-peptide signaling and genome-associated regulatory mechanisms. Published preclinical and in-vitro literature has utilized the parent peptide (Ala-Glu-Asp-Gly) in experimental contexts including:\n\nCellular differentiation models: analysis of transcriptional and translational changes during neurogenesis and lineage specification in controlled cell culture systems.\nGene expression profiling: evaluation of cytoskeletal and developmental marker expression (e.g., Nestin, GAP43, βIII-tubulin, Doublecortin).\nRedox biochemistry assays: assessment of lipid peroxidation-associated products and oxidative protein modification markers in animal-based experimental models.\nTelomere and telomerase studies: in-vitro evaluation of telomerase activity and telomere-associated molecular readouts in somatic cell systems.\nSystems-level animal investigations: longitudinal evaluation of survival curves and spontaneous tumor incidence under defined illumination and housing conditions.\nCircadian-associated molecular pathways: investigation of clock gene–linked regulation (e.g., PER1) and pineal-associated biochemical rhythms in preclinical settings.\n\nExperimental design, control selection, and analytical endpoints should be determined by the investigator and aligned with the specific mechanistic hypothesis under investigation."
      },
      {
        "heading": "N-Acetyl Epithalon Amidate: Preclinical Research Summary",
        "content": "Neurogenesis-associated molecular programs: Cell culture studies have reported modulation of gene expression and protein synthesis markers associated with neuronal lineage specification following exposure to the Ala-Glu-Asp-Gly peptide scaffold, with proposed involvement of epigenetic regulatory mechanisms [1], [2].\n\nSkin-derived cellular systems: In-vitro investigations utilizing skin-derived cell cultures have documented changes in proliferation and functional activity of fibroblast-associated cell populations in animal-derived models [3], [4].\n\nImmune-related gene expression: Experimental studies have reported altered expression of immune-associated signaling molecules, including CD5, IL-2, and interferon gamma–linked pathways, under controlled exposure conditions in preclinical models [5].\n\nOncology-associated animal models: Rodent studies have evaluated spontaneous tumor development and tumor-associated parameters under defined experimental conditions, including illumination-controlled environments [6], [13].\n\nCircadian and pineal-associated outputs: Preclinical investigations have examined modulation of circadian-associated molecular rhythms and pineal-derived biochemical outputs in animal systems [8].\n\nRedox-associated molecular endpoints: Animal studies have reported changes in free-radical processes and oxidative modification markers following exposure to bioactive tetrapeptides [10].\n\nTelomerase and telomere-associated readouts: In-vitro studies in human somatic cell models have documented induction of telomerase activity and telomere elongation-associated molecular readouts under controlled experimental conditions [11]."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "n-acetyl selank amidate": {
    "title": "N-Acetyl Selank Amidate 10mg",
    "url": "https://www.peptidesciences.com/n-acetyl-selank-amidate-10mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "2212313-10-6",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "In laboratory research environments, N-Acetyl Selank Amidate has been applied as a tool compound for:\n\nEvaluation of peptide-mediated transcriptional modulation in neuronal and immune-related cell cultures\nInvestigation of glyproline transport dynamics across cellular barrier models\nAssessment of cytokine-associated signaling pathways in rodent systems\nComparative analysis of peptide stability and receptor affinity following terminal modification"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Across published preclinical literature, Selank and structurally modified analogues have been reported to influence transcriptional accessibility, cytokine expression profiles, and receptor-associated signaling cascades in cellular and animal models. Observed effects are interpreted within experimental frameworks focused on molecular regulation rather than physiological outcomes. These findings support continued use of Selank-based peptides as mechanistic probes in neurogenetic and immunoregulatory research."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "The main research direction of Svetlana Limborska is molecular human genetics, including the study of the structural and functional organization of the genome, molecular genetic analysis of populations and the identification of the molecular basis of hereditary and socially important diseases including stroke. It was determined the molecular mechanisms of genomic alterations for a number of human diseases, including hemoglobinopathies, thalassemia, myodystrophy, torsion dystonia, Parkinson's disease, Wilson's disease and others; it was discovered a family of hypervariable DNAs, which were universally distributed in the genomes of all living organisms and were found to be suitable for both the personal identification and kinship purposes; some new brain-specific human genes were found and characterized, and it was identified wide-scale changes in the transcriptome of nerve cells after ischemia and under the action of peptide drugs.\n\nDr. Svetlana Limborska is being referenced as one of the leading scientists involved in the research and development of Cardiogen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Svetlana Limborska is l",
    "citations": []
  },
  "n-acetyl semax amidate": {
    "title": "N-Acetyl Semax Amidate 30mg",
    "url": "https://www.peptidesciences.com/n-acetyl-semax-amidate-30mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "2920938-90-3",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "N-Acetyl Semax is used in preclinical research settings to examine peptide-driven modulation of molecular and transcriptional networks. Common laboratory applications include:\n\nGene expression analysis in neural tissue following peptide exposure\nInvestigation of signaling pathways associated with neurotrophic factor regulation\nAssessment of vascular- and immune-related transcriptional responses in animal models\nExploration of peptide effects on mitochondrial and oxidative-stress–related pathways"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical investigations of N-Acetyl Semax primarily involve in vivo rodent models and in vitro molecular assays. Published studies describe time-dependent changes in gene expression within the hippocampus, frontal cortex, and vascular-associated tissues. These data sets are used to characterize transcriptional dynamics and pathway-level responses following peptide exposure.\n\nAdditional studies evaluate N-Acetyl Semax as a research tool for examining relationships between neurotrophic factor signaling and cellular adaptation under experimentally induced stress conditions."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Igor Ivanovich Bobyntsev researches at the Kursk State Medical University within the Department of Pathophysiology. His main goal is to find new, more effective methods for teaching morphological disciplines… such as histology, cytology, embryology, human anatomy, pathological anatomy, the study of the morphological manifestation of stress-limiting effects of neuropeptides and their synthetic analogues. His key interests pertain to Antioxidants, Free Radicals, Antioxidant Activity, Free Radical Scavengers, Reactive Oxygen Species, Lipid Peroxidation, SOD, Oxidative Stress Biomarkers, Inflammatory Biomarkers, and Oxidative Stress. He specifically studied the influence of Semax on the morphofunctional state of hepatocytes, and lipid peroxidation in the liver, when under chronic emotional and painful stress.\n\nDr. Igor Ivanovich Bobyntsev is being referenced as one of the leading scientists involved in the research and development of Semax. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Igor Ivanovich Bobyntsev is listed in [8] and [9] under the",
    "citations": [
      "I. S. Lebedeva et al., “Effects of Semax on the Default Mode Network of the Brain,” Bull. Exp. Biol. Med., vol. 165, no. 5, pp. 653–656, Sep. 2018. [PubMed]",
      "E. V. Medvedeva et al., “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis,” BMC Genomics, vol. 15, p. 228, Mar. 2014. [PubMed]",
      "E. I. Gusev, M. Y. Martynov, E. V. Kostenko, L. V. Petrova, and S. N. Bobyreva, “[The efficacy of semax in the tretament of patients at different stages of ischemic stroke],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 118, no. 3. Vyp. 2, pp. 61–68, 2018. [PubMed]",
      "T. I. Agapova et al., “[Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex],” Mol. Genet. Mikrobiol. Virusol., no. 3, pp. 28–32, 2008. [PubMed]",
      "M. H. Scantlebury, K.-C. Chun, S.-C. Ma, J. M. Rho, and D. Y. Kim, “Adrenocorticotropic Hormone Protects Learning and Memory Function in Epileptic Kcna1-null mice,” Neurosci. Lett., vol. 645, pp. 14–18, Apr. 2017. [PubMed]",
      "T. Deltheil et al., “Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice,” Neuropharmacology, vol. 55, no. 6, pp. 1006–1014, Nov. 2008. [PubMed]",
      "Ivanov, Alexander & Bobyntsev, Igor & Shepeleva, Olga & Kryukov, Alexey & Andreeva, L & Myasoedov, N. (2017). Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress. Bulletin of experimental biology and medicine. 163. [Research Gate]",
      "Bobyntsev, Igor & Kryukov, Alexey & Shepeleva, Olga & Ivanov, Alexander. (2015). The effect of ACTH-4-7-PGP peptide on lipid peroxidation in liver and activity of serum transaminases in rats under acute and chronic immobilization stress conditions. 78. 18-21. [Research Gate]"
    ]
  },
  "nad+": {
    "title": "NAD+",
    "url": "https://www.peptidesciences.com/nad-100mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "53-84-9",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "In laboratory research, NAD⁺ is used as a reference compound or experimental variable in:\n\nRedox biochemistry and mitochondrial metabolism assays\nEnzyme activity measurements involving sirtuins, PARPs, and dehydrogenases\nTranscriptomic and metabolomic profiling studies reporting NAD⁺-associated expression patterns\nCellular stress and aging-associated model systems\nExtracellular signaling experiments measuring nucleotide release and receptor-linked responses\n\nAll applications are limited to controlled in vitro or animal-model research environments."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Mitochondrial and Metabolic Models\n\nAnimal and cell-based studies describe associations between NAD⁺ availability and measured mitochondrial parameters, including oxidative phosphorylation markers and redox state indicators. These findings are reported as dataset-level observations derived from preclinical models.\n\nGene Expression and Aging-Associated Datasets\n\nTranscriptomic analyses in aging-related models report differential expression patterns among nuclear and mitochondrial gene sets in experimental conditions involving altered NAD⁺ levels. Interpretation is limited to reported expression profiles rather than direct claims of functional restoration.\n\nNeurodegeneration-Oriented Models\n\nIn mouse models of neurodegenerative disease, published studies report associations between NAD⁺ exposure and measured neuronal survival markers, oxidative stress indicators, and mitochondrial readouts. These observations are presented as preclinical correlations within disease-model systems.\n\nInflammation-Related Measurements\n\nSeveral studies reference NAD⁺-linked datasets involving NAMPT, cytokine measurements, and inflammatory signaling components. Reported outcomes are based on gene-expression profiles, enzyme activity measurements, or pathway-level annotations.\n\nCollectively, the literature positions NAD⁺ as a biochemical variable used to explore metabolism-, aging-, and stress-related mechanisms in non-clinical research systems."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "oxytocin": {
    "title": "Oxytocin 10mg (6000 IU)",
    "url": "https://www.peptidesciences.com/oxytocin-10mg-6000iu",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "50-56-6",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Oxytocin is supplied for laboratory research and may be used as a tool compound in controlled non-clinical studies involving:\n\nOxytocin receptor (OXTR) pharmacology, ligand binding, and receptor-selectivity experiments\nSecond-messenger and downstream signaling studies (e.g., intracellular calcium dynamics and kinase/transcriptional responses)\nNeuroendocrine research models evaluating stress responsivity, social behavior paradigms, and neuronal plasticity endpoints\nReproductive physiology signaling studies (uterine contractility pathways, lactation-related signaling, and tissue-level responses)\nInflammation and wound-healing research frameworks assessing cytokine signatures and repair-related biomarkers\nCardiometabolic and vascular signaling investigations in preclinical models (blood pressure, metabolic endpoints, and inflammatory mediators)\n\nAll applications are restricted to in-vitro and in-vivo animal research contexts and are not intended for human diagnostic or therapeutic use."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "1. Wound Healing, Inflammation, and Social Stress Biology\n\nResearch has examined oxytocin-related physiology in the context of interpersonal interaction, inflammatory signaling, and repair outcomes. Human and translational studies have evaluated associations among relationship behaviors, hormone-related dynamics, cytokine activity, and wound healing trajectories [1], [2].\n\n2. Cardiovascular and Vascular-Inflammatory Signaling Frameworks\n\nReviews and preclinical investigations have discussed oxytocin signaling in cardiovascular risk frameworks, including potential links to blood pressure regulation, inflammatory modulation, and receptor-mediated pathways relevant to atherosclerotic disease mechanisms [3], [4], [5].\n\n3. Metabolic Homeostasis (Obesity & Dysglycemia Models)\n\nOxytocin signaling has been explored in energy balance and metabolic homeostasis research, including studies evaluating adiposity-related endpoints and insulin sensitivity in controlled models. Literature reviews and experimental work discuss phenotype-dependent responses (e.g., lean vs. obese contexts) and summarize clinical-adjacent trial observations in obesity and dysglycemia research [8], [9], [10].\n\n4. Stress, Cognition, and Anxiety-Related Behavioral Models\n\nPreclinical research has evaluated oxytocin within stress paradigms and developmental adversity models, including learning/cognition measures, anxiety-like behavior endpoints, and hippocampal signaling marker assessments [11], [12].\n\n5. Social Bonding, Attachment, and OXTR Epigenetic/Genetic Associations\n\nA substantial body of work examines oxytocin receptor biology (including genetics and epigenetics) in relation to social and anxiety phenotypes. Reviews and cohort studies have evaluated oxytocin receptor methylation and broader oxytocin-related signaling correlates in social anxiety and behavioral dimensions [13], [14], [15].\n\n6. Neural Circuitry and Feeding Regulation\n\nOxytocin signaling has also been discussed in neural circuit research relevant to hunger and feeding behavior, contributing to broader mapping of neuroendocrine regulation of energy intake [16].\n\nOxytocin exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Oxytocin for sale is limited to educational and scientific research only, not for human consumption. Only buy Oxytocin if you are a licensed researcher."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "ovagen": {
    "title": "Ovagen 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/ovagen-20mg-bioregulator",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Ovagen: Research Applications",
        "content": "Ovagen is supplied exclusively for laboratory research use. Reported research applications include in-vitro and in-vivo experimental designs examining peptide-mediated regulation of hepatic and gastrointestinal cellular systems. Typical use cases include: (i) studies of transcriptional regulation and chromatin accessibility in liver-derived cells; (ii) evaluation of extracellular matrix and fibrotic-marker expression in animal models; (iii) gastrointestinal epithelial barrier and mucosal signaling assays; and (iv) enzymatic interaction studies in virological or biochemical assay systems where peptide–enzyme binding is investigated under controlled conditions."
      },
      {
        "heading": "Ovagen: Preclinical Research Summary",
        "content": "Preclinical investigations cited for Ovagen include in-vitro biochemical assays and animal-based experimental models. In hepatic systems, studies examine peptide-associated changes in fibrotic markers, cellular proliferation indices, and transcriptional activity under experimentally induced stress or injury paradigms. Gastrointestinal research focuses on epithelial and mucosal signaling readouts relevant to barrier integrity and cellular turnover within controlled animal models.\n\nAdditional biochemical research evaluates Ovagen in enzyme-inhibition assays involving viral proteases. These studies are conducted using isolated enzymes and synthetic substrates, with outcomes reported as concentration-dependent effects on enzymatic activity. All findings are presented within the scope of exploratory, non-clinical laboratory research."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "pancragen": {
    "title": "Pancragen 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/pancragen-20mg-bioregulator",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Pancragen is utilized in laboratory research to investigate peptide-mediated regulation of pancreatic cellular state and signaling behavior. Typical research-only applications include: (i) in-vitro studies examining gene expression, protein abundance, and proliferation or differentiation markers in pancreatic cell cultures; (ii) in-vivo animal studies assessing biochemical endpoints related to pancreatic endocrine output and systemic metabolic signaling; and (iii) exploratory epigenetic investigations evaluating peptide-associated modulation of transcriptional regulation across defined experimental durations."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Across the cited literature, Pancragen is reported in cellular and animal models to correlate with changes in biochemical indices associated with pancreatic endocrine activity. Experimental studies in rodents and non-human primates describe modulation of glucose–insulin axis biomarkers under controlled laboratory conditions, with some investigations employing reference compounds solely as experimental comparators. Additional in-vitro research reports altered expression of molecular markers associated with extracellular matrix remodeling, cellular signaling, and cell state dynamics, including matrix metalloproteinases (MMP2, MMP9), selected signaling proteins, and proliferation-associated markers such as PCNA and Ki67. Concurrent observations include shifts in apoptosis-associated signaling proteins, interpreted within the literature as reflective of transcriptional and epigenetic regulatory mechanisms operating during defined experimental time courses."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "pe-22-28": {
    "title": "PE-22-28 8mg",
    "url": "https://www.peptidesciences.com/pe-22-28",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "PE-22-28: Research Applications",
        "content": "PE-22-28 is applied in experimental neuroscience and ion-channel research to evaluate TREK-1 channel inhibition, potassium conductance modulation, and downstream effects on neuronal firing dynamics.\n\nTypical research applications include electrophysiological recordings, calcium imaging, synaptic density analysis, and transcriptional profiling in cellular cultures and rodent models.\n\nThe peptide is additionally investigated as a probe for studying neuroplasticity-associated pathways, including markers of neuronal proliferation, synapse formation, and transcription factor activation under controlled laboratory conditions."
      },
      {
        "heading": "PE-22-28: Preclinical Research Summary",
        "content": "In preclinical rodent studies, PE-22-28 has been evaluated for its effects on hippocampal cell proliferation, synaptic density, and neuronal firing patterns. Experimental outcomes are measured using BrdU incorporation assays, electrophysiological recordings, and regional protein expression analyses.\n\nAdditional investigations explore TREK-1 involvement in seizure susceptibility, neuroprotection against excitotoxic stress, and modulation of mechanosensitive signaling pathways across central and peripheral tissues in animal models."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Jean Mazella obtained his PhD in 1984 from the University of Nice, France, and fulfilled the role of Assistant Professor at the Montreal Neurological Institute, Canada, from 1994-95. He is currently leading the ‘Cellular Biology of Neuropeptides and Associated Pathologies’ project at the Institute of Molecular and Cellular Pharmacology (IPMC) in France, and is Coordinator for ANR’s ENCOD (2012-14) and MEDINCOD (2014-17) programmes. His pioneering research about Spadins and the subsequent analog PE-22-28 seems to partly originate from him investigating the Sortilin/neurotensin receptor-3 system that, once knocked-out, exhibited similar effects to Spadin and PE-22-28 peptides like reduced fibrosis and higher 5-HT firing rate.\n\nDr. Jean Mazella is being referenced as one of the leading scientists involved in the research and development of PE-22-28. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Jean Mazella is listed in [1] under the",
    "citations": []
  },
  "pinealon": {
    "title": "Pinealon 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/pinealon-20mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Pinealon: Research Applications",
        "content": "Pinealon is employed in laboratory research settings to evaluate peptide-mediated regulation of gene expression in neural, muscular, and epithelial cell models. Experimental systems utilize Pinealon to examine changes in transcriptional profiles associated with oxidative stress, hypoxic exposure, and metabolic perturbation.\n\nAdditional applications include investigation of cell cycle modulation, redox-sensitive signaling networks, and peptide-driven epigenetic effects observed in controlled rodent and cellular model systems."
      },
      {
        "heading": "Pinealon: Preclinical Research Summary",
        "content": "Preclinical studies conducted in cell cultures and animal models have explored Pinealon-associated modulation of transcriptional activity, oxidative stress response pathways, and caspase-linked signaling cascades. Observations from these models are used to characterize molecular responses under experimentally induced stress conditions.\n\nReported findings include altered expression of genes involved in redox balance, mitochondrial-associated signaling, and programmed cell turnover. These outcomes are interpreted strictly within a mechanistic and exploratory research framework without translational inference.\n\nSource: Semantic Scholar"
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of aging and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of g",
    "citations": []
  },
  "pnc-27": {
    "title": "PNC-27 5mg",
    "url": "https://www.peptidesciences.com/pnc-27-5mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "PNC-27: Research Applications",
        "content": "PNC-27 is used in preclinical research settings as a tool compound for investigations such as:\n\nPeptide–protein binding studies involving HDM-2/MDM2-associated interaction motifs\nAssessment of peptide localization to membrane compartments in engineered or model systems\nStructure–function exploration of p53-derived binding regions in controlled experimental formats\nMethod development for membrane interaction assays (e.g., microscopy-based localization, biochemical fractionation)\n\nObservations are specific to the experimental systems used (e.g., in-vitro cell models, isolated membranes, or preclinical model designs) and should be interpreted only within the scope of those systems."
      },
      {
        "heading": "PNC-27: Preclinical Research Summary",
        "content": "In preclinical publications, PNC-27 has been used in experimental oncology research models to study the relationship between MDM2/HDM2 membrane-associated localization and peptide interaction behavior. Reported experiments include in-vitro and other non-clinical models designed to characterize mechanistic features (e.g., binding dependence and cellular localization patterns).\n\nCitations are provided below exactly as listed in the original content to document the historical research context."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology..",
    "scientificJournalAuthor": "Wilbur B. Bowne, M.D., FACS, is an Associate Professor of Surgical Oncology and Cellular/Molecular Biology at Drexel University College of Medicine (DUCOM). He is a recipient of The American Association of Cancer Research (AACR) Young Investigator and The American College of Surgeons Faculty Fellowship Research Awards for his research in pancreatic cancer. Dr. Bowne’s laboratory research is focused on developing novel anticancer targeted therapies against oncoprotein and cell cycle regulation in pancreatic cancer. He is extensively published with over 130 peer-reviewed articles, abstracts, and book chapters. He has received numerous awards for outstanding service, teaching excellence and outstanding skills and commitment in the clinical care of patients. Dr. Bowne and colleagues developed a scoring system to improve patient safety for pancreatic surgery developed from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP). Dr. Bowne takes great pride in being a member of DUCOM multidisciplinary cancer team that treats the most complex patient situations whatever the circumstances or nature of the condition.\n\nDr. Wilbur B. Bowne, M.D. is being referenced as one of the leading scientists involved in the research and development of FOXO4-DRI. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Science",
    "citations": []
  },
  "prostamax": {
    "title": "Prostamax 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/prostamax-20mg-bioregulator",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Prostamax is supplied strictly for laboratory research use. Documented experimental applications include organotypic tissue cultures, lymphocyte-based assays, and rodent models designed to examine peptide-mediated regulation of chromatin structure, ribosomal biogenesis, and transcriptional dynamics. Research use cases include analysis of heterochromatin accessibility, evaluation of immune-cell transcriptional readiness, and investigation of epigenetic regulation under experimentally induced stress or inflammatory conditions."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical investigations of Prostamax include in-vitro lymphocyte cultures, organ-specific tissue explants, and in-vivo rodent models. Within these experimental systems, the peptide is associated with observed changes in chromatin condensation, cellular composition, and tissue-level remodeling parameters. Animal studies evaluating experimentally induced inflammatory models report altered vascular and immune-cell markers following peptide exposure.\n\nComparative epigenetic studies further identify Prostamax-like peptides in long-lived rodent species, where they are examined in the context of lifespan-associated chromatin regulation. These findings are presented as mechanistic observations within experimental frameworks and do not imply translational or applied outcomes."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "p21": {
    "title": "P21 (P021) 5mg",
    "url": "https://www.peptidesciences.com/p21-p021-5mg",
    "whatIs": "P21 Peptide Structure\nP21",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "P21 Research",
        "content": "How was P21 Developed?\n\nP21 was developed using epitope-mapping strategies designed to identify minimal peptide sequences capable of modulating CNTF-associated signaling environments. Antibodies directed against CNTF receptor–associated epitopes were used to define target interaction regions and to screen synthetic peptide candidates for interference with antibody binding under controlled experimental conditions. This process led to identification of DGGL-based peptide motifs suitable for mechanistic studies.\n\nSubsequent chemical modification through addition of an adamantylated glycine residue was employed to enhance experimental stability and persistence in preclinical model systems. These features render P21 suitable for controlled laboratory investigation of neurotrophic signaling pathways.\n\nMechanistic and Pathway Context\n\nPreclinical investigations in rodent models have associated P21 exposure with altered cellular proliferation and differentiation markers within the dentate gyrus of the hippocampal formation. The dentate gyrus is a well-characterized neurogenic niche frequently used to study transcriptional and signaling events associated with neuronal lineage progression in adult mammals.\n\nExperimental observations include increased incorporation of bromodeoxyuridine (BrdU) and elevated expression of neuronal markers such as NeuN in defined hippocampal subregions. These readouts are interpreted as indicators of altered cell-cycle dynamics and neuronal maturation under experimental conditions.\n\nRepresentative BrdU and NeuN immunolabeling patterns reported in rodent experimental models.\n\nSignaling Network Associations\n\nMechanistic studies describe modulation of signaling pathways involving leukemia inhibitory factor (LIF), JAK/STAT-associated transcriptional regulation, and neurotrophin-linked signaling cascades. Inhibition of LIF-associated signaling has been discussed as a permissive factor for differentiation-associated gene expression in neural precursor populations.\n\nAdditional experimental reports describe altered expression or activity of molecular intermediates associated with BDNF, PI3K, and GSK-3β pathways. These nodes are widely studied in neuroscience research as regulators of cytoskeletal organization, synaptic architecture, and transcriptional plasticity.\n\nChanges in expression of synaptic markers including MAP2, synapsin I, GluR1, and NR1 have been reported in animal models exposed to P21. These proteins are commonly employed as molecular readouts in studies of synaptogenesis and neuronal connectivity in both baseline and disease-model contexts.\n\nSummary\n\nP21 is a synthetic CNTF-derived peptide used exclusively as a laboratory research tool for investigating neurotrophic signaling, neurogenesis-associated transcriptional programs, and pathway-level regulation in preclinical experimental systems. All reported findings derive from in vitro assays or in vivo animal studies and are presented for scientific and educational purposes only."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Khalid Iqbal is Professor and Chairman, Department of Neurochemistry, at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York. He received his Ph.D. in Biochemistry in 1969 from the University of Edinburgh, Edinburgh, U.K. Dr. Iqbal was the first to describe in 1974 the bulk isolation and protein composition of neurofibrillary tangles/paired helical filaments (PHF) from Alzheimer disease brains. In 1986 he, along with Dr. Inge Grundke-Iqbal, discovered that the PHF protein and the microtubule-associated protein tau are the same and that tau in PHF is hyperphosphorylated. Their search for an upstream-to-tau-pathology event led them to neurotrophic factors. In 1999 they discovered that CNTF could neutralize the FGF-2-mediated tau hyperphosphorylation in adult rat hippocampal neuroprogenitor cells and then, in 2003, they demonstrated that the pharmacologic enhancement of the dentate gyrus neurogenesis could improve the cognitive performance in adult rats. These pioneering studies led Drs. Iqbal and Grundke-Iqbal to the development of CNTF peptidergic compounds and a novel therapeutic approach that involved shifting the balance from neurodegeneration to the regeneration of the brain. They have shown that the CNTF peptidergic compounds can rescue cognitive impairment by rescuing the neurogenesis and the neuronal plasticity deficits in rodent models of familial and sporadic Alzheimer disease and Down syndrome.\n\nDr. Iqbal is the reci",
    "citations": []
  },
  "selank": {
    "title": "Selank 10mg",
    "url": "https://www.peptidesciences.com/selank-10mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "129954-34-3",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Selank: Research Applications",
        "content": "Selank is utilized in preclinical research environments to examine peptide-driven modulation of molecular signaling networks. Common experimental applications include:\n\nGene expression profiling related to neurotransmitter-associated pathways\nInvestigation of GABAergic signaling components in rodent neural tissue\nAnalysis of enkephalin-degrading enzyme activity in biochemical assays\nImmune-related gene transcription studies involving cytokines and chemokines\nEvaluation of peptide stability and receptor-associated signaling dynamics"
      },
      {
        "heading": "Selank: Preclinical Research Summary",
        "content": "Preclinical studies involving Selank have primarily utilized rodent models and in vitro biochemical systems. Published data describe changes in transcriptional profiles of neural and immune tissues, including genes associated with inflammatory signaling, neurotransmitter receptor modulation, and stress-responsive pathways.\n\nAnimal-based experiments have further evaluated Selank as a tool for studying peptide-mediated regulation of gene networks involved in neuroimmune communication. These investigations emphasize pathway-level observations rather than organism-level outcomes."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Petr Slominsky's 169 research works with 803 citations. 12 of those papers pertain to the examination of Selank’s diverse, multifaceted effects e.g. anxiety reduction, changes in the transcription profile of the hippocampus, and changes in expression of the genes for chemokines, cytokines, and their receptors. Dr. Slominsky is particularly interested in the epigenetic effects of Selank and other disease-state pathologies.\n\nDr. Petr Slominsky is being referenced as one of the leading scientists involved in the research and development of Selank. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Petr Slominsky is listed in [7] under the",
    "citations": [
      "A. Volkova et al., “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission,” Front. Pharmacol., vol. 7, Feb. 2016. [PubMed]",
      "A. A. Zozulya et al., “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity,” Bull. Exp. Biol. Med., vol. 131, no. 4, pp. 315–317, Apr. 2001. [PubMed]",
      "O. Y. Sokolov, V. K. Meshavkin, N. V. Kost, and A. A. Zozulya, “Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions,” Bull. Exp. Biol. Med. [PubMed]",
      "O. N. Uchakina et al., “[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 5, pp. 71–75, 2008. [PubMed]",
      "A. A. Zozulia et al., “[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 4, pp. 38–48, 2008. [PubMed]",
      "T. Kolomin, M. Shadrina, L. Andreeva, P. Slominsky, S. Limborska, and N. Myasoedov, “Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank,” Regul. Pept., vol. 170, no. 1–3, pp. 18–23, Oct. 2011. [PubMed]",
      "T. I. Agapova et al., “[Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex],” Mol. Genet. Mikrobiol. Virusol., no. 3, pp. 28–32, 2008. [PubMed]",
      "T. P. Semenova, I. I. Kozlovskiĭ, N. M. Zakharova, and M. M. Kozlovskaia, “[Experimental optimization of learning and memory processes by selank],” Eksp. Klin. Farmakol., vol. 73, no. 8, pp. 2–5, Aug. 2010. [PubMed]",
      "T. P. Semenova, M. M. Kozlovskaya, N. M. Zakharova, I. I. Kozlovskii, and A. V. Zuikov, “Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny,” Bull. Exp. Biol. Med., vol. 144, no. [PubMed]"
    ]
  },
  "semax": {
    "title": "Semax 30mg",
    "url": "https://www.peptidesciences.com/semax-30mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "80714-61-0",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Semax is a synthetic analogue of an ACTH fragment, corresponding to amino acids 4–10 of ACTH with a C-terminal Pro-Gly-Pro motif. In laboratory research, Semax is used in preclinical models to probe pathway-level regulation of:\n\nNeurotrophin-linked transcription: experimental readouts involving BDNF and NGF gene-expression dynamics in CNS-relevant regions [5].\nSystems-level brain network activity: research imaging endpoints assessing resting-state network behavior and connectivity patterns [1].\nNeurovascular and immune-associated gene programs: genome-wide transcriptional profiling in animal models with emphasis on vascular-system and immune-system gene sets in brain tissue [3].\nLearning/memory model endpoints: mechanistic comparisons using ACTH-related peptides in rodent genetic models with cognition-focused behavioral readouts [6].\nMonoaminergic signaling markers: studies of serotonergic pathway measures and neurotrophin-dependent behavioral paradigms in rodents [7].\nOxidative stress biomarker panels: liver-associated morphofunctional and lipid peroxidation endpoints under stress-model conditions [8] [9]."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Pathway / Mechanistic Context\n\nAcross cited preclinical literature, Semax is evaluated as a modulator of gene-expression programs and systems-level neural network activity. Reported endpoints include transcriptomic changes in CNS tissue, neurotrophin-associated transcriptional dynamics, and network-level activity patterns measured by experimental neuroimaging approaches. In addition, publications describe Semax-associated shifts in peripheral oxidative stress biomarker panels and hepatic tissue readouts under stress-model conditions.\n\n1. Resting-State Network Readouts\n\nExperimental imaging work reports changes in resting-state network behavior after Semax exposure, including measured effects on the default mode network as defined within that study’s analytic framework [1]. Background literature on default mode and social-cognition network relationships is commonly used to interpret these kinds of resting-state measures in neuroscience research [2].\n\nImage showing the overlap of activation between the resting mode network and parts of the brain responsible social cognition.\nSource: PubMed\n\n2. Genome-Wide Transcriptional Profiling in a Rodent Ischemia Model\n\nIn a rat model of focal brain ischemia, genome-wide transcriptional analysis reported Semax-associated changes in expression across immune- and vascular-system related gene sets in brain tissue, providing a molecular context for mechanistic investigation of neurovascular and inflammatory pathway regulation in this model [3].\n\n3. Neurotrophin-Related Gene Expression Dynamics\n\nRodent studies report that Semax exposure is associated with time-dependent gene expression changes in the hippocampus and frontal cortex, including reported effects on BDNF and NGF gene-expression measures within the study design [5].\n\n4. ACTH-Related Peptides in a Genetic Epilepsy Model\n\nPreclinical work in a Kcna1-null mouse model reports that ACTH exposure is associated with preservation of learning and memory readouts in the experimental paradigm, providing comparative context for research on ACTH-derived peptide fragments such as Semax [6].\n\n5. Serotonergic and Neurotrophin-Linked Behavioral Paradigms\n\nRodent studies evaluating altered hippocampal BDNF levels report behavioral and serotonergic consequences in experimental models, supporting broader mechanistic frameworks that connect neurotrophin abundance, serotonergic pathway markers, and behavioral outputs in preclinical research [7].\n\n6. Peripheral Oxidative Stress and Hepatic Biomarker Readouts\n\nAdditional cited studies describe Semax-associated effects on hepatic morphofunctional endpoints and lipid peroxidation markers in rat stress-model conditions, including biochemical measures relevant to oxidative stress research workflows [8] [9]."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Dr. Igor Ivanovich Bobyntsev researches at the Kursk State Medical University within the Department of Pathophysiology. His main goal is to find new, more effective methods for teaching morphological disciplines… such as histology, cytology, embryology, human anatomy, pathological anatomy, the study of the morphological manifestation of stress-limiting effects of neuropeptides and their synthetic analogues. His key interests pertain to Antioxidants, Free Radicals, Antioxidant Activity, Free Radical Scavengers, Reactive Oxygen Species, Lipid Peroxidation, SOD, Oxidative Stress Biomarkers, Inflammatory Biomarkers, and Oxidative Stress. He specifically studied the influence of Semax on the morphofunctional state of hepatocytes, and lipid peroxidation in the liver, when under chronic emotional and painful stress.\n\nDr. Igor Ivanovich Bobyntsev is being referenced as one of the leading scientists involved in the research and development of Semax. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Igor Ivanovich Bobyntsev is listed in [8] and [9] under the",
    "citations": [
      "I. S. Lebedeva et al., “Effects of Semax on the Default Mode Network of the Brain,” Bull. Exp. Biol. Med., vol. 165, no. 5, pp. 653–656, Sep. 2018. [PubMed]",
      "E. V. Medvedeva et al., “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis,” BMC Genomics, vol. 15, p. 228, Mar. 2014. [PubMed]",
      "E. I. Gusev, M. Y. Martynov, E. V. Kostenko, L. V. Petrova, and S. N. Bobyreva, “[The efficacy of semax in the tretament of patients at different stages of ischemic stroke],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 118, no. 3. Vyp. 2, pp. 61–68, 2018. [PubMed]",
      "T. I. Agapova et al., “[Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex],” Mol. Genet. Mikrobiol. Virusol., no. 3, pp. 28–32, 2008. [PubMed]",
      "M. H. Scantlebury, K.-C. Chun, S.-C. Ma, J. M. Rho, and D. Y. Kim, “Adrenocorticotropic Hormone Protects Learning and Memory Function in Epileptic Kcna1-null mice,” Neurosci. Lett., vol. 645, pp. 14–18, Apr. 2017. [PubMed]",
      "T. Deltheil et al., “Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice,” Neuropharmacology, vol. 55, no. 6, pp. 1006–1014, Nov. 2008. [PubMed]",
      "Ivanov, Alexander & Bobyntsev, Igor & Shepeleva, Olga & Kryukov, Alexey & Andreeva, L & Myasoedov, N. (2017). Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress. Bulletin of experimental biology and medicine. 163. [Research Gate]",
      "Bobyntsev, Igor & Kryukov, Alexey & Shepeleva, Olga & Ivanov, Alexander. (2015). The effect of ACTH-4-7-PGP peptide on lipid peroxidation in liver and activity of serum transaminases in rats under acute and chronic immobilization stress conditions. 78. 18-21. [Research Gate]"
    ]
  },
  "tb-500 fragment": {
    "title": "TB-500 Fragment (17-23) 10mg",
    "url": "https://www.peptidesciences.com/tb-500-fragment-17-23-10mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "476014-70-7",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "TB-500 Fragment (17-23): Research Applications",
        "content": "Thymosin Beta-4 Fragment (17–23) is employed exclusively in research environments to examine:\n\nActin monomer sequestration and filament assembly\nCellular migration and cytoskeletal remodeling\nIntracellular signal transduction pathways\nProtein–protein interaction dynamics\nRegulation of inflammatory mediators in animal models\n\nAll applications are limited to non-clinical experimental models."
      },
      {
        "heading": "TB-500 Fragment (17-23): Preclinical Research Summary",
        "content": "Published preclinical literature describes investigation of thymosin beta-4–derived fragments in rodent and cellular systems. Experimental observations include modulation of fibroblast migration, endothelial cell organization, and cytokine signaling under controlled laboratory conditions.\n\nAdditional studies in neural and musculoskeletal animal models have explored molecular responses related to cytoskeletal plasticity, inflammatory mediator balance, and cellular differentiation markers. These findings are presented strictly as experimental observations without clinical extrapolation."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Geoffrey M. Cooper is professor of biology at Boston University. He served as chair of the department of biology for a number of years, and subsequently as associate dean of the faculty for the natural sciences in the university's college of arts & sciences.\n\nCooper earned his Ph.D. at the University of Miami in 1973, and was a postdoctoral fellow with nobel laureate, Howard Temin. His work includes cellular growth control, cancer, and signal transduction. More specifically, he focuses on \"the roles of proto-oncogene proteins as elements of signal transduction pathways that control proliferation, differentiation, and survival of mammalian cells.\"\n\nGeoffrey M. Cooper is being referenced as one of the leading scientists involved in the research and development of TB-500 Fragment (17-23). In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Geoffrey M. Cooper is listed in [2] under the",
    "citations": []
  },
  "tesamorelin": {
    "title": "Tesamorelin 2mg (10 Vial Kit)",
    "url": "https://www.peptidesciences.com/tesamorelin-2mg-10-vial-kit",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "901758-09-6",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Tesamorelin Research",
        "content": "As a GHRH analogue, tesamorelin is used in laboratory research to probe GHRHR activation and downstream signaling associated with GH/IGF-axis regulation. In experimental contexts, GHRHR engagement is commonly associated with GPCR-mediated signaling (often Gs/cAMP-linked), modulation of kinase activity, and transcriptional programs that influence endocrine signaling dynamics. The trans-3-hexanoic acid modification is used in peptide engineering to support reproducible exposure profiles in controlled research workflows and to facilitate mechanistic interrogation of receptor signaling and feedback regulation.\n\n1. Experimental Modeling of Visceral Adiposity & Lipid Biomarkers\n\nPublished studies have evaluated tesamorelin and related growth hormone–releasing factor analogues in research cohorts using metabolic endpoints and biomarker readouts. Reported analyses include associations between changes in visceral adipose tissue measures and lipid parameters such as triglycerides [3], [4]. These citations are provided strictly for scientific background and do not imply any intended medical, diagnostic, or therapeutic use.\n\nFigure included as an educational reference to the cited publication record.\nSource: PubMed\n\n2. Endocrine Axis Research in Chronic Infection Models\n\nReviews and mechanistic discussions have described endocrine and metabolic alterations observed in chronic infection research settings, including reported changes in growth hormone axis parameters [5]. In RUO laboratories, tesamorelin may be used as a receptor-directed probe to evaluate signaling relationships and endocrine feedback behavior under controlled experimental conditions.\n\n3. Peripheral Nerve Biology & Growth Hormone Axis Augmentation (Preclinical Context)\n\nThe growth hormone axis has been discussed in preclinical literature as a modulator of cellular environments relevant to peripheral nerve injury models and regenerative biology research. Reviews have summarized potential mechanistic links between endocrine signaling and experimental outcomes in nerve repair paradigms [6]. These discussions support hypothesis generation for mechanistic studies (e.g., growth factor signaling, Schwann cell-associated pathways, and axonal outgrowth processes) in non-clinical settings.\n\n4. Neuroendocrine Signaling & Biomarker Readouts in Cognitive Research\n\nGHRH analogues have been evaluated in published research using biomarker and neurochemical readouts, including spectroscopy-associated measures and neurotransmitter-related endpoints, as part of broader investigations into neuroendocrine signaling in aging models [7]. References are provided for pathway context only.\n\nFigure included as an educational reference to the cited publication record.\nSource: PubMed"
      },
      {
        "heading": "2. Endocrine Axis Research in Chronic Infection Models",
        "content": "Reviews and mechanistic discussions have described endocrine and metabolic alterations observed in chronic infection research settings, including reported changes in growth hormone axis parameters [5]. In RUO laboratories, tesamorelin may be used as a receptor-directed probe to evaluate signaling relationships and endocrine feedback behavior under controlled experimental conditions."
      },
      {
        "heading": "4. Neuroendocrine Signaling & Biomarker Readouts in Cognitive Research",
        "content": "GHRH analogues have been evaluated in published research using biomarker and neurochemical readouts, including spectroscopy-associated measures and neurotransmitter-related endpoints, as part of broader investigations into neuroendocrine signaling in aging models [7]. References are provided for pathway context only.\n\nFigure included as an educational reference to the cited publication record.\nSource: PubMed"
      },
      {
        "heading": "Future Tesamorelin Research",
        "content": "Because tesamorelin is a well-characterized GHRH-pathway probe, ongoing research interest includes additional mechanistic mapping of GHRHR signaling kinetics, receptor desensitization, and endocrine feedback behavior in controlled experimental systems. Additional preclinical directions discussed in the literature include exploratory study designs that evaluate biomarker relationships in metabolic research and neuroendocrine signaling frameworks, as well as non-clinical investigations of endocrine influences on peripheral nerve biology [1]. Any mention of “trials” or “approval” in external sources is not an indication of intended use for this product; this material is supplied strictly for laboratory research.\n\nThis product is furnished exclusively for scientific research and educational purposes in controlled laboratory environments."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "testagen": {
    "title": "Testagen 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/testagen-20mg-bioregulator",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Testagen: Research Applications",
        "content": "Testagen is utilized as a laboratory reagent in research programs focused on:\n\n• transcriptional regulation within pituitary-derived endocrine signaling pathways,\n\n• peptide-mediated modulation of thyroid-responsive gene-expression networks in animal models,\n\n• investigation of peptide penetration across cellular and nuclear membranes,\n\n• epigenetic regulation of genes involved in endocrine and immune-related differentiation pathways, and\n\n• mechanistic studies of hemostasis-associated gene-expression regulation in preclinical systems."
      },
      {
        "heading": "Testagen: Preclinical Research Summary",
        "content": "The peer-reviewed literature evaluating Testagen includes:\n\n• avian models examining pituitary–thyroid signaling following experimental peptide exposure,\n\n• cellular studies of peptide–DNA interactions and nuclear localization,\n\n• investigations into transcriptional regulation of differentiation-associated genes, and\n\n• experimental assessments of gene-expression changes related to immune-system lineage development and hemostasis-associated pathways.\n\nAll findings remain limited to controlled laboratory systems and established preclinical models."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "thymagen": {
    "title": "Thymagen (Thymogen) 20mg",
    "url": "https://www.peptidesciences.com/thymagen-bioregulator-20mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "38101-59-6",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Thymagen (Thymogen): Research Applications",
        "content": "Thymagen is utilized in research environments as a biochemical probe for immune-associated signaling and differentiation studies. Common experimental applications described in the literature include:\n\nSecond-messenger signaling studies: evaluation of cyclic nucleotide pools, phosphodiesterase activity, and downstream kinase signaling in lymphoid cells.\nImmune differentiation models: examination of T-lymphocyte precursor maturation and phenotypic transitions in thymus and spleen systems.\nCytokine and interferon pathway assays: measurement of interferon-associated signaling outputs and transcriptional markers.\nHost-response challenge models: controlled animal experiments assessing immune signaling allocation during defined microbial exposure paradigms.\nTissue stress-response systems: exploratory use in isolated tissue preparations to study biochemical responses under controlled stress conditions.\n\nEndpoints in these studies are biochemical, cellular, or molecular in nature and are consistent with research-only investigation frameworks."
      },
      {
        "heading": "Thymagen (Thymogen): Preclinical Research Summary",
        "content": "Preclinical investigations have evaluated Thymagen in lymphoid tissue systems, controlled microbial challenge models, metabolic-disease-associated immune dysfunction paradigms, and isolated tissue stress experiments. These studies emphasize immune differentiation markers, cytokine-associated signaling profiles, and biochemical stress-response parameters rather than organism-level outcomes.\n\nRodent studies examining radiation exposure and chemically induced tumor models have explored relationships between thymic peptide signaling and immune surveillance metrics. Mechanistic interpretation in these reports centers on modulation of innate immune signaling and immune-cell functional allocation under experimental conditions.\n\nCollectively, the preclinical literature positions Thymagen as a research reagent for studying immune-system signaling efficiency, differentiation control, and coordination of innate and adaptive immune responses in model systems."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited, and organized by Dr. E. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology. Authorship attribution identifies the individual responsible for compiling and presenting the referenced scientific material in a research-focused format.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "thymosin alpha-1": {
    "title": "Thymosin Alpha-1",
    "url": "https://www.peptidesciences.com/thymosin-alpha-1-3mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "62304-98-7",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Thymosin Alpha-1: Research Applications",
        "content": "Innate immune signaling: experimental systems evaluating Toll-like receptor (TLR)-associated signaling, interferon-linked transcriptional responses, and cytokine network dynamics under defined stimulation conditions.\nAntigen-presenting cell biology: dendritic cell maturation, antigen processing/presentation markers, and downstream effects on T-cell priming in cell culture and animal models.\nT-cell polarization and adaptive signaling: assays measuring Th1/Th2-associated cytokine patterns, CD4/CD8 compartment behavior, and activation marker profiles in controlled experimental paradigms.\nHost–pathogen model endpoints: in vivo and in vitro models that quantify immune pathway biomarkers during bacterial, viral, or fungal challenge studies.\nNeuroimmune interactions: preclinical models evaluating immune-linked gene programs associated with neurodevelopmental and neuroinflammatory signaling readouts.\nOncology research endpoints: cell-based proliferation/migration assays and animal tumor-model readouts used to explore immune-modulated pathway behavior in experimental settings.\nEnzymology and peptide–protein interaction studies: biochemical screens assessing ACE-inhibitory activity and redox-associated markers as measured endpoints in defined assay conditions."
      },
      {
        "heading": "Thymosin Alpha-1: Preclinical Research Summary",
        "content": "1. Immune Signaling Modulation in Experimental Models\n\nReviews and primary studies describe Tα1-associated changes in immune signaling states, including cytokine profile shifts and activation-marker endpoints in controlled experimental systems [1]. In vaccine-adjuvant models, recombinant fusion peptide constructs incorporating Tα1 have been evaluated for immune-adjuvant properties using inactivated antigen preparations, with study endpoints including antigen-specific response markers quantified in preclinical settings [2].\n\n2. Dendritic Cell Maturation and Antifungal Response Models\n\nIn experimental antifungal models, dendritic cell maturation and Toll-like receptor signaling are reported as mechanistic nodes influenced by Tα1, with downstream Th1-associated resistance markers measured as outcomes in defined study designs [5]. Additional work discusses Tα1 as an endogenous regulator of inflammation, immunity, and tolerance, focusing on pathway-level signals and immune-network behavior as experimental endpoints [6].\n\n3. Neuroimmune Gene Programs in Developing Mouse Models\n\nPreclinical mouse studies report that systemic immune-bias modulation is associated with measured changes in neurogenesis-linked readouts and cognition-associated assay outcomes in developing animals, with gene-expression analyses used to define affected pathways [4].\n\nA. 4-week-old mice given thymosin alpha-1 learn how to escape from mazes faster.\nSource: PubMed\n\n4. Cell-Based Oncology Endpoints and Immune-Linked Biomarkers\n\nCell culture studies in epithelial adenocarcinoma model systems report Tα1-associated changes in proliferation and migration assays, alongside redox-related laboratory endpoints [11]. Separate preclinical investigations describe long-acting Tα1 fusion constructs evaluated in vivo, with measured outcomes including tumor-model endpoints and immune cell marker changes in controlled study designs [14] [15].\n\n5. Enzyme-Target Assays and Redox-Associated Readouts\n\nBiochemical studies report ACE-inhibitory activity for Tα1 in defined assay conditions, alongside antioxidant/ROS-associated endpoints measured in laboratory systems [10].\n\n6. Additional Preclinical Contexts in the Cited Literature\n\nThe referenced citations include a broad range of experimental contexts (e.g., infection-model research, inflammation/tolerance frameworks, and biomarker studies). Where present in the literature, these investigations are characterized by preclinical endpoints, pathway-level biomarkers, and controlled experimental designs suitable for mechanistic interpretation [8] [9] [16] [17]."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Allan L. Goldstein, MD, Allan L. Goldstein is professor and Catharine B. & William McCormick Chair of the department of Biochemistry and Molecular Biology at The George Washington University School of Medicine and Health Sciences, where he has served since 1978. Thymosins were discovered in the mid 1960’s, when Allan Goldstein from the Laboratory of Abraham White at the Albert Einstein College of Medicine in New York studied the role of the thymus in development of the vertebrate immune system. He is a world-renowned authority on the thymus gland and the workings of the immune system, and co-discoverer of the thymosins. Dr. Goldstein is the author of over 400 scientific articles in professional journals, the inventor on more than 15 U.S. Patents, and the editor of several books in the fields of biochemistry, biomedicine, immunology and neuro-science. He is on the editorial boards of numerous scientific and medical journals and has been a consultant to many re-search organizations in industry and government; co-founder of The Institute for Advanced Studies in Aging and Geriatric Medicine, a non-profit research and educational institute; a member of the Board of Trustees of the Albert Sabin Vaccine Institute; and serves as the Chairman of the Board of RegeneRx Biopharmaceuticals. Dr. Goldstein received his B.S. from Wagner College in 1959 and his M.S. and Ph.D. from Rutgers University in 1964. He served as a faculty member of the Albert Einstein College of Medicine from 1964 to",
    "citations": []
  },
  "thymalin": {
    "title": "Thymalin 20mg",
    "url": "https://www.peptidesciences.com/thymalin-20mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "63958-90-7",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Thymalin is supplied exclusively for laboratory research and may be utilized in studies including (non-exhaustive):\n\nT-cell lineage and thymocyte differentiation assays (cellular immunology workflows)\nNatural killer (NK) cell and lymphocyte subpopulation profiling in experimental models\nCytokine/chemokine signaling modulation studies in immune-cell culture systems\nNeuroimmune and circadian-associated immune fluctuation models in animals\nExploratory tumor–immune interaction studies in vivo (immune organ readouts under controlled conditions)"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "1. Biochemical Characterization and Thymic-Factor Activity Models\n\nFoundational work describing serum thymic factor/thymulin includes biochemical characterization and activity modeling that established a framework for subsequent immune-cell readouts and assay development[4].\n\n2. Experimental Immune Modulation in Animal Models\n\nAnimal studies have evaluated thymulin-related peptides in models assessing thymocyte proliferation/apoptosis dynamics and endocrine–immune interactions (e.g., post-surgical endocrine manipulation paradigms), supporting investigation of thymus-linked regulation under controlled conditions[9].\n\n3. Circadian-Associated Immune Fluctuation Frameworks\n\nPreclinical literature has examined age- and rhythm-associated immune fluctuations and the relationship of thymic factors to immune phenotype variability in animal models, providing experimental context for neuroimmune and endocrine coupling investigations[21].\n\n4. Lipid/Inflammation-Linked Experimental Models\n\nRabbit research has explored thymic-factor peptides in experimental hyperlipidemia/atherosclerosis settings with laboratory endpoints that include lipid measures and immune readouts within that model framework[22].\n\n5. Tumor–Immune Contexts in Vivo\n\nIn vivo studies have examined thymic peptides in tumor-bearing animal models, reporting tumor- and thymus-associated endpoints under defined experimental conditions, supporting continued mechanistic interrogation of immune-organ responses in oncology research contexts[13].\n\n6. Zinc-Dependent Thymulin Activity\n\nBecause thymulin activity is discussed as zinc-dependent in mechanistic literature, experimental work has evaluated how nutritional/trace-element variables relate to thymic-factor activity readouts, informing assay design and interpretation where metal-ion availability is a controlled variable[25]."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "trh thyrotropin": {
    "title": "TRH Thyrotropin (Protirelin)",
    "url": "https://www.peptidesciences.com/trh-thyrotropin-protirelin-50mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "24305-27-9",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "TRH Thyrotropin (Protirelin): Research Applications",
        "content": "Neuroendocrine signaling models: TRH is used as a probe for hypothalamic–pituitary axis circuitry, TRHR pharmacology, and hormone-release pathway mapping in cell-based, ex vivo, and in vivo animal systems.\nCerebellar synaptic plasticity: TRH has been studied as a modulatory input in rodent models investigating cerebellar long-term depression (LTD) and associated motor-learning phenotypes.\nAutonomic network physiology: In rodent preparations, TRH has been evaluated for effects on integrative brainstem outputs, including experimentally measured respiratory and cardiovascular parameters.\nAnalog comparison studies: TRH is frequently benchmarked against metabolically stabilized analogs (e.g., taltirelin) to evaluate duration-of-action and signaling persistence in preclinical assay systems."
      },
      {
        "heading": "TRH Thyrotropin (Protirelin): Preclinical Research Summary",
        "content": "Cerebellar LTD and motor learning (rodent models): Genetic and experimental paradigms have been used to evaluate the contribution of TRH signaling to cerebellar LTD and performance across repeated motor task trials in mice[5].\n\nKnockout mice treated with TRH learned much faster after four trials, with time before falling from rotating rod being nearly twice that of untreated mice. This shows improved rates of motor learning\nSource: PubMed\n\nRespiratory physiology (anesthetized rat preparations): TRH and TRH analogs have been assessed in rodent paradigms quantifying ventilation under pharmacologically induced respiratory depression[7].\n\nHemodynamic stress models (rat hemorrhage): Metabolically stabilized TRH analogs (e.g., taltirelin) have been examined in acute rat models measuring arterial pressure, respiratory parameters, and blood gas/acid–base indices following controlled hemorrhage[8].\n\nNeuroanatomical/circuit context: Reviews summarize TRH localization, receptor distribution, and proposed neuromodulatory roles in cerebellar and broader CNS networks relevant to plasticity and motor coordination research[6]."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Prof. Walter Pierpaoli was born in 1934 in Milan. He graduated with honors in Medicine and Surgery in 1960. After a major in Cardiology and a period as Assistant Hospital and practical activity (Medical Office), taught as an Assistant at the Institute of General Pathology, University of Milan, conducting research in biophysics (photodynamic effect) and taking advantage of a scholarship of the Atomic Energy Commission of the United States. Prof. Pierpaoli promoted first by many years the medical interdisciplinary now called \"Neuroimmunomodulation\", to which now devote thousands of researchers. He devised, based on his original research, interventions against diseases of aging and is conducting for many years in Seattle, in the United States, with a group of researchers at the well-known Fred Hutchinson Cancer Research Center, research started in 1978 and based on a new method of transplants that can modify the immune system and prevent the organ rejection. This project, protected by worldwide patents, is in a very advanced stage of development and will provide the first clinical internships widespread pathologies, including diabetes and cancer. Prof. Pierpaoli has published over 140 scientific papers experimental, published in the best scientific journals such as Nature, (7 items), the Journal of the National Cancer Institute - USA, Proceedings of the National Academy of Sciences - USA and many others.\n\nNotable achievements:\n\nFounded the Stromboli Conference on Aging and Cance",
    "citations": [
      "L. B. Marangell et al., “Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients,” Arch. Gen. Psychiatry, vol. 54, no. 3, pp. 214–222, Mar. 1997. [PubMed]",
      "R. Bunevicius and V. Matulevicius, “Short-lasting behavioural effects of thyrotropin-releasing hormone in depressed women: results of placebo-controlled study,” Psychoneuroendocrinology, vol. 18, no. 5–6, pp. 445–449, 1993. [PubMed]",
      "A. M. Callahan et al., “Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics,” Biol. Psychiatry, vol. 41, no. 3, pp. 264–272, Feb. 1997. [PubMed]",
      "M. P. Szuba et al., “Rapid antidepressant response after nocturnal TRH administration,” J. Clin. Psychopharmacol. [PubMed]",
      "M. Watanave et al., “Contribution of Thyrotropin-Releasing Hormone to Cerebellar Long-Term Depression and Motor Learning,” Front. Cell. Neurosci., 2018. [PubMed]",
      "N. Shibusawa et al., “Thyrotropin-releasing hormone (TRH) in the cerebellum,” Cerebellum, 2008. [PubMed]",
      "J. D. Boghosian et al., “Intravenous and Intratracheal Thyrotropin Releasing Hormone…,” J. Pharmacol. Exp. Ther., 2018. [PubMed]",
      "H. Asai et al., “Reversal of hemorrhagic shock in rats…,” J. Recept. Signal Transduct. Res., 2011. [PubMed]",
      "E. Fliers et al., “Decreased hypothalamic thyrotropin-releasing hormone gene expression…,” J. Clin. Endocrinol. Metab., 1997. [PubMed]",
      "W. Pierpaoli, “Aging-reversing properties of thyrotropin-releasing hormone,” Curr. Aging Sci., 2013. [PubMed]",
      "A. M. Mellow et al., “Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer’s disease,” Psychopharmacology, 1989. [PubMed]",
      "L. Luo et al., “Thyrotropin releasing hormone (TRH) in the hippocampus of Alzheimer patients,” J. Alzheimers Dis., 2002. [PubMed]"
    ]
  },
  "vesugen": {
    "title": "Vesugen 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/vesugen-20mg-bioregulator",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Vesugen: Research Applications",
        "content": "Vesugen is employed in experimental research to investigate peptide-driven regulation of endothelial function, neuronal gene expression, and metabolic signaling pathways. Its biochemical properties make it suitable for mechanistic studies examining oxidative stress responses, transcriptional regulation, and peptide-mediated modulation of intracellular enzymes in preclinical models.\n\nEndothelial cell proliferation and gene expression studies\nNeuronal differentiation and survival signaling research\nSirtuin-associated metabolic pathway investigations\nOxidative stress and hypoxia-response models\nEpigenetic regulation and transcriptional control assays"
      },
      {
        "heading": "Vesugen: Preclinical Research Summary",
        "content": "In-vitro and in-vivo animal studies have examined Vesugen in the context of endothelial regulation, neuronal marker expression, oxidative stress modulation, and metabolic signaling. Rodent-based models have been utilized to explore its effects on vascular integrity, lipid-associated pathways, and transcriptional regulation of cellular survival mechanisms.\n\nAdditional investigations have evaluated Vesugen within experimental neurobiology and metabolic research frameworks, focusing on hypoxia-response pathways, mitochondrial regulation, and epigenetic control of gene expression. All findings remain confined to exploratory preclinical research."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "vesilute": {
    "title": "Vesilute 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/vesilute-bioregulator-20mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "3918-84-1",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Vesilute: Research",
        "content": "Vesilute is thought to have anti-aggregation effects on the muscles of the bladder wall. In muscle, glycogen serves as an important form of energy storage. This multibranched polysaccharide is a short-term energy storage solution and is found primarily in muscle and liver cells. It makes up approximately 2% of muscle mass where it serves as an immediate source of glucose to maintain contraction.\n\nGlycogen is broken down by an enzyme called glycogen phosphorylase. At rest, glycogen phosphorylase B is in a tense state due to the presence of ATP and certain enzymes. In its tense form, phosphorylation B is unable to bind with glycogen and therefore cannot break it down[4], [5]. Without the ability to breakdown glycogen into glucose, muscle is unable to maintain contraction and is forced to relax.\n\nThere are multiple stimuli for aggregation in skeletal muscle including the generation of thermal energy (heat), increases in AMP levels, and increases in calcium ion levels. Vesilute appears to interfere with the process of aggregation at a universal step, thereby preventing glycogen breakdown by any mechanism. This, in turn, induces smooth muscle relaxation. Relaxation of smooth muscle ends the signals calling for more energy and can help to break the cycle that leads to spasm. Because smooth muscle is dependent on calcium signals for maintenance, breaking the spasmodic cycle by reducing calcium levels and dissipating heat can lead to long-term relief from spasm. These effects would be highly prominent in the urinary tract where smooth muscle is abundant.\n\nVesilute and Blood Vessels\n\nThe effects of Vesilute, which is considered to be a cytomedine peptide, would also be prominent in the vasculature where smooth muscle reigns supreme. Cytomedines, according to Vladimir Khavinson, are peptide bioregulators that prevent premature aging[6]. In this case, interruption of aggregation would lead to vessel relaxation. This would lead to lower blood pressure, reduced energy expenditure in the heart, and improved nutrient delivery to organs throughout the body. Thus, Vesilute 20mg likely has beneficial effects on blood pressure, the long-term health of the vascular system, and several end organs like the heart, brain, and kidneys.\n\nIt is thought that the benefits of Vesilute on the prostate are due to its microvascular effects. Improved circulation in the prostate helps to reduce inflammation, improve blood flow, and rid the prostate of toxins. The net effect of improved microvascular circulation in the prostate is a decrease in fibrosis and enlargement of the prostate gland. Research shows that prostate massage has a similar effect.\n\nVesilute and Fertility\n\nInterestingly, decreasing prostatitis by increasing microvascular supply to the gland via cytomedines like Vesilute appears to have an impact on spermatogenesis. Sperm levels following treatment of prostatitis increase as much as 29% and show more than a 14% increase in viability[7]. Research shows that men treated with cytomedines like Vesilute experience an increase in fertility without intolerable side effects.\n\nVesilute Summary\n\nVesilute is a Khavinson peptide with research exploring its role in regulating the urinary tract and prostate gland. Research evidence indicates that Vesilute may help to relieve symptoms associated with bladder and urinary tract dysfunction. Vesilute and other cytomedines have been shown to reduce prostate dysfunction and are thought to act by improving microcirculation in the prostate and by reducing cell proliferation. The latter effect may be due to changes in chromosome density and epigenetic factors, a mechanism of cellular regulation that is common among Khavinson peptides."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "vilon": {
    "title": "Vilon 20mg (Bioregulator)",
    "url": "https://www.peptidesciences.com/vilon-20mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Vilon: Research Applications",
        "content": "Vilon is used as a research reagent in laboratory workflows focused on preclinical and mechanistic endpoints, including:\n\n• Epigenetics and chromatin biology: interrogation of chromatin accessibility states (euchromatin/heterochromatin balance) and transcriptional reactivation in cultured cells.\n\n• Immunology and cytokine-gene regulation: evaluation of transcriptional control of immune signaling genes (e.g., interleukin pathway transcripts) in ex vivo or in vitro immune-cell preparations.\n\n• Transcriptomics and gene-expression profiling: analysis of tissue-level gene-expression changes using array-based or sequencing-based methods in rodent models.\n\n• Tumor biology (preclinical): investigation of peptide-associated modulation of tumor growth kinetics and immune/tissue transcriptional programs in established animal models.\n\n• Microvascular biology and extracellular matrix signaling: assessment of signaling mediators implicated in microvessel permeability and tissue remodeling under experimentally induced conditions."
      },
      {
        "heading": "Vilon: Preclinical Research Summary",
        "content": "The peer-reviewed literature commonly cited for Vilon includes:\n\n• Cell-based / ex vivo immune-cell studies evaluating chromatin accessibility and transcriptional reactivation in lymphocyte systems under laboratory conditions.\n\n• In vitro studies assessing cytokine-gene expression (including IL-2 transcript regulation) in splenocyte preparations.\n\n• Culture studies of thymus-derived cells in which lymphocyte proliferation markers and population shifts are measured in controlled environments.\n\n• Rodent studies reporting associations with spontaneous tumor growth parameters and survival endpoints, interpreted as preclinical observations in established animal models.\n\n• Rodent studies of gastrointestinal tissue enzyme activity and nutrient-transport readouts as experimental markers of age-associated intestinal functional change.\n\n• Mouse heart gene-expression profiling using microarray approaches to quantify transcriptional shifts after experimental exposure.\n\n• Experimental renal stress models evaluating signaling mediators (including TGF-β–linked pathways) and microvascular permeability-associated parameters.\n\nInterpretation of these findings should remain constrained to the specific experimental systems, endpoints, and model organisms described in the cited publications."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of ",
    "citations": []
  },
  "vip": {
    "title": "VIP 6mg",
    "url": "https://www.peptidesciences.com/vip-6mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "VIP is widely utilized in experimental systems investigating:\n\nNeuroimmune signaling and cytokine network modulation\nEpithelial barrier integrity and tight-junction dynamics\nSmooth muscle cell proliferation and differentiation\nFibrotic pathway regulation in pulmonary and cardiac tissue models\nNeurotrophic factor expression and synaptic maintenance\n\nUse of VIP in these contexts is restricted to mechanistic and observational research frameworks."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "In animal and ex-vivo tissue models, VIP has been associated with measured changes in:\n\nImmune cell infiltration indices\nFibrosis-associated gene expression profiles\nEpithelial permeability and tight-junction protein distribution\nNeurotrophic factor secretion levels\n\nThese findings represent reported experimental endpoints and observed associations within controlled research environments and do not imply functional outcomes outside laboratory models."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "bpc-157, tb-500": {
    "title": "BPC-157, TB-500 (Blend)",
    "url": "https://www.peptidesciences.com/bpc-157-tb-500-20mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "BPC-157, TB-500 Blend: Research Applications",
        "content": "The combined study of BPC-157 and TB-500 is primarily relevant to research questions where cell recruitment, migration, and coordinated remodeling are limiting factors. Example research contexts include:\n\nWound repair models requiring fibroblast migration, extracellular matrix deposition, and remodeling\nTendon/ligament repair models focused on cell survival, outgrowth, and restoration of tissue organization[1]\nFibrosis and remodeling research where thymosin beta-4–related pathways are of interest[2]\nAngiogenesis-associated repair questions (e.g., vascular support as a rate limiter in tissue regeneration)[5]\n\nBecause “synergy” is an outcome claim that must be demonstrated experimentally, this page frames synergy as a hypothesis: if BPC-157 and TB-500 affect different bottlenecks in repair (gene expression vs. cytoskeletal mobilization, for example), combined administration in preclinical designs may produce additive or multiplicative improvements in migration speed, wound closure kinetics, tissue organization, or histologic markers of remodeling—depending on model choice and endpoints."
      },
      {
        "heading": "BPC-157, TB-500 Blend: Preclinical Research Summary",
        "content": "The primary evidence base referenced here consists of: (1) tendon-oriented work linking BPC-157 to outgrowth, survival, and migration processes relevant to repair[1], and (2) thymosin beta-4 literature discussing pathway-level roles in remodeling and fibrosis-related biology[2], as well as angiogenesis and wound healing contexts[5].\n\nFrom these sources, a reasonable preclinical summary is:\n\nBPC-157: associated with tissue repair behaviors that include cell survival and migration in tendon-focused models[1].\nThymosin beta-4/TB-500 context: discussed in relation to fibrosis/remodeling pathways and repair-associated angiogenesis across multiple research domains[2], [5].\nIntersection concept: migration and remodeling biology (actin-driven movement + repair-program signaling) provides a mechanistic bridge for combination testing.\n\nBecause “synergy” is a higher bar than “overlap,” rigorous evaluation typically requires combination arms vs. single-peptide arms, standardized injury models, and predefined endpoints (migration assays, histology, collagen organization, vascular markers, inflammatory markers, and functional recovery metrics)."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Allan L. Goldstein, MD, Allan L. Goldstein is professor and Catharine B. & William McCormick Chair of the department of Biochemistry and Molecular Biology at The George Washington University School of Medicine and Health Sciences, where he has served since 1978. Thymosins were discovered in the mid 1960’s, when Allan Goldstein from the Laboratory of Abraham White at the Albert Einstein College of Medicine in New York studied the role of the thymus in development of the vertebrate immune system. He is a world-renowned authority on the thymus gland and the workings of the immune system, and co-discoverer of the thymosins. Dr. Goldstein is the author of over 400 scientific articles in professional journals, the inventor on more than 15 U.S. Patents, and the editor of several books in the fields of biochemistry, biomedicine, immunology and neuro-science. He is on the editorial boards of numerous scientific and medical journals and has been a consultant to many re-search organizations in industry and government; co-founder of The Institute for Advanced Studies in Aging and Geriatric Medicine, a non-profit research and educational institute; a member of the Board of Trustees of the Albert Sabin Vaccine Institute; and serves as the Chairman of the Board of RegeneRx Biopharmaceuticals. Dr. Goldstein received his B.S. from Wagner College in 1959 and his M.S. and Ph.D. from Rutgers University in 1964. He served as a faculty member of the Albert Einstein College of Medicine from 1964 to",
    "citations": [
      "Song, Ran & Choi, Hyun & Yang, Hyung-In & Yoo, Myung & Park, Yong-Beom & Kim, Kyoung. (2012). Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy. Clinical rheumatology. 31. 1253-8. 10.1007/s10067-012-2011-7. [Research Gate]",
      "Philp, D., et al. “Thymosin β4 Promotes Angiogenesis, Wound Healing, and Hair Follicle Development.” Mechanisms of Ageing and Development, vol. 125, no. 2, Feb. 2004, pp. 113–115, 10.1016/j.mad.2003.11.005. [PubMed]"
    ]
  },
  "bpc-157, tb-500, ghk-cu": {
    "title": "BPC-157, TB-500, GHK-Cu (Glow Blend)",
    "url": "https://www.peptidesciences.com/bpc-157-tb-500-ghk-cu-30mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "BPC-157 + TB500 (Thymosin Beta 4) + GHK-Cu Blend: Research Applications",
        "content": "This blend is utilized in research environments investigating coordinated regulation of inflammation, angiogenesis, fibroblast activity, and cellular stress responses. Experimental applications include in vitro cell culture systems, ex vivo tissue models, and animal studies designed to observe multi-pathway modulation following peptide exposure.\n\nSpecific areas of investigation include:\n\nRegulation of nitric oxide and endothelial signaling pathways\nActin dynamics and cell migration processes\nExtracellular matrix deposition and remodeling\nOxidative stress mitigation and redox balance\nGene expression modulation related to repair and immune signaling\n\nThe combined formulation allows researchers to evaluate overlapping and divergent signaling effects without the need for parallel administration protocols."
      },
      {
        "heading": "BPC-157 + TB500 (Thymosin Beta 4) + GHK-Cu Blend: Preclinical Research Summary",
        "content": "Preclinical studies of BPC-157 demonstrate widespread tissue distribution and modulation of inflammatory responses across multiple organ systems. Experimental models suggest rapid peptide uptake and sustained biological activity at the tissue level.\n\nTB500 has been evaluated in diverse animal and cellular models, where it is associated with enhanced cellular migration, angiogenic signaling, and regulation of immune cell activity. Its involvement in cytoskeletal regulation positions it as a central mediator of coordinated tissue responses.\n\nGHK-Cu has been investigated for its role in oxidative stress control, extracellular matrix turnover, and gene expression modulation. Transcriptomic analyses indicate broad influence over genes associated with inflammation, repair, and cellular maintenance.\n\nWhile combination-specific outcomes remain an area of ongoing investigation, existing preclinical data support the rationale for studying these peptides together in controlled experimental systems."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Patrycja Kleczkowska, Assoc. Prof. Ph.D. Eng., is an employee of the Military Institute of Hygiene and Epidemiology as a Deputy Director for scientific affairs. As an employee of the Maria Sklodowska-Curie Medical Academy in Warsaw, she deals with didactic activities and scientific work focusing on the field of pharmacology. As an employee of the Polish Academy of Sciences from 2005 to 2015, she began her work on designing and synthesizing drugs with biological activity, mainly in the area of analgesic and neuroprotective effects. Currently, she is expanding her knowledge and skills on the toxicity of new biologically active potential therapeutic substances and defining their safety profiles.\n\nPatrycja Kleczkowska, Assoc. Prof. Ph.D. Eng is being referenced as one of the leading scientists involved in the research and development of BPC-157, TB-500 and GHK-Cu. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Patrycja Kleczkowska, Assoc. Prof. Ph.D. Eng is listed in [2] under the",
    "citations": []
  },
  "bpc-157, tb-500, kpv, ghk-cu": {
    "title": "BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend)",
    "url": "https://www.peptidesciences.com/bpc-157-tb-500-ghk-cu-kpv-80mg-glow-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "BPC-157, TB-500, KPV, GHK-Cu Blend: Research Applications",
        "content": "This peptide blend is of interest for research in tissue regeneration, musculoskeletal injury, inflammatory disorders, fibrosis prevention, and aging-associated tissue decline. Investigational models include skin wounds, tendon and ligament injury, muscle degeneration, gastrointestinal inflammation, pulmonary injury, and neuroinflammatory conditions.\n\nThe combination allows exploration of how coordinated modulation of nitric oxide signaling, cytokine production, extracellular matrix remodeling, and stem-cell-related pathways influences healing speed, scar quality, and long-term tissue function.\n\nAdditional areas of research interest include angiogenesis, immune cell recruitment, oxidative stress mitigation, and regulation of gene expression patterns associated with chronic inflammation and aging."
      },
      {
        "heading": "BPC-157, TB-500, KPV, GHK-Cu Blend: Preclinical Research Summary",
        "content": "Preclinical studies of BPC-157 demonstrate accelerated wound closure, enhanced angiogenesis, reduced inflammatory infiltration, and improved functional outcomes in tendon, muscle, gastrointestinal, and cardiovascular injury models. TB-500 has shown efficacy in promoting cell migration, reducing fibrosis, and enhancing regeneration in cardiac, muscular, ocular, and dermal injury models.\n\nGHK-Cu has been shown to improve wound healing rates, reduce infection incidence, modulate gene expression associated with tissue regeneration, and protect against oxidative and inflammatory injury in pulmonary, dermal, and neural tissues. KPV has demonstrated broad anti-inflammatory activity across multiple organ systems, with particular efficacy in reducing scarring and pathological inflammation.\n\nCollectively, these peptides demonstrate complementary effects that suggest additive or synergistic outcomes when combined, particularly in models of chronic inflammation, delayed healing, and age-associated tissue degeneration."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Patrycja Kleczkowska, Assoc. Prof. Ph.D. Eng., is an employee of the Military Institute of Hygiene and Epidemiology as a Deputy Director for scientific affairs. As an employee of the Maria Sklodowska-Curie Medical Academy in Warsaw, she deals with didactic activities and scientific work focusing on the field of pharmacology. As an employee of the Polish Academy of Sciences from 2005 to 2015, she began her work on designing and synthesizing drugs with biological activity, mainly in the area of analgesic and neuroprotective effects. Currently, she is expanding her knowledge and skills on the toxicity of new biologically active potential therapeutic substances and defining their safety profiles.\n\nPatrycja Kleczkowska, Assoc. Prof. Ph.D. Eng is being referenced as one of the leading scientists involved in the research and development of BPC-157, TB-500, GHK-Cu and KPV. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Patrycja Kleczkowska, Assoc. Prof. Ph.D. Eng is listed in [3] under the",
    "citations": []
  },
  "cjc-1295, ghrp-2": {
    "title": "CJC-1295 (no DAC), GHRP-2 10mg (Blend)",
    "url": "https://www.peptidesciences.com/cjc-1295-ghrp-2-10mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "This peptide blend is used in preclinical research to examine pulsatile GH secretion patterns, receptor activation timing, and coordination between GHRH and GHSR signaling pathways. Experimental systems include isolated pituitary tissues and animal models utilized to study endocrine signal integration.\n\nAdditional applications include investigation of downstream signaling events, transcriptional regulation, and second-messenger dynamics associated with somatotroph cell activation under controlled laboratory conditions."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Published preclinical studies involving GHRH analogues and GHSR agonists have examined GH secretion dynamics, receptor activity, and associated molecular markers in animal models. Observations are reported within controlled laboratory environments.\n\nAll findings are interpreted strictly within the scope of basic research and do not imply any clinical, diagnostic, or applied outcomes."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.\n\nDr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [7] under the",
    "citations": [
      "M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]",
      "D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1,” Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008. [PubMed]",
      "V. Bodart et al., “Identification and characterization of a new growth hormone-releasing peptide receptor in the heart,” Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999. [PubMed]",
      "D. D. Taub, W. J. Murphy, and D. L. Longo, “Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways,” Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010. [PubMed]",
      "S. L. Teichman, A. Neale, B. Lawrence, C. Gagnon, J.-P. Castaigne, and L. A. Frohman, “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults,” J. Clin. Endocrinol. Metab., vol. 91, no. 3, pp. 799–805, Mar. 2006. [PubMed]",
      "Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]"
    ]
  },
  "cjc-1295, ghrp-6": {
    "title": "CJC-1295 (no DAC), GHRP-6 10mg (Blend)",
    "url": "https://www.peptidesciences.com/cjc-1295-ghrp-6-10mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "This blend is used in preclinical research designs focused on:\nComparative analysis of GHRHR vs. GHSR-1a receptor activation and downstream signaling output\nCharacterization of pulsatile endocrine signaling patterns and receptor cross-talk in pituitary-derived tissues\nInvestigation of growth hormone axis feedback regulation and downstream insulin-like growth factor (IGF) pathway markers in animal models\nIn-vitro receptor binding, second messenger (cAMP and Ca2+) assays, and signal transduction profiling under controlled conditions"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Published research has evaluated GHRH analogs and growth hormone secretagogues in non-clinical systems to characterize pulsatile growth hormone secretion, receptor selectivity, and endocrine signaling dynamics. Studies have examined persistence of pulsatile secretion during sustained GHRH analog stimulation as well as mechanistic outcomes associated with ghrelin receptor activation in cellular and animal models. All findings referenced for these peptide classes are derived from preclinical research contexts and are used to inform mechanistic hypotheses and experimental design."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Márta Korbonits graduated in Medicine in Budapest and undertook her early clinical training at the Internal Medicine Department of the Postgraduate Medical School, Budapest. She joined the Department of Endocrinology at St. Bartholomew’s Hospital under the mentorship of Professors Ashley Grossman and Michael Besser. Her MD and later PhD studies contributed to the understanding of the effects of growth hormone secretagogues on hypothalamic hormone release and the nature and causes of pituitary tumorigenesis. She was awarded an MRC Clinician Scientist Fellowship and commenced studies that produced novel insights into ghrelin physiology and genetics. Her findings related to the regulation of the metabolic enzyme AMPK by ghrelin, cannabinoid and glucocorticoid opened a new aspect of hormonal regulation of metabolism. In 2008, Márta Korbonits was promoted to Professor of Endocrinology and Metabolism and since 2012, has led the Centre of Endocrinology at Barts and the London School of Medicine. In 2016, Márta Korbonits was appointed a Deputy Head of the William Harvey Research Institute. Professor Korbonits continues to integrate human studies alongside with laboratory-based research and has pioneered several projects in translational medicine.\n\nMárta Korbonits is being referenced as one of the leading scientists involved in the research and development of GHRP-6. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. T",
    "citations": [
      "[1] M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]",
      "[2] S. L. Teichman, A. Neale, B. Lawrence, C. Gagnon, J.-P. Castaigne, and L. A. Frohman, “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults,” J. Clin. Endocrinol. Metab., vol. 91, no. 3, pp. 799–805, Mar. 2006. [PubMed]",
      "[4] M. Fernández-Mayola et al., “Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study,” Int. Wound J., vol. 15, no. 4, pp. 538–546, Aug. 2018. [PubMed]",
      "[5] H.-J. Huang et al., “The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice,” Neuropharmacology, May 2019. [PubMed]",
      "[6] N. Subirós et al., “Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy,” Neurol. Res., vol. 38, no. 3, pp. 187–195, Mar. 2016. [PubMed]",
      "[7] Korbonits, Marta, and Ashley B. Grossman. “Growth Hormone-Releasing Peptide and Its Analogues.” Trends in Endocrinology & Metabolism, vol. 6, no. 2, Mar. 1995, pp. 43–49 [PubMed]"
    ]
  },
  "cjc-1295, hexarelin": {
    "title": "CJC-1295 (no DAC), Hexarelin 10mg (Blend)",
    "url": "https://www.peptidesciences.com/cjc-1295-hexarelin-10mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Experimental applications for Hexarelin + CJC-1295 co-administration designs include:\nCharacterization of pituitary receptor cross-talk and endocrine pulsatility under dual-receptor stimulation\nSignal transduction profiling in cell-based assays (e.g., cAMP readouts, Ca2+ flux, MAPK/ERK pathway activation)\nPreclinical evaluation of tissue-specific receptor expression and downstream molecular responses in cardiovascular and metabolic research models"
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Non-clinical studies have investigated hexarelin in cardiovascular research models, including rodent and murine ischemia/reperfusion paradigms and diabetic model systems, with emphasis on cardiomyocyte signaling, inflammatory mediator pathways, and intracellular calcium regulation[1]–[3]. Additional animal studies have examined hexarelin-associated alterations in lipid metabolism markers within insulin-resistant model systems[4]. Separate preclinical investigations have explored growth hormone secretagogues, including hexarelin, in skeletal muscle models evaluating mitochondrial integrity and calcium homeostasis under chemotherapy-associated stress paradigms in rodents[5], [6]. All referenced findings are derived from laboratory and animal research settings and are used to inform mechanistic hypotheses."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Aline Moulin’s research contributions include studies involving ghrelin receptor pharmacology and evaluation of compounds for their capacity to modulate hexarelin-associated signaling readouts in experimental systems. Her work spans development and characterization efforts relevant to receptor ligand profiling, quality frameworks, and research operations across multiple scientific settings.\n\nAline Moulin is referenced solely to acknowledge scientific contributions in this field. No endorsement, affiliation, or advocacy is implied. Aline Moulin is listed in [8] under the",
    "citations": [
      "X. Zhang, L. Qu, L. Chen, and C. Chen, “Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats,” Physiol. Rep., vol. 6, no. 4, 2018. [PubMed]",
      "J. Huang, Y. Li, J. Zhang, Y. Liu, and Q. Lu, “The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway,” Int. Heart. J., vol. 58, no. 2, pp. 257–263, Apr. 2017. [PubMed]",
      "R. Mosa et al., “Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice,” Endocrinology, vol. 158, no. 10, pp. 3174–3187, 01 2017. [PubMed]",
      "E. Conte et al., “Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia,” J. Cachexia Sarcopenia Muscle, vol. 8, no. 3, pp. 386–404, Jun. 2017. [PubMed]",
      "X. Zhang, L. Qu, L. Chen, and C. Chen, “Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats,” Physiol. Rep., vol. 6, no. 4, 2018. [PubMed]",
      "Torsello, Antonio & Bresciani, Elena & Tamiazzo, Laura & Bulgarelli, Ilaria & Caporali, Simona & Moulin, Aline & Fehrentz, jean-alain & Martinez, Jean & Perissoud, Daniel & Locatelli, Vittorio. (2008). Novel potent and selective non-peptide ligands of ghrelin receptor : characterization of endocrine and extraendocrine actions. [Research Gate]"
    ]
  },
  "cjc-1295, ipamorelin, ghrp-2": {
    "title": "CJC-1295 (no DAC), Ipamorelin, GHRP-2 (Blend)",
    "url": "https://www.peptidesciences.com/cjc1295-ipamorelin-ghrp-2-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "fragment, cjc-1295, ipamorelin": {
    "title": "Fragment, CJC-1295 (no DAC), Ipamorelin 12mg (Blend)",
    "url": "https://www.peptidesciences.com/fragment-cjc1295-ipamorelin-12mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "In preclinical research, Fragment 176–191 is studied for its role in adipocyte lipid metabolism, energy partitioning, and regulation of lipolytic signaling pathways. Investigations focus on adipose tissue–specific responses independent of classical growth hormone receptor activation."
      },
      {
        "heading": "Research Applications",
        "content": "This peptide is utilized in laboratory research to examine hypothalamic–pituitary signaling, growth hormone release kinetics, receptor responsiveness, and downstream insulin-like growth factor (IGF) pathway modulation in preclinical models."
      },
      {
        "heading": "Research Applications",
        "content": "Ipamorelin is employed in preclinical studies to evaluate ghrelin receptor–dependent signaling, intracellular calcium mobilization, phospholipase C activation, and selective modulation of growth hormone secretagogue pathways in animal and cellular models."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical studies involving these peptides have examined endocrine pulsatility, receptor selectivity, adipocyte metabolism, skeletal matrix markers, and feedback regulation within growth hormone–associated pathways. All findings referenced in the scientific literature are derived exclusively from cellular assays and animal models and are intended to advance mechanistic and biochemical understanding."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.\n\nDr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [10] under the",
    "citations": [
      "M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. [PubMed]",
      "R. Ferrer-Lorente, C. Cabot, J.-A. Fernández-López, and M. Alemany, “Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats,” Life Sci., vol. 77, no. 16, pp. 2051–2058, Sep. 2005. [PubMed]",
      "F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. [PubMed]",
      "M. C. Van Hout and E. Hearne, “Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions,” Subst. Use Misuse, vol. 51, no. 1, pp. 73–84, Jan. 2016. [PubMed]",
      "K. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]",
      "E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]",
      "J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]",
      "M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]",
      "M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]",
      "Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]"
    ]
  },
  "fragment, modified grf, ipamorelin": {
    "title": "Fragment, Modified GRF, Ipamorelin 12mg (Blend)",
    "url": "https://www.peptidesciences.com/fragment-modified-grf-ipamorelin-12mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "Dr. Jan Izdebski has been listed as a noteworthy Chemist, researcher by Marquis Who's Who. He attained a Master of Science from University Warsaw, Poland, 1959 and is a Doctor of Philosophy, University Warsaw, Poland, 1965, along with a Doctor of Science, University Warsaw, Poland, 1979. He studied how GRF 1-29 is more resistant to enzymatic degradation and how that affects its half-life.\n\nDr. Jan Izdebski is being referenced as one of the leading scientists involved in the research and development of GRF 1-29. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Jan Izdebski is listed in [9] under the",
    "citations": [
      "T. Ito et al., “GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity,” Peptides, vol. 22, no. 7, pp. 1139–1151, Jul. 2001. [PubMed]",
      "M. Waelbroeck, P. Robberecht, D. H. Coy, J.-C. Camus, P. D. Neef, and J. Christophe, “Interaction of Growth Hormone-Releasing Factor (GRF) and 14 GRF Analogs with Vasoactive Intestinal Peptide (VIP) Receptors of Rat Pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(l-29)-NH2 as a VIP Antagonist,” Endocrinology, vol. 116, no. 6, pp. 2643–2649, Jun. 1985. [PubMed]",
      "A. V. Schally, X. Zhang, R. Cai, J. M. Hare, R. Granata, and M. Bartoli, “Actions and potential therapeutic applications of growth hormone-releasing hormone agonists,” Endocrinology. [PubMed]",
      "N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]",
      "Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]",
      "M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. [PubMed]",
      "R. Ferrer-Lorente, C. Cabot, J.-A. Fernández-López, and M. Alemany, “Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats,” Life Sci., vol. 77, no. 16, pp. 2051–2058, Sep. 2005. [PubMed]",
      "F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. [PubMed]"
    ]
  },
  "mod grf, ghrp-2": {
    "title": "Mod GRF, GHRP-2 10mg (Blend)",
    "url": "https://www.peptidesciences.com/mod-grf-ghrp-2-10mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "In laboratory research environments, GHRH analogues and GHSR agonists are used to investigate the regulation of GH secretion patterns in animal models. These peptides support experimental evaluation of pulsatile hormone release, receptor activation timing, and interactions with inhibitory regulators such as somatostatin.\n\nAdditional applications include mechanistic studies examining downstream signaling pathways associated with GH release, including transcriptional regulation and secondary messenger activity in endocrine tissues."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Published studies conducted in rodent models and isolated tissue systems have characterized the biochemical and signaling effects of GHRH analogues and GHSR agonists. These investigations report measurable changes in GH secretion profiles, receptor activity, and associated molecular markers under controlled experimental conditions.\n\nObservations reported in the scientific literature are interpreted exclusively within the scope of basic research and endocrine physiology. No clinical, diagnostic, or applied implications are derived from these findings."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Dr. Jan Izdebski has been listed as a noteworthy Chemist, researcher by Marquis Who's Who. He attained a Master of Science from University Warsaw, Poland, 1959 and is a Doctor of Philosophy, University Warsaw, Poland, 1965, along with a Doctor of Science, University Warsaw, Poland, 1979. He studied how GRF 1-29 is more resistant to enzymatic degradation and how that affects its half-life.\n\nDr. Jan Izdebski is being referenced as one of the leading scientists involved in the research and development of GRF 1-29. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Jan Izdebski is listed in [7] under the",
    "citations": [
      "[1] M. Waelbroeck, P. Robberecht, D. H. Coy, J.-C. Camus, P. D. Neef, and J. Christophe, “Interaction of Growth Hormone-Releasing Factor (GRF) and 14 GRF Analogs with Vasoactive Intestinal Peptide (VIP) Receptors of Rat Pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(l-29)-NH2 as a VIP Antagonist,” Endocrinology, vol. 116, no. 6, pp. 2643–2649, Jun. 1985. [PubMed]",
      "[2] A. V. Schally, X. Zhang, R. Cai, J. M. Hare, R. Granata, and M. Bartoli, “Actions and potential therapeutic applications of growth hormone-releasing hormone agonists,” Endocrinology. [PubMed]",
      "[3] E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]",
      "[4] D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]",
      "[5] N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]",
      "[6] J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]"
    ]
  },
  "mod grf, ghrp-6": {
    "title": "Mod GRF, GHRP-6 10mg (Blend)",
    "url": "https://www.peptidesciences.com/mod-grf-ghrp-6-10mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "mod grf, hexarelin": {
    "title": "Mod GRF, Hexarelin 10mg (Blend)",
    "url": "https://www.peptidesciences.com/mod-grf-hexarelin-10mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "mod grf, ipamorelin": {
    "title": "Mod GRF, Ipamorelin 10mg (Blend)",
    "url": "https://www.peptidesciences.com/modified-grf-ipamorelin-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "mod grf, ipamorelin, ghrp-2": {
    "title": "Mod GRF, Ipamorelin, GHRP-2 (Blend)",
    "url": "https://www.peptidesciences.com/modified-grf-ipamorelin-ghrp2-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "sermorelin, ghrp-2": {
    "title": "Sermorelin, GHRP-2 10mg (Blend)",
    "url": "https://www.peptidesciences.com/sermorelin-ghrp-2-10mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "sermorelin, ghrp-6": {
    "title": "Sermorelin, GHRP-6 10mg (Blend)",
    "url": "https://www.peptidesciences.com/sermorelin-ghrp-6-10mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "sermorelin, ipamorelin": {
    "title": "Sermorelin, Ipamorelin 10mg (Blend)",
    "url": "https://www.peptidesciences.com/sermorelin-ipamorelin-10mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "In preclinical research, sermorelin is utilized to study GHRH-mediated signaling, somatotroph activation, and downstream transcriptional regulation. Ipamorelin is employed to evaluate ghrelin receptor signaling dynamics, calcium mobilization, and secretagogue pathway selectivity. Combined experimental paradigms focus on endocrine pulsatility, receptor cross-talk, and downstream molecular responses."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Animal and in-vitro studies have investigated GHRH and ghrelin receptor expression in cardiac, neural, skeletal, and gastrointestinal tissues. Experimental findings include observations related to cellular survival signaling, inflammatory marker modulation, vascular remodeling processes, neural receptor interactions, skeletal metabolism markers, pancreatic signaling pathways, and gastrointestinal motility models. All findings originate from preclinical laboratory research and are used solely to advance mechanistic understanding."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "Richard F. Walker, Ph.D, R.Ph, lead author of A better approach to management of adult-onset growth hormone insufficiency?”, received a BS in pharmacy from Rutgers University, a MS in Biochemistry from New Mexico State University and a PhD in a physiology from Rutgers University. He holds postdoctoral fellowships in neuroendocrinology and neuropharmacology at Duke University College of Medicine (Center for the Study of Aging and Human Development) and the University of California, Berkeley, respectively.\n\nRichard F. Walker, Ph.D, R.Ph is being referenced as one of the leading scientists involved in the research and development of Sermorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Richard F. Walker, Ph.D, R.Ph is listed in [11] under the",
    "citations": [
      "L. L. Bagno et al., “Growth Hormone–Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy,” J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis., vol. 4, no. 4, Mar. 2015. [PubMed]",
      "R. M. Kanashiro-Takeuchi et al., “New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor,” Oncotarget, vol. 6, no. 12, pp. 9728–9739, Mar. 2015. [PubMed]",
      "T. Tokudome, K. Otani, M. Miyazato, and K. Kangawa, “Ghrelin and the heart,” Peptides, vol. 111, pp. 42–46, 2019. [PubMed]",
      "S. Tang et al., “Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy,” Sci. Rep., vol. 7, Dec. 2017. [PubMed]",
      "B. S. Shepherd et al., “Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss),” Comp. Biochem. Physiol. A. Mol. Integr. Physiol., vol. 146, no. 3, pp. 390–399, Mar. 2007. [PubMed]",
      "N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]",
      "J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]",
      "N. K. Aagaard et al., “Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 19, no. 5, pp. 426–431, Oct. 2009. [PubMed]",
      "E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]",
      "D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]",
      "R. F. Walker, “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?,” Clin. Interv. Aging, vol. 1, no. 4, pp. 307–308, Dec. 2006. [PubMed]"
    ]
  },
  "sermorelin, ghrp-6, ghrp-2": {
    "title": "Sermorelin, GHRP-6, GHRP-2 9mg (Blend)",
    "url": "https://www.peptidesciences.com/sermorelin-ghrp-6-ghrp-2-9mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Sermorelin, GHRP-6, GHRP-2 Blend: Research Applications",
        "content": "This peptide combination is utilized in laboratory research focused on neuroendocrine signaling, pituitary hormone regulation, and ghrelin-axis biology. Common experimental applications include receptor cross-talk analysis, second-messenger coordination studies, transcriptional profiling, and evaluation of tissue-specific GHS-R1a expression in preclinical systems.\n\nThe formulation supports research into signaling dynamics across central and peripheral tissues, including investigation of receptor-mediated effects on cellular metabolism, protein turnover, and neuroendocrine feedback mechanisms described in animal and cell-based models."
      },
      {
        "heading": "Sermorelin, GHRP-6, GHRP-2 Blend: Preclinical Research Summary",
        "content": "Preclinical in vitro and animal studies have demonstrated that GHRH analogues and ghrelin receptor agonists exert overlapping yet distinct molecular effects on endocrine signaling, receptor distribution, and intracellular pathway activation.\n\nComparative studies of GHRP-2 and GHRP-6 highlight differences in receptor responsiveness, signal duration, and downstream effector engagement, providing valuable tools for mechanistic interrogation of ghrelin-axis regulation without implying clinical relevance."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Richard F. Walker, Ph.D, R.Ph, lead author of A better approach to management of adult-onset growth hormone insufficiency?”, received a BS in pharmacy from Rutgers University, a MS in Biochemistry from New Mexico State University and a PhD in a physiology from Rutgers University. He holds postdoctoral fellowships in neuroendocrinology and neuropharmacology at Duke University College of Medicine (Center for the Study of Aging and Human Development) and the University of California, Berkeley, respectively.\n\nRichard F. Walker, Ph.D, R.Ph is being referenced as one of the leading scientists involved in the research and development of Sermorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Richard F. Walker, Ph.D, R.Ph is listed in [22] under the",
    "citations": [
      "D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1,” Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008. [PubMed]",
      "L. T. Phung et al., “The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine,” Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000.[PubMed]",
      "B. Laferrère, C. Abraham, C. D. Russell, and C. Y. Bowers, “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men,” J. Clin. Endocrinol. Metab., vol. 90, no. 2, pp. 611–614, Feb. 2005.[PubMed]",
      "G. Muccioli et al., “Growth hormone-releasing peptides and the cardiovascular system,” Ann. Endocrinol., vol. 61, no. 1, pp. 27–31, Feb. 2000. [PubMed]",
      "V. Bodart et al., “Identification and characterization of a new growth hormone-releasing peptide receptor in the heart,” Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999. [PubMed]",
      "D. D. Taub, W. J. Murphy, and D. L. Longo, “Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways,” Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010. [PubMed]",
      "G. Copinschi et al., “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man,” Neuroendocrinology, vol. 66, no. 4, pp. 278–286, Oct. 1997. [PubMed]",
      "P. Zeng et al., “Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice,” Peptides, vol. 55, pp. 103–109, May 2014. [PubMed]",
      "C.-C. Huang, D. Chou, C.-M. Yeh, and K.-S. Hsu, “Acute food deprivation enhances fear extinction but inhibits long-term depression in the lateral amygdala via ghrelin signaling,” Neuropharmacology, vol. 101, pp. 36–45, Feb. 2016. [PubMed]",
      "K. Tóth, K. László, and L. Lénárd, “Role of intraamygdaloid acylated-ghrelin in spatial learning,” Brain Res. Bull., vol. 81, no. 1, pp. 33–37, Jan. 2010. [PubMed]",
      "N. Subirós et al., “Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy,” Neurol. Res., vol. 38, no. 3, pp. 187–195, Mar. 2016. [PubMed]",
      "M. Fernández-Mayola et al., “Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study,” Int. Wound J., vol. 15, no. 4, pp. 538–546, Aug. 2018. [PubMed]",
      "J. Berlanga et al., “Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction,” Clin. Sci. Lond. Engl. 1979, vol. 112, no. 4, pp. 241–250, Feb. 2007. [PubMed]",
      "H.-J. Huang et al., “The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice,” Neuropharmacology, May 2019. [PubMed]",
      "R. F. Walker, “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?,” Clin. Interv. Aging, vol. 1, no. 4, pp. 307–308, Dec. 2006. [PubMed]"
    ]
  },
  "tesamorelin, cjc-1295, ipamorelin": {
    "title": "Tesamorelin, CJC-1295 (no DAC), Ipamorelin 12mg (Blend)",
    "url": "https://www.peptidesciences.com/tesamorelin-cjc1295-ipamorelin-12mg-blend",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "This peptide is employed in cellular assays and in-vivo animal studies to investigate pulsatile growth hormone release, insulin-like growth factor signaling, and feedback regulation within the hypothalamic–pituitary axis."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical investigations have examined sustained growth hormone signaling patterns and serum protein profile changes following GHRH analog exposure. All reported findings originate from controlled laboratory or translational research environments."
      },
      {
        "heading": "Research Applications",
        "content": "Research applications include analysis of ghrelin-mediated intracellular signaling, calcium flux dynamics, and comparative secretagogue activity in rodent and cellular systems."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Animal-based studies have explored ipamorelin-associated signaling effects on skeletal development parameters and gastrointestinal motility models. All data are derived exclusively from non-clinical research settings."
      },
      {
        "heading": "Research Applications",
        "content": "The peptide is utilized in preclinical studies examining insulin-like growth factor signaling, lipid metabolism markers, and vascular-associated biochemical endpoints in cellular and animal models."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Published studies have explored tesamorelin-associated changes in adipose distribution markers, inflammatory signaling indicators, and endocrine feedback mechanisms. These findings are limited to experimental research contexts."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "igf-1 lr3  x 10 vials": {
    "title": "IGF-1 LR3 (Receptor Grade) 100mcg x 10 Vials",
    "url": "https://www.peptidesciences.com/igf-1-lr3-receptor-grade-100mcg-x-10-vials",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "IGF-1 LR3 (Receptor Grade): Research Applications",
        "content": "IGF-1 receptor binding and activation assays\nSignal transduction studies involving PI3K/AKT and MAPK/ERK pathways\nComparative analyses of IGFBP-dependent versus IGFBP-resistant IGF analogs\nCell proliferation, differentiation, and apoptosis modeling in cultured cell systems\nReceptor kinetics and downstream phosphorylation mapping\nPreclinical in-vivo (animal) studies examining IGF-axis biology\n\nReceptor Grade IGF-1 LR3 is commonly selected for experiments requiring robust and sustained IGF-1R engagement under tightly controlled laboratory conditions."
      },
      {
        "heading": "IGF-1 LR3 (Receptor Grade): Preclinical Research Summary",
        "content": "Preclinical investigations utilizing IGF-1 LR3 focus on elucidating IGF-axis biology rather than organism-level outcomes. In cell-based and animal models, IGF-1 LR3 has been employed to:\n\nCharacterize receptor binding affinity and internalization dynamics\nQuantify downstream phosphorylation profiles of IGF-1R substrates\nModel regulatory mechanisms governing cell survival and programmed cell death\nExamine differentiation pathways in lineage-specific progenitor cells\n\nAll findings reported in the literature are derived from controlled in-vitro or animal-based experimental systems and are interpreted strictly within a mechanistic research framework."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "bioregulators": {
    "title": "Bioregulators",
    "url": "https://www.peptidesciences.com/bioregulators",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "acetyl hexapeptide-3": {
    "title": "Acetyl Hexapeptide-3 (Argireline) 200mg (Topical)",
    "url": "https://www.peptidesciences.com/acetyl-hexapeptide-3-argireline-200mg-topical",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "1. SNARE Complex Assembly Studies\n\nArgireline is employed in cell-free and cellular models to examine competitive inhibition of SNAP-25 participation in SNARE complex formation. These studies help elucidate the molecular requirements for vesicle docking and fusion.\n\n2. Neurotransmitter Vesicle Dynamics\n\nIn neuronal and neurosecretory cell models, Argireline is used to investigate the modulation of calcium-dependent exocytosis and vesicle release kinetics by altering SNARE protein interactions.\n\n3. Protein–Protein Interaction Assays\n\nDue to its defined binding motif, Argireline serves as a probe for studying SNARE-associated protein interfaces, enabling characterization of binding affinity, conformational changes, and complex stability under controlled experimental conditions."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical research involving Argireline includes in-vitro studies using neuronal cell lines, fibroblast cultures, and reconstructed tissue models. These investigations focus on SNARE complex modulation, vesicle trafficking efficiency, and downstream signaling effects. All findings are confined to experimental laboratory systems and are used exclusively to advance understanding of vesicular transport biology."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "ahk": {
    "title": "AHK (Tripeptide-3) 200mg (Topical)",
    "url": "https://www.peptidesciences.com/ahk-tripeptide-3-200mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Fibroblast activation studies: Examination of peptide-driven changes in fibroblast proliferation and ECM-related gene expression.\n\nExtracellular matrix research: Investigation of collagen and elastin synthesis pathways in cultured connective tissue cells.\n\nEndothelial signaling: Analysis of vascular endothelial growth factor (VEGF)–associated pathways in cellular and animal models.\n\nGrowth factor modulation: Studies focused on transforming growth factor beta-1 (TGF-β1) regulation and its role in connective tissue biology.\n\nPeptide–metal interaction research: Use of AHK as a reference peptide in copper coordination and redox-related biochemical experiments."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "In vitro and animal-model studies have evaluated AHK as a regulator of fibroblast-associated ECM synthesis. In cultured dermal fibroblasts, exposure to AHK has been associated with increased collagen type I expression under specific experimental conditions, supporting its use as a mechanistic probe in collagen-related research [1].\n\nAdditional preclinical investigations have explored AHK-driven modulation of angiogenesis-related signaling, including effects on endothelial growth factor expression and vascular-associated cellular responses in experimental hair follicle models [2,3]. These studies are frequently cited to contextualize AHK within broader connective tissue and vascular biology research frameworks."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "ahk-cu": {
    "title": "AHK-Cu 200mg (Topical)",
    "url": "https://www.peptidesciences.com/ahk-cu-200mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Fibroblast signaling studies: Investigation of peptide-mediated modulation of fibroblast activation markers and ECM-associated gene expression.\n\nExtracellular matrix research: Evaluation of collagen/elastin biosynthesis pathways and matrix remodeling programs in cellular and tissue models.\n\nEndothelial biology: Exploration of pathways governing endothelial cell proliferation, differentiation, and survival in preclinical systems.\n\nGrowth factor signaling: Studies of VEGF- and TGF-β1–linked signaling nodes and transcriptional responses following AHK-Cu exposure.\n\nMetal–peptide coordination: Use as a reference compound in experiments assessing copper binding, stability, and structure–activity relationships of copper-peptide complexes."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical laboratory studies (including in vitro cellular systems and animal-model research) have evaluated AHK-Cu–associated changes in fibroblast behavior and ECM-related protein expression. In cultured skin-derived cells, AHK-Cu exposure has been associated with increased collagen type I production under specific experimental conditions, supporting continued use as a probe for collagen-linked transcriptional and translational pathways [1].\n\nAdditional benchtop and preclinical investigations have explored AHK-Cu in experimental designs evaluating follicle-associated cell populations and angiogenesis-related signaling (including VEGF-linked responses) [2]. These studies are commonly referenced for mechanistic context when modeling peptide-driven effects on vascular and connective tissue cell systems in vitro."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "decapeptide-12": {
    "title": "Decapeptide-12 (Topical)",
    "url": "https://www.peptidesciences.com/decapeptide-12",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Tyrosinase enzymology: Evaluation of peptide-mediated modulation of tyrosinase-catalyzed oxidation reactions in in-vitro assay systems.\n\nMelanogenesis pathway modeling: Investigation of upstream regulatory effects on pigment-associated biochemical endpoints in cellular research models.\n\nComparative enzyme structure–function studies: Assessment of tyrosinase activity across species and isoforms using peptide interaction probes.\n\nPhenolic oxidation research: Use in experimental systems modeling enzymatic browning and quinone formation from phenolic substrates.\n\nInsect biochemistry studies: Examination of tyrosinase-linked pathways involved in pigment and cuticle-associated biochemical processes."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical investigations have evaluated decapeptide-12 in isolated enzyme assays and pigment-related cellular models. In vitro studies using cultured pigment-producing cells have reported measurable reductions in melanin-associated biochemical markers consistent with upstream tyrosinase modulation under defined experimental conditions.\n\nComparative assay designs often include reference tyrosinase inhibitors to contextualize activity modulation. Such benchmarking is limited to analytical comparison within laboratory systems and does not imply applicability beyond research use."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "ghk-cu 1gram": {
    "title": "GHK-Cu 1gram (Copper Peptide) (1000mg) (Topical)",
    "url": "https://www.peptidesciences.com/ghk-cu-1gram-copper-peptide-1000mg-topical",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "89030-95-5",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "GHK-Cu 1gram (Copper Peptide): Research Applications",
        "content": "GHK-Cu is supplied exclusively as a research reagent for laboratory-based investigation. Common experimental applications include studies of copper-peptide coordination chemistry, modulation of transcriptional networks, extracellular matrix turnover, angiogenic signaling pathways, antimicrobial peptide interactions, and cellular stress-response mechanisms. The peptide is frequently employed in cell culture systems, biochemical assays, and controlled animal models to explore pathway-level responses to copper-bound peptide signaling."
      },
      {
        "heading": "GHK-Cu 1gram (Copper Peptide): Preclinical Research Summary",
        "content": "The referenced literature comprises exclusively preclinical investigations conducted in cell-based systems and animal models. These studies examine GHK-Cu–associated modulation of extracellular matrix synthesis, antimicrobial activity in vitro, neurovascular signaling pathways, inflammatory mediator regulation, and apoptosis-related molecular mechanisms. Observations reported in the cited publications are limited to defined experimental contexts and do not extend beyond laboratory research models."
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Loren Pickart, Ph.D. has released 109 publications and is developing patents and analyzing GHK's effects on human gene expression of 4,192 genes. In addition to GHK's published potential uses on skin inflammation, metastatic cancer and COPD, it appears to have beneficial effects on other tissue systems such as the nervous system, gastrointestinal system, and mitochondrial system. His brief but detailed autobiography dives into the motivations and background behind his dedicating to skin, anti-aging, and life-long training.\n\nLoren Pickart, Ph.D is being referenced as one of the leading scientists involved in the research and development of GHK-Cu. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Loren Pickart, Ph.D is listed in [1] [3] and [8] under the",
    "citations": [
      "A. Gruchlik, E. Chodurek, and Z. Dzierzewicz, “Effect of GLY-HIS-LYS and its copper complex on TGF-β secretion in normal human dermal fibroblasts,” Acta Pol. Pharm., vol. 71, no. 6, pp. 954–958, Dec. 2014. [PubMed]",
      "L. Pickart and A. Margolina, “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data,” Int. J. Mol. Sci., vol. 19, no. 7, Jul. 2018. [PubMed]",
      "X. Wang et al., “GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis,” Wound Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair Soc., vol. 25, no. 2, pp. 270–278, 2017. [PubMed]",
      "G. D. Mulder et al., “Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper,” Wound Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair Soc., vol. 2, no. 4, pp. 259–269, Oct. 1994. [PubMed]",
      "S. O. Canapp et al., “The effect of topical tripeptide-copper complex on healing of ischemic open wounds,” Vet. Surg. VS, vol. 32, no. 6, pp. 515–523, Dec. 2003. [PubMed]",
      "L. Pickart, J. M. Vasquez-Soltero, and A. Margolina, “The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline,” Brain Sci., vol. 7, no. 2, Feb. 2017. [PubMed]",
      "H. Zhang, Y. Wang, and Z. He, “Glycine-Histidine-Lysine (GHK) Alleviates Neuronal Apoptosis Due to Intracerebral Hemorrhage via the miR-339-5p/VEGFA Pathway,” Front. Neurosci., vol. 12, p. 644, 2018. [PubMed]",
      "X.-M. Zhou et al., “GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFβ1/Smad-Mediated Epithelial-to-Mesenchymal Transition,” Front. Pharmacol., vol. 8, p. 904, 2017. [PubMed]",
      "J.-R. Park, H. Lee, S.-I. Kim, and S.-R. Yang, “The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice,” Oncotarget, vol. 7, no. 36, pp. 58405–58417, Sep. 2016. [PubMed]",
      "L. А. Sever’yanova and D. V. Plotnikov, “Binding of Glyprolines to L-Arginine Inverts Its Analgesic and Antiagressogenic Effects,” Bull. Exp. Biol. Med., vol. 165, no. 5, pp. 621–624, Sep. 2018. [PubMed]"
    ]
  },
  "melanostatin dm": {
    "title": "Melanostatin DM 200mg (Topical)",
    "url": "https://www.peptidesciences.com/melanostatin-dm-200mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Melanostatin DM: Research Applications",
        "content": "Melanostatin DM is utilized in laboratory research to investigate regulation of melanocyte signaling and melanin synthesis. Experimental applications include in vitro melanocyte cultures and animal models to evaluate modulation of α-MSH–mediated pathways and downstream enzymatic processes associated with melanin production."
      },
      {
        "heading": "Melanostatin DM: Preclinical Research Summary",
        "content": "Preclinical investigations involving Melanostatin DM include animal models and cultured melanocyte systems assessing changes in melanin synthesis following α-MSH pathway inhibition. Experimental observations report reduced melanin production metrics relative to control conditions. These findings are used to examine melanocortin pathway regulation and peptide structure–function relationships under controlled research conditions."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "nonapeptide-1": {
    "title": "Nonapeptide-1 200mg (Topical)",
    "url": "https://www.peptidesciences.com/nonapeptide-1-200mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "-",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Nonapeptide-1: Research Applications",
        "content": "Nonapeptide-1 is utilized in laboratory research to investigate regulation of melanin synthesis and pigment-related cellular signaling. Experimental applications include fungal systems, cultured melanocyte models, and in vivo animal studies to evaluate peptide effects on tyrosinase activity and melanin content under controlled conditions.\n\nAdditional preclinical investigations explore Nonapeptide-1 interactions with neurochemical signaling pathways in animal models, including receptor systems associated with dopaminergic and opioid signaling, to characterize broader peptide–receptor structure–function relationships."
      },
      {
        "heading": "Nonapeptide-1: Preclinical Research Summary",
        "content": "Preclinical research involving Nonapeptide-1 includes fungal assays, cultured melanocyte experiments, and animal models evaluating changes in melanin synthesis following peptide exposure. Experimental observations report measurable reductions in tyrosinase activity and melanin production relative to controls. These findings are used to characterize pigment-regulatory biochemical pathways and peptide structure–activity relationships without implication of applied outcomes."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "pal-ghk": {
    "title": "Pal-GHK 200mg (Palmitoyl Tripeptide-1) (Topical)",
    "url": "https://www.peptidesciences.com/pal-ghk-200mg-palmitoyl-tripeptide-1",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Fibroblast / ECM studies: Investigation of fibroblast-associated ECM gene programs, including collagen- and elastin-related expression in cell culture and animal models.\n\nPeptide lipidation research: Comparative studies of peptide vs. lipopeptide behavior to evaluate the impact of palmitoylation on membrane affinity and cellular uptake.\n\nSignal transduction mapping: Profiling of peptide-driven changes in growth-factor and cytokine signaling networks relevant to connective tissue biology under controlled experimental conditions.\n\nCombination-design experiments: Use in multi-peptide research designs to assess additive or interaction effects on mechanistic readouts in vitro or in vivo models [1]."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical literature describing palmitoylated tripeptides and related GHK-based systems has evaluated changes in ECM-associated readouts, including collagen- and elastin-linked expression patterns, using experimental skin-relevant models and cell culture platforms [2]. In these contexts, Pal-GHK is frequently discussed as part of broader ingredient systems and multi-component research formulations [1].\n\nPublished work on over-the-counter topical agent evaluation and erythema/photoaging management includes clinical framing; however, within an RUO context, these reports may be used strictly as background references for mechanistic hypotheses, assay design, and selection of laboratory endpoints (e.g., ECM markers, inflammatory mediators, oxidative-stress gene panels) rather than as evidence of outcomes in any intended-use setting [3–5]."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "palmitoyl dipeptide-6": {
    "title": "Palmitoyl Dipeptide-6 200mg (Topical)",
    "url": "https://www.peptidesciences.com/palmitoyl-dipeptide-6-200mg-topical",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "pentapeptide-18": {
    "title": "Pentapeptide-18 (Leuphasyl) 200mg (Topical)",
    "url": "https://www.peptidesciences.com/pentapeptide-18-leuphasyl-200mg-topical",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Pentapeptide-18 (Leuphasyl): Research Applications",
        "content": "Pentapeptide-18 is utilized in laboratory research to investigate modulation of neuromuscular junction activity. Experimental applications include in vitro neuronal–muscle co-culture assays and in vivo animal models assessing peptide effects on synaptic signaling dynamics and muscle fiber activation parameters."
      },
      {
        "heading": "Pentapeptide-18 (Leuphasyl): Preclinical Research Summary",
        "content": "Preclinical studies involving Pentapeptide-18 include animal models and in vitro neuromuscular assays evaluating changes in synaptic transmission and muscle contractile signaling following peptide exposure. Experimental observations report reversible modulation of neuromuscular activity, supporting investigation of enkephalin-derived peptide structure–function relationships in controlled research settings."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "rigin": {
    "title": "Rigin 200mg (Palmitoyl Tetrapeptide-7) (Topical)",
    "url": "https://www.peptidesciences.com/rigin-200mg-palmitoyl-tetrapeptide-7",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Use as a lipopeptide probe in preclinical models to evaluate cytokine-linked signaling networks (including IL-6–associated pathways) and downstream transcriptional responses.\nInvestigation of ECM homeostasis and remodeling programs, including collagen/elastin-associated readouts and matrix turnover markers in cellular systems and in vivo animal studies.\nEvaluation of matrix metalloproteinase (MMP)–regulated ECM degradation processes using biochemical assays, gene expression endpoints, and protein-level markers in vitro.\nComparative studies of tetrapeptide vs palmitoylated tetrapeptide to assess how lipidation alters physicochemical behavior and experimental performance in defined assay conditions."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical publications describe rigin (and/or Pal-GQPR) in experimental contexts that include immunomodulatory pathway assessment, cytokine-linked signaling readouts, and ECM remodeling endpoints in cell culture and animal models [2–4]. Additional reports discuss use in multi-ingredient research systems that pair palmitoylated peptides to explore combined effects on matrix-associated markers under controlled experimental conditions [3,5]. These findings should be interpreted strictly as preclinical observations for mechanistic investigation and assay design."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "syn-ake": {
    "title": "Syn-AKE 200mg (Topical)",
    "url": "https://www.peptidesciences.com/syn-ake-200mg-topical",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Syn-AKE: Research Applications",
        "content": "Syn-AKE is utilized in research models to study modulation of neuromuscular signal transmission. In vivo animal studies and in vitro neuromuscular junction assays employ Syn-AKE to evaluate changes in muscle fiber activation resulting from competitive inhibition of acetylcholine-mediated signaling. These investigations support mechanistic characterization of peptide–receptor interactions at the synaptic interface."
      },
      {
        "heading": "Syn-AKE: Preclinical Research Summary",
        "content": "Preclinical studies involving Syn-AKE include animal models and in vitro neuromuscular assays evaluating peptide-mediated inhibition of acetylcholine receptor signaling. Experimental observations demonstrate transient, reversible modulation of muscle contractile signaling following exposure to Syn-AKE. These findings are used to characterize structure–function relationships of venom-derived peptide analogs without implication of applied or therapeutic outcomes."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "syn-coll": {
    "title": "Syn-Coll (Palmitoyl Tripeptide-5) 200mg (Topical)",
    "url": "https://www.peptidesciences.com/syn-coll-palmitoyl-tripeptide-5-200mg-topical",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Syn-Coll (Palmitoyl Tripeptide-5): Research Applications",
        "content": "Syn-Coll is employed in laboratory research to examine molecular regulation of type I and type III collagen synthesis and extracellular matrix turnover. Type I collagen represents a principal fibrillar component of connective tissue matrices, while type III collagen contributes to organization of compliant matrix systems. Experimental use includes in vitro fibroblast cultures and in vivo animal models to assess collagen-associated gene expression, protein synthesis, and matrix deposition under controlled experimental conditions."
      },
      {
        "heading": "Syn-Coll (Palmitoyl Tripeptide-5): Preclinical Research Summary",
        "content": "Preclinical and in vitro studies involving Palmitoyl Tripeptide-5 report increased collagen-associated transcriptional and protein expression markers alongside altered matrix metalloproteinase activity in experimental models. These findings are used to characterize extracellular matrix signaling and remodeling mechanisms without implication of applied, cosmetic, physiological, or therapeutic outcomes."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "tripeptide-29": {
    "title": "Tripeptide-29 200mg (Collagen peptide) (Topical)",
    "url": "https://www.peptidesciences.com/tripeptide-29-200mg-collagen-peptide",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Tripeptide-29: Research Applications",
        "content": "Tripeptide-29 and related collagen-mimetic tripeptides are used in controlled laboratory workflows as:\n\nMinimal motifs for collagen-recognition studies (e.g., receptor binding assays and competitive inhibition formats).\nBuilding blocks for collagen model peptides or hydrolysate mixtures to evaluate sequence-dependent physicochemical properties (e.g., solubility, aggregation propensity, and redox-relevant readouts in defined chemical systems).\nTools for studying enzyme interactions with collagen-derived peptides (e.g., peptidase inhibition assays in vitro) and downstream pathway mapping in cell-based models where appropriate.\nComponents in biomaterials and ECM-inspired research where short motifs are used to tune assembly or interaction profiles in synthetic matrices."
      },
      {
        "heading": "Tripeptide-29: Preclinical Research Summary",
        "content": "Collagen-Mimetic Repeats and GPVI Signaling (In Vitro)\n\nPublished in vitro work has described monomeric collagen-like repeat sequences as partial agonists of GPVI in platelet-focused experimental designs, and has further evaluated how multivalency/crosslinking can alter activation magnitude. These systems are used to parse receptor activation rules (e.g., avidity and spatial presentation) under defined assay conditions.\n\nCollagen Model Peptides: Stability Determinants\n\nBenchtop studies of collagen model peptides have examined how specific tripeptide units contribute to stability readouts. Such work is commonly used to guide rational design of collagen-mimetic sequences in structural biology and biomaterials research.\n\nCollagen Hydrolysates and Chemical Redox Readouts\n\nPreclinical and biochemical literature has evaluated collagen hydrolysates in chemical radical-scavenging assays, with emphasis on how peptide composition and sequence influence assay performance. These findings are generally applied as mechanistic inputs to formulation and structure–activity discussions in controlled experimental contexts (without implying biological outcomes in humans).\n\nDPP4 Inhibition by Collagen-Derived Tripeptides\n\nIn vitro studies have reported inhibitory activity of collagen-derived tripeptides against DPP4 enzymatic function. Separately, animal-model studies have investigated DPP4 inhibition as a mechanistic variable in fibrosis-associated endpoints. Together, these reports support continued mechanistic investigation of how defined short peptides interact with peptidases and how protease modulation maps onto pathway-level readouts in preclinical systems.\n\nImportant RUO Note: Any research discussion on this page is limited to mechanistic, in vitro, or preclinical animal-model contexts. No statements are made regarding human safety, efficacy, or intended use."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "vialox": {
    "title": "Vialox (Pentapeptide-3V) 200mg (Topical)",
    "url": "https://www.peptidesciences.com/vialox-pentapeptide-3v-200mg-topical",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Vialox (Pentapeptide-3V): Research Applications",
        "content": "Vialox is utilized in research settings to investigate peripheral neuromuscular junction signaling and receptor–ligand interactions. Experimental use includes in vitro neuromuscular junction assays and in vivo animal models to evaluate selective inhibition of acetylcholine-mediated signal transmission at muscle endplates, without engagement of central neuronal receptor populations."
      },
      {
        "heading": "Vialox (Pentapeptide-3V): Preclinical Research Summary",
        "content": "Preclinical investigations involving Vialox include animal models and in vitro receptor-binding assays assessing neuromuscular signal modulation. Reported findings describe transient, reversible inhibition of acetylcholine receptor activity and corresponding changes in muscle contractile signaling parameters. These studies are used to characterize structure–function relationships of venom-derived peptide analogs under controlled experimental conditions."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "pal-ahk": {
    "title": "Pal-AHK 200mg (Topical)",
    "url": "https://www.peptidesciences.com/pal-ahk-200mg-topical",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Fibroblast signaling research: Investigation of peptide-mediated activation and transcriptional regulation within fibroblast cell populations.\n\nExtracellular matrix dynamics: Analysis of collagen and elastin synthesis pathways in cellular and tissue-level experimental models.\n\nTGF-β pathway studies: Evaluation of transforming growth factor-β–associated signaling cascades and downstream gene expression.\n\nAngiogenic signaling research: Examination of VEGF-related molecular responses in preclinical in vitro and in vivo models.\n\nLipidated peptide transport: Study of fatty acid–conjugated peptide uptake and intracellular distribution."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "Preclinical studies employing cellular systems and animal models have evaluated Pal-AHK for its influence on fibroblast activity and ECM-associated protein expression. Experimental findings describe increased transcriptional activity linked to collagen and elastin synthesis pathways under controlled laboratory conditions.\n\nComparative studies between lipidated and non-lipidated AHK variants highlight the role of palmitoylation in enhancing membrane permeability and intracellular engagement, supporting its use as a research tool for peptide delivery and signaling investigations."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  },
  "bpc-157": {
    "title": "BPC-157",
    "url": "https://www.peptidesciences.com/bpc-157-5mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "BPC-157: Research Applications",
        "content": "BPC-157 is supplied exclusively for laboratory research use and has been employed in controlled experimental studies examining:\n\nFibroblast proliferation and directional migration\nEndothelial cell growth and angiogenic pattern formation\nExtracellular matrix deposition and remodeling\nCytoskeletal organization and focal adhesion signaling\nOxidative stress marker modulation in animal models\nNitric oxide–associated biochemical pathways\n\nAll applications are limited to non-clinical research systems designed to elucidate fundamental biological mechanisms."
      },
      {
        "heading": "BPC-157: Preclinical Research Summary",
        "content": "Published preclinical literature documents the activity of BPC-157 across multiple experimental models. In rodent systems, the peptide has been investigated in studies examining vascular collateral formation, gastrointestinal tissue integrity, and connective tissue remodeling under controlled laboratory conditions.\n\nAdditional investigations in avian and invertebrate models have explored peptide stability and tissue-level stress responses, contributing to broader understanding of conserved biological signaling mechanisms.\n\nBPC-157 concentration versus vascular endothelial cell growth\nSource: PubMed"
      }
    ],
    "articleAuthor": "Article Author\n\nThe above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.",
    "scientificJournalAuthor": "Predrag Sikiric, lead author of “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing”, and co-author of “Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions,” is a Professor of Medical Department at University of Zagreb. Predrag Sikiric is listed in [9] and [16] under the",
    "citations": []
  },
  "triptorelin": {
    "title": "Triptorelin (GnRH) 2mg",
    "url": "https://www.peptidesciences.com/triptorelin-gnrh-2mg",
    "whatIs": "",
    "mechanismOfAction": "",
    "sequence": "",
    "molecularFormula": "",
    "molecularWeight": "",
    "casNumber": "57773-63-4",
    "pubChem": "",
    "researchSections": [
      {
        "heading": "Research Applications",
        "content": "Triptorelin is supplied for laboratory research and is commonly utilized as a mechanistic probe in controlled non-clinical studies involving:\n\nGnRH receptor (GnRHR) activation, desensitization, and internalization dynamics under pulsatile vs. continuous exposure paradigms\nLH/FSH secretion modeling and endocrine feedback-loop investigations in preclinical systems\nHormone-trajectory studies relevant to androgen deprivation and ovarian suppression research frameworks\nComparative endocrine pharmacology vs. other GnRH analogs (agonists/antagonists) in receptor pharmacology experiments\nExploratory translational literature reviews in oncology and reproductive endocrinology (non-product-claims; background only)\n\nAll applications are restricted to controlled in-vitro and in-vivo animal research contexts and are not intended for diagnostic or therapeutic use."
      },
      {
        "heading": "Preclinical Research Summary",
        "content": "1. Protocol-Dependent Outcomes (Stimulation vs. Suppression)\n\nResearch and clinical literature consistently emphasizes that GnRH agonist outcomes are protocol-dependent: early-phase gonadotropin and testosterone increases can occur before suppression with sustained exposure (often described as a flare phenomenon). These dynamics inform endocrine modeling and timing-sensitive study designs in non-clinical and clinical-adjacent research contexts.\n\n2. Oncology-Adjacent Research Contexts (Breast & Prostate)\n\nTriptorelin is widely discussed in the literature in connection with hormone suppression strategies in oncology, including ovarian function suppression in certain breast cancer regimens and androgen deprivation therapy in prostate cancer settings [2], [3], [4]. These sources are provided as background references and do not imply product claims for any experimental use.\n\n3. Reproductive Endocrinology and Gynecologic Research\n\nAdditional referenced literature discusses triptorelin in fertility-preservation contexts during chemotherapy and in gynecologic research areas such as endometriosis and adenomyosis, supporting broader investigation of GnRH-axis modulation in controlled research settings [8], [9], [12].\n\n4. Endocrine–Immune Interaction (Preclinical)\n\nPreclinical work has explored LHRH/GnRH agonist signaling in relation to thymic parameters and aging-associated immune changes, including thymus weight and thymocyte proliferative measures in experimental models [14].\n\nTriptorelin exhibits moderate side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Triptorelin for sale is limited to educational and scientific research only, not for human consumption. Only buy Triptorelin if you are a licensed researcher."
      },
      {
        "heading": "2. Oncology-Adjacent Research Contexts (Breast & Prostate)",
        "content": "Triptorelin is widely discussed in the literature in connection with hormone suppression strategies in oncology, including ovarian function suppression in certain breast cancer regimens and androgen deprivation therapy in prostate cancer settings [2], [3], [4]. These sources are provided as background references and do not imply product claims for any experimental use."
      },
      {
        "heading": "3. Reproductive Endocrinology and Gynecologic Research",
        "content": "Additional referenced literature discusses triptorelin in fertility-preservation contexts during chemotherapy and in gynecologic research areas such as endometriosis and adenomyosis, supporting broader investigation of GnRH-axis modulation in controlled research settings [8], [9], [12]."
      }
    ],
    "articleAuthor": "",
    "scientificJournalAuthor": "",
    "citations": []
  }
}